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Abstract	Epigenetic	modifications	have	drawn	 significant	 attention	due	 to	 their	 crucial	 roles	 in	development	and	disease.	The	recent	emergence	of	epigenome	editing	tools	provides	an	attractive	 strategy	 for	 manipulating	 chromatin	 structure	 and	 gene	 expression.	 They	have	been	shown	to	successfully	activate	and	silence	targeting	genes	in	conjunction	with	chromatin	modifying	 enzymes.	A	major	 gap	 in	 knowledge	pertains	 to	how	epigenome	editing	differs	in	efficiency	at	distinct	DNA	contexts.	The	focus	of	this	thesis	was	to	build	a	 novel	 system,	 chromatin	 inducible	 targeting	 (CIT),	 to	 test	 the	 effect	 of	 sequence	context	 on	 the	 efficiency	of	 chromatin	modifying	 enzymes	 to	 control	 gene	 expression.	Specifically,	 I	 tested	 the	 effect	 of	 CAG/CTG	 repeat	 expansion	 on	 the	 ability	 of	HDAC5,	HDAC3,	and	DNMT1	targeting	to	modify	chromatin	structure.	CIT	can	be	divided	into	three	major	components.	First,	a	GFP-based	reporter	monitors	gene	expression.	 It	 contains	an	 intron	carrying	a	varying	number	of	CAG/CTG	triplets.	Second,	I	adapted	the	ParB-INT	targeting	system	such	that	any	protein	of	interest	can	be	recruited	 within	 300bp	 of	 the	 expanded	 CAG/CTG	 repeat	 tract.	 Third,	 an	 ABA-based	chemical	 inducible	 proximity	 system	 that	 allows	 for	 spatiotemporal	 and	 reversible	targeting	 of	 proteins	 to	 chromatin.	 Notably,	 CIT	 is	 also	 well	 suited	 to	 ask	 whether	chromatin	modifying	enzymes	work	locally	to	regulate	gene	expression	or	in	trans.		I	 found	 that	HDAC5	 targeting	silences	 the	GFP	reporter	while	decreasing	 local	histone	acetylation.	 Interestingly,	 HDAC5	 preferentially	 silences	 the	 reporter	with	 the	 shorter	repeat	 tract,	probably	because	of	 the	 lower	 levels	of	histone	acetylation	present	at	 the	expanded	 repeat	 tract	 before	 targeting.	 HDAC5	 is	 thought	 to	 deacetylate	 histones	 by	recruiting	 another	 HDAC,	 HDAC3.	 Surprisingly,	 however,	 HDAC3	 targeting	 increased	GFP	expression,	and	its	effect	is	insensitive	to	the	size	of	the	repeat	tract.	This	effect	is	controversial	to	the	current	models	of	HDAC3	function	that	deacetylation	of	histone	tails	by	HDAC3	in	gene	body	improves	transcriptional	output.	Moreover,	I	found	that	Dnmt1	targeting	has	a	similar	effect	on	gene	silencing	as	HDAC5	targeting:	it	is	more	efficient	in	the	context	of	shorter	CAG/CTG	repeats.	CIT	provides	a	novel	strategy	to	optimize	the	efficiency	of	epigenome	editing	in	a	highly	controlled	and	flexible	manner.	Our	data	uncover	novel	mechanisms	of	gene	regulation	by	these	chromatin	modifiers	and	guides	their	use	in	manipulating	chromatin	structure.	CIT	 is	 suitable	 for	 screening	 and	 can	 be	 adapted	 to	 study	 the	 effect	 of	 virtually	 any	sequences	on	epigenome	editing.	
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Sommaire	Les	modifications	épigénétiques	ont	attiré	une	grande	attention	en	raison	de	 leurs	rôles	cruciaux	dans	 le	 développement	 et	 dans	 plusieurs	 pathologies.	 L'émergence	 récente	 d'outils	 d'édition	 de	l'épigénome	constitue	une	stratégie	 intéressante	pour	manipuler	 la	structure	de	 la	chromatine	et	l'expression	 des	 gènes.	 Il	 a	 été	 démontré	 qu'il	 est	 possible	 d’activent	 et	 de	 bloquer	 avec	 succès	l’expression	des	gènes	en	recrutant	des	enzymes	modifiant	la	chromatine.	Une	lacune	majeure	dans	la	 compréhension	 de	 ce	 processus	 concerne	 la	 façon	 dont	 l'édition	 de	 l'épigénome	 diffère	 en	efficacité	 dans	 des	 contextes	 d'ADN	 distincts.	 L'objectif	 de	 cette	 thèse	 était	 de	 construire	 un	nouveau	système	de	ciblage	de	la	chromatine	inductible	(CIT),	pour	tester	l'effet	du	contexte	de	la	séquence	sur	 l'efficacité	des	enzymes	modifiant	 la	chromatine	à	contrôler	 l'expression	des	gènes.	Spécifiquement,	j'ai	testé	l'effet	de	l'expansion	de	répétition	CAG	/	CTG	sur	la	capacité	du	ciblage	de	HDAC5,	HDAC3,	et	DNMT1	de	modifier	la	structure	de	la	chromatine.	CIT	peut	être	divisé	en	trois	principaux	composants.	Tout	d'abord,	un	rapporteur	basé	sur	 la	GFP	pour	quantifier	 l'expression	des	gènes.	Il	contient	un	intron	portant	un	nombre	variable	de	triplets	CAG	/	CTG.	Deuxièmement,	j'ai	 adapté	 le	 système	de	 ciblage	ParB-INT	de	 telle	 sorte	que	 toute	protéine	d'intérêt	puisse	 être	recrutée	 à	 moins	 de	 300	 pb	 de	 l’expansion	 de	 triplets.	 Troisièmement,	 notre	 outil	 contient	 un	système	de	proximité	inductible	chimique	à	base	d'ABA	permettant	un	recrutement	spatiotemporel	et	 réversible	 des	 protéines	 à	 la	 chromatine.	 Notamment,	 CIT	 est	 également	 bien	 adapté	 pour		déterminer	si	les	enzymes	modifiant	la	chromatine	travaillent	localement	pour	réguler	l'expression	des	 gènes	 ou	 en	 trans.	 J'ai	 trouvé	 que	 le	 ciblage	 HDAC5	 fait	 taire	 le	 rapporteur	 GFP	 tout	 en	diminuant	 l'acétylation	 locale	 des	 histones.	 Fait	 intéressant,	 HDAC5	 diminue	 l’expression	 du	rapporteur	GFP	de	manière	préférentielle	avec	la	répétition	la	plus	courte,	probablement	en	raison	des	 niveaux	 inférieurs	 d'acétylation	 des	 histones	 présents	 près	 des	 expansion	 avant	 le	 ciblage.	HDAC5	est	censé	de	désacétyler	les	histones	en	recrutant	une	autre	HDAC,	HDAC3.	Étonnamment,	cependant,	le	recruitment	de	HDAC3	au	rapporteur	a	augmenté	son	expression	peu	importe	la	taille	de	 la	région	répétée.	Cet	effet	est	en	désaccord	avec	 les	modèles	actuels	de	 la	 fonction	de	HDAC3	qui	 stipulent	 que	 la	 désacétylation	 des	 queues	 d'histones	 par	 HDAC3	 dans	 le	 corps	 de	 gènes	améliore	la		transcription.	De	plus,	j'ai	trouvé	que	le	ciblage	de	Dnmt1	a	un	effet	similaire	à	HDAC5	sur	 l’expression	 génique:	 il	 réduit	 le	 niveau	 de	 GFP	 plus	 efficacement	 dans	 le	 contexte	 de	répétitions	CAG	/	CTG	plus	courtes.	CIT	fournit	une	nouvelle	stratégie	pour	optimiser	l'efficacité	de	l'édition	de	 l’épigénome	d'une	manière	hautement	 contrôlée	et	 flexible.	Nos	données	 révèlent	de	nouveaux	mécanismes	de	régulation	des	gènes	par	ces	modificateurs	de	 la	chromatine	et	guident	leur	utilisation	dans	la	manipulation	de	la	structure	de	la	chromatine.	Le	CIT	convient	au	criblage	et	peut	 être	 adapté	 pour	 étudier	 l'effet	 de	 pratiquement	 toutes	 les	 séquences	 sur	 l'édition	 de	l'épigénome.
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The	 human	 genome	 is	 highly	 organized	 in	 the	 nucleus	 and	 packaged	 into	 a	structure	 called	 chromatin.	 About	 147bp	 of	 negatively	 charged	 DNA	 wrapped	around	a	positively	charged	histone	protein	complex	containing	two	copies	of	each	H2A,	 H2B,	 H3	 and	 H4,	 to	 form	 one	 nucleosome	 (Margueron	 and	 Reinberg,	 2010;	Rando	and	Chang,	2009;	Shahbazian	and	Grunstein,	2007;	Venkatesh	and	Workman,	2015).	Nucleosomes	are	 further	packaged	 into	a	 complex,	and	controversial	 three-dimensional	(3D)	chromatin	structure.		Based	on	distinct	compaction	levels	based	on	the	density	of	DNA	staining	during	interphase,	chromatin	is	further	grouped	into	two	forms:	 euchromatin	 and	 heterochromatin.	 Euchromatin	 is	 lightly	 stained	 and	 is	transcriptionally	 highly	 active,	 accompanied	 by	 typical	 histone	 marks	 like	acetylation	in	histone	H3	tail.	Heterochromatin,	by	contrast,	shows	more	condensed	staining,	 low	 transcriptional	 activity	 and	 more	 DNA	 methylation	 at	 CpG	dinucleotides.	Heterochromatic	histone	marks	 include	trimethylation	of	histone	H3	at	 lysine	9	and	27,	among	others.	Nevertheless,	how	chromatin	modifying	enzymes	alter	 gene	 regulations	 is	 still	 unclear.	 It	 has	 been	 shown	 chromatin	 structure	 is	tightly	correlated	with	cancer	and	neurological	disorders	(Beltran	et	al.,	2008;	Dion	and	Wilson,	 2009;	 Egger	 et	 al.,	 2004;	 Feinberg,	 2007;	 Portela	 and	 Esteller,	 2010;	Robertson,	 2005;	 Robertson	 and	 Wolffe,	 2000).	 The	 hypothesis	 is	 manipulating	chromatin	structure,	and	gene	expression	 in	a	controllable	manner	may	contribute	to	 the	 alleviation	 of	 disease	 symptoms.	 However,	 having	 chromatin	 modifying	enzymes	to	influence	gene	expression	at	will	is	not	trivial.	This	is	the	main	reason	I	am	interested	in	epigenome	editing	and	gene	regulation.			I	 will	 focus	 on	 newly	 developed	 epigenome	 editing	 tools	 and	 inducible	proximity	 systems	 to	 evaluate	 their	 applicability	 to	 manipulating	 chromatin	 and	gene	 expression.	 I	will	 also	describe	 a	 novel	 inducible	 chromatin	 targeting	 system	that	 I	 have	 developed	 to	 study	 the	 relationship	 between	 sequence	 context	 and	epigenome	 editing	 as	 well	 as	 to	 uncover	 novel	 mechanisms	 regulating	 gene	expression.			
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1.	Epigenome	editing	tools	
	Chromatin	 modifications	 have	 long	 been	 known	 to	 correlate	 with	 gene	expression	 tightly.	 However,	 the	 mechanisms	 of	 gene	 regulation	 by	 chromatin	structures	were	difficult	to	assess,	especially	through	loss-of-function	studies.	This	is	because	chromatin	modifying	enzymes	 loss	of	activity	often	has	pleiotropic	effects.	The	 recent	 rise	 of	 epigenome	 editing	 tools,	 with	 their	 potential	 for	 spatial	 and	temporal	regulation	as	well	as	reversibility,	has	created	a	significant	opportunity	for	both	 basic	 research	 and	 translational	 studies.	 The	 discovery	 and	 development	 of	customizable	sequence-specific	DNA	binding	peptides	make	it	possible	to	recognize	endogenous	DNA	sequences	 and	bring	 chromatin	modifying	 enzymes	 to	 a	 locus	of	choice	and	catalyze	histone	or	DNA	modifications	(Groote	et	al.,	2012).			Three	 primary	 epigenome	 editing	 techniques	 are	 currently	 in	 use	 are	 zinc	finger	 proteins	 (ZFs),	 transcription	 activator-like	 effectors	 (TALEs)	 and	 Clustered	Regularly	 Interspaced	 Short	 Palindromic	Repeats	 (CRISPR)	 and	 CRISPR-associated	(Cas)	proteins	 (Waryah	et	 al.,	 2018).	 	 In	 the	 following	 sections,	 these	 tools	will	 be	discussed	from	their	history,	structural	properties,	mechanisms	of	action,	as	well	as	their	applications	and	limitations.	
	
	
	
	
	
	
	
	
	
	
	
Figure II. 1. Epigenome editing tools applications. Epigenome editing 
tools can be used to study gene function, chromatin biology, cell 
reprogramming and further medical fields. (Derived from Kungulovski,	G.	et	al.	Trends	Genet,	2016)	
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1.1	Zinc	Finger	proteins	(ZFs)	
1.1.1	Discovery,	working	mechanism,	and	design	A.	 Klug	 and	 colleagues	 first	 reported	 zfs	 in	 1985	 (Miller	 et	 al.,	 1985).	 They	found	a	small	protein	containing	repetitive	zinc-binding	domains	with	7	 to	11	zinc	atoms	that	could	bind	to	the	5S	RNA	genes	in	Xenopus	Laevis	oocytes	extracts	(Miller	et	 al.,	 1985).	 This	 small	 protein	 Zif268	 can	 bind	 to	 DNA	 tightly	 and	 RNA	 as	 well	(Blancafort	et	al.,	1999;	Moore	et	al.,	2001).	The	ZFs	bind	to	the	major	groove	of	DNA	via	 an	α-helix	 of	 the	 ZFs	with	 the	N-terminal	 close	 to	 the	DNA	and	 the	C-terminal	located	away	from	the	binding	site	(Elrod-Erickson	et	al.,	1996;	Fairall	et	al.,	1993;	Pavletich	and	Pabo,	1991).	Each	zinc	finger	protein	can	recognize	three	bps	of	DNA	so	that	individual	finger	can	be	assembled	to	match	more	extended	target	sequences	(Segal	 et	 al.,	 1999).	 After	 zinc	 finger	 nucleases	 (ZFNs)	 screening,	 the	 efficiency	 of	FokI	cleavage	driven	by	ZFs	recognition	are	successfully	reach	15.7%	(Wang	et	al.,	2013).	The	high	efficiency	of	targeting	has	been	observed	in	human	embryonic	stem	cells	OCT4	gene,	which	on-target	efficiency	can	reach	94%	(Hockemeyer	et	al.,	2009).	In	one	word,	ZFs	can	be	engineered	to	target	DNA	locus	with	high	efficiency.		
1.1.2	ZFs	in	gene	activation	Since	ZFs	or	multiple	ZFs	complexes	can	not	modulate	epigenome	themselves,	gene	 activators	 or	 repressors	 need	 to	 be	 linked	 to	 ZFs	 to	 do	 the	 work.	 Synthetic	transcription	 activation	 domain	 VP64	 had	 been	 used	 as	 effector	 domains	 in	conjunction	 with	 ZFs	 to	 achieve	 an	 erbB-2-luciferase	 reporter	 activated	transcription	in	HeLa/tet-off	cell	line	(Beerli	et	al.,	2000;	Beltran	et	al.,	2007;	Liu	et	al.,	 2001;	 Zhang	 et	 al.,	 2000).	Human	histone	 acetyltransferase	P300	 core	 fused	 to	ZFs	 also	 managed	 to	 target	 ICAMI	 promoter	 and	 activate	 gene	 transcription	 in	HEK293T	 cells	 (Hilton	 et	 al.,	 2015).	 All	 of	 those	 show	 ZFs	 can	 be	 fused	 to	transcription	activators	and	induce	gene	activation.			
1.1.3	ZFs	in	gene	silencing	ZFs	 have	 been	 widely	 used	 in	 conjunction	 with	 DNA	 methyltransferases	 to	induce	 local	 methylation	 and	 transcription	 silencing.	 One	 early	 report	 in	 1997	showed	 ZFs	 fused	 to	 the	 bacterial	 DNA	 methyltransferase	 M.SssI	 successfully	methylated	the	5’	side	of	the	ZF	binding	site	(Xu	and	Bestor,	1997).	After	this,	several	
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ZFs-DNA	methyltransferases	fusions,	for	instance,	using	the	catalytic	domain	of	DNA	methyltransferase	3a	(DNMT3a)	and	DNMT3b,	all	increased	DNA	methylation	levels	locally	 and	 repress	 transcription	 (Li	 et	 al.,	 2007;	Nunna	et	 al.,	 2014).	Beyond	DNA	methyltransferases,	 histone	methyltransferases	 G9a	 and	 SUV39-H1	 also	 efficiently	silenced	their	target	genes	when	recruited	via	synthetic	ZFs	(Snowden	et	al.,	2002;	Falahi	 et	 al.,	 2013).	 A	 ZF	 fusion	 with	 Kruppel-associated	 box	 domain	 (KRAB)	recruited	 cofactor	 KAP1	 and	 resulted	 in	 the	 loss	 of	 histone	 acetylation,	 a	 gain	 in	histone	 methylation,	 and	 a	 long-range	 gene	 silencing	 (Groner	 et	 al.,	 2010;	Stolzenburg	 et	 al.,	 2012).	 Interestingly,	 a	 genome-wide	 study	on	 zinc	 finger	 fusion	protein	 with	 artificial	 transcription	 factors	 (ATFs)	 super	 KRAB	 domain	 (SKD)	targeting	 to	 the	 human	 SOX2	 promoter	 in	 MCF7	 breast	 cancer	 cells	 revealed	thousands	of	off-target	binding	sites	by	ChIP-seq	(Grimmer	et	al.,	2014).	Majority	of	the	 off-target	 genes	 showed	 no	 expression	 differences.	 Also,	 ATF-SKD	 induced	transcription	 repression	 did	 not	 affect	 histone	 modifications	 like	 H3K4me3	 and	H3K9ac	(Grimmer	et	al.,	2014).	Above	all,	ZFs	shows	usage	widely	in	silencing	gene	with	a	variety	of	factors	combined.				
1.1.4	ZFs	in	the	clinical	trial	ZFs	show	potential	clinical	usage	thanks	to	its	small	size,	high	expression	level	and	 toleration	 of	 variable	 chromatin	 contexts	 (Beltran	 et	 al.,	 2008;	 Gregory	 et	 al.,	2013).	 Clinical	 trials	 have	 been	 conducted	 using	 ZFs	 for	 diabetic	 neuropathy	 and	completed	 in	2016	(Eisenstein,	2012).	Sangamo	Biosciences	conducted	this	clinical	phase	2	trial	with	ZF	proteins	linked	to	the	P65	transcription	activator	to	induce	the	expression	 of	 the	 vascular	 endothelial	 growth	 factor	 A	 (VEGFA)	 in	 diabetic	neuropathy	patients.	Unfortunately,	the	trial	failed	because	the	treated	group	failed	to	display	significant	improvements	compared	to	placebo	(Eisenstein,	2012).			
	
1.1.5	ZFs	limitations	Despite	the	ZFs'	high	efficiency	of	epigenome	editing	capabilities,	the	off-target	effects	remain	a	significant	concern	(Grimmer	et	al.,	2014).	Off-target	rates	 for	ZFs	can	reach	8%,	which	is	18	fold	more	than	the	empty	vector	with	no	ZFs.	Its	off-target	binding	 sites	 can	 be	 located	 in	 other	 promoters	 and	 thus	 enact	 changes	 in	 gene	expression	 (Huisman	 et	 al.,	 2015).	 Optimization	 could	 significantly	 increase	 the	
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specificity	 of	 ZFs	 and	 help	 epigenome	 editing	 become	 safe	 enough	 for	 clinical	 use	(Hurt	et	al.,	2003).	However,	newer	technologies	appear	to	be	more	flexible	in	design	and	more	comfortable	to	use,	and	thus	ZF	technologies	are	being	phased	out.		
1.2	Transcription	Activator-Like	Effectors	(TALEs)	
1.2.1	Discovery,	working	mechanism	and	design	TALEs	 are	 another	 customizable	 DNA	 binding	 domains	 used	 for	 epigenome	editing.	 TALEs	 are	 proteins	 secreted	 by	Xanthomonas	 spp	 bacteria	 that	 alter	 gene	expression	in	their	host	plants	(Joung	and	Sander,	2013).	Then	how	TALEs	recognize	DNA	 was	 uncovered	 in	 2009	 by	 the	 Bonas	 group	 (Boch	 et	 al.,	 2009).	 One	 TALE	repeat	can	bind	one	base	of	DNA	via	amino	acids	12	and	13.	This	recognition	site	is	also	 located	 in	 the	major	 groove	 of	 DNA,	 similar	 to	 ZF-mediated	 binding,	 thereby	making	base-specific	contacts	with	the	target	sequence	(Deng	et	al.,	2012).	Changing	amino	 acids	 at	 position	 12	 and	 13	 changes	 the	 specificity	 of	 binding,	 allowing	 for	recognition	of	a	wide	array	of	sequences	through	multiplexing	of	TALE	repeats.	This	protein-DNA	 recognition	 can	 be	 widely	 used	 for	 genome	 editing	 and	 epigenome	engineering	 by	 assembling	 specific	 TALE	 repeats	 based	 on	 targeting	 sequences.	Using	 a	 puromycin	 expression	 driven	 by	 TALEN	 cleavage	 and	 recombination,	 the	efficiency	 of	 TALENs	 on-target	 cleavage	 varies	 between	 different	 tissues	 and	genomic	 locations.	 It	 shows	 similar	 efficiency	as	ZFs,	 reaching	more	 than	90%	on-target	 cleavage	with	 a	mean	 of	 22.2%	 (Hockemeyer	 et	 al.,	 2011).	 An	 endogenous	EGFP	 transgene	 disruption	 test	 with	 48	 engineered	 TALENs	 in	 human	 cells	 also	revealed	 the	 highest	 on-targeting	 cleavage	 rate	was	 around	 60-70%	 (Reyon	 et	 al.,	2012).	 In	 conclusion,	 TALEs	 could	 be	 another	 epigenome	 editing	 tool	 with	 the	relatively	high	efficiency	of	recognizing	on-targeting	sequences.		
1.2.2	TALEs	in	gene	activation	Similar	 to	 the	 applications	 described	 above	 with	 ZFs,	 TALEs	 are	 used	 to	activate	 gene	 expression	 by	 fusing	 them	 to	 synthetic	 transcription	 activation	domains	like	VP16	and	VP64	(Bultmann	et	al.,	2012;	Konermann	et	al.,	2013;	Zhang	et	 al.,	 2011).	 TALEs	 themselves	 can	 activate	 transcription.	 At	 promoter	 regions	 of	
SOX2,	KLF4,	c-MYC,	and	OCT4	targeted	by	TALEs	in	293FT	cells,	TALEs	were	able	to	increase	Sox2	and	KLF4	transcription	by	5.5	fold	and	2.2	fold	respectively	(Zhang	et	
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al.,	 2011).	 This	 may	 indicate	 that	 epigenome	 editing	 by	 TALEs	 depends	 on	 the	sequence	 context.	 Studies	 using	 TALE-VP16	 fusions	 showed	 that	 multiple	 TALEs	have	 the	 better	 efficiency	 to	 promote	 gene	 transcription	 (Maeder	 et	 al.,	 2013a;	Perez-Pinera	 et	 al.,	 2013a).	 Ten-Eleven	 Dioxygenase-1	 (TET1)	 had	 been	 shown	 in	conjunction	with	TALEs	 and	 optogenetic	 tools,	 two	 light	 inducible	 complementary	fusion	 protein	 constructs	 (Konermann	 et	 al.,	 2013),	 to	 demethylate	 DNA	 and	increase	the	levels	of	Ascl1	mRNA	by	2.5	fold	in	rat	striatal	neural	stem	cell	(Lo	et	al.,	2017).	Thus,	TALEs,	 like	ZFs,	can	efficiently	modify	chromatin	and	DNA	to	activate	gene	expression.		
1.2.3	TALEs	in	gene	repression	TALEs	 have	 been	 used	 for	 epigenome	 silencing	 by	 fusing	 them	 to	KRAB	 and	mSin	 interaction	 domain	 (SID).	 They	 were	 shown	 to	 repress	 endogenous	 SOX2	expression	 in	 HEK293FT	 cells	 (Cong	 et	 al.,	 2012).	 	 SID	 can	 further	 assemble	 into	SID4X,	 which	 in	 turn	 reduces	 H3K9	 acetylation	 and	 silences	 transcription	(Konermann	et	al.,	2013).	DNA	methyltransferase	3a	(DNMT3a)	fused	to	TALEs	was	similarly	 shown	 to	 induce	 DNA	 methylation	 at	 the	 Ascl1	 gene	 in	 dorsal	 root	ganglion-derived	neural	stem	cell	(NSC),	which	resulted	in	gene	silencing	(Lo	et	al.,	2017).	 TALEs-lysine-specific	 demethylase	 1	 (LSD1)	 fusion	 reduced	 both	 H3K4	methylation	and	H3K27	acetylation,	presumably	due	to	crosstalk	with	HDACs	(Lee	et	al.,	2006;	Shi	et	al.,	2004).	The	TALEs-LSD1	fusion	was	capable	of	reducing	H3K4me2	and	 H3K27ac	 levels	 and	 further	 repressing	 genes	 by	 targeting	 their	 enhancer	regions	in	K562	erythroleukemia	cells	(Mendenhall	et	al.,	2013).	So	TALEs	show	not	only	 the	 gene	 activation	 ability	 but	 also	 silencing	 gene	 with	 chromatin	modifying	enzymes	cooperation.			
1.2.4	TALEs	in	the	clinical	trial	There	has	been	no	report	of	clinical	trials	involving	TALE-mediated	epigenome	editing,	 only	 one	 patient	 test	with	 its	 nuclease	 version.	What	 has	 been	 done	 is	 to	transplant	TALEN	edited	universal	 CAR19	T	 cell	 to	 leukemia	patient	 (Qasim	et	 al.,	2015).	 TALEN	 induced	 T	 cell	 receptor	 alpha	 constant	 chain	 expression	 disruption	and	CD52	gene	silencing	 in	T	cell	 transplantation	showed	no	significant	 toxicity	 in	
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this	patient.	It	provides	an	early	proof-of-concept	for	the	strategy,	but	a	 large-scale	study	remains	to	be	conducted	to	confirm	or	refute	clinical	efficacy	and	safety.	
	
1.2.5	TALEs	limitations	TALEs	 targeting	 showed	off-target	 effects	 due	 to	 a	 particular	 subset	 of	 TALE	repeat	by	high	 throughput	 sequencing	or	protein-binding	microarray	 (Guilinger	 et	al.,	2014;	Juillerat	et	al.,	2014;	Meckler	et	al.,	2013;	Rogers	et	al.,	2015).	However,	the	off-targeting	effect	is	not	always	the	case	depend	on	TALE	length	and	targeting	loci.	TALE	fused	to	histone	demethylase	LSD1	successfully	removed	enhancer-associated	modification	 to	 downregulate	 gene	 expression	 but	 not	 in	 control	 TALE	 construct	treatment	group	in	K562	cells	(Mendenhall	et	al.,	2013).	In	a	genome-wide	ChIP-seq	study,	 TALEs-VP64	 activated	 IL1RN	 or	 HBG1/2	 have	 been	 shown	 31	 off-target	binding	sites	and	 four	off-target	binding	sites	respectively.	However,	no	significant	changes	 in	 gene	 expression	were	detected	on	 these	off-target	 sites	 (Polstein	 et	 al.,	2015).	They	also	 found	all	off-target	sites	contain	a	GC-rich	3’	end	that	overlapped	with	 TALEs	 recognition	 motif.	 Off-target	 effects	 could	 be	 reduced	 by	 engineering	longer	 TALENs	 (between	 15	 to	 19	 repeats)	 to	 achieve	 significantly	 increased	specificity	 (Rinaldi	et	al.,	2017).	TALEs	also	appears	closely	related	 to	sequence	or	chromatin	contexts	like	DNA	methylation	(Chen	et	al.,	2013;	Cong	et	al.,	2012).	Using	a	different	TALE	repeat	N*	with	no	extensive	 involvement	 into	DNA	major	groove,	TALEN	 can	 successfully	 disrupt	 endogenous	 methylated	 XPC1	 in	 HEK293H	 cells	(Valton	et	al.,	2012).	Above	all,	TALEs	also	obsess	off-target	effect	 like	ZFs,	and	 its	DNA	context	sensitivity	may	affect	targeting	efficiency.		Compare	 to	 ZFs,	 the	 modular	 assembly	 of	 TALEs	 improves	 the	 rapidity	 and	simplicity	of	design	and	production.	However,	the	resulting	TALEs	DNA	sequence	is	highly	 repetitive,	 which	 promotes	 deletion	 and	 recombination	 when	 propagating	them	in	bacteria	and	after	viral	delivery	(Holkers	et	al.,	2013).				
1.3	Catalytic	dead	CRISPR-associated	(dCas9)	
1.3.1	Discovery,	working	mechanism	and	design	CRISPR-Cas9	has	been	developed	into	a	widely	used	genome	engineering	tool	in	the	last	five	years.	Nakata	and	colleagues	first	discovered	it	in	1987,	but	it	was	not	
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extensively	used	until	it	was	shown	to	be	an	RNA-targeted	nuclease	that	its	genome	editing	 potential	 was	 uncovered	 (Ishino	 et	 al.,	 1987;	 Jinek	 et	 al.,	 2012).	 This	 was	quickly	 followed	 by	 genome	 editing	 in	 mammals	 (Cong	 et	 al.,	 2013;	 Mali	 et	 al.,	2013a).	 Cas9	 is	 guided	 by	 a	 noncoding	 trans-activating	 crRNA	 (tracrRNA)	 and	mature	 crRNA	 to	 target	 DNA	 and	 perform	 cleavage.	 This	 is	 dramatically	 different	from	 the	 protein-DNA	 recognition	mechanisms	 of	 ZFs	 and	 TALEs.	 CRISPR-Cas9	 is	widely	applicable	in	different	models	including	yeast	(Jacobs	et	al.,	2014),	zebrafish	(Chang	et	al.,	2013;	Hruscha	et	al.,	2013;	Hwang	et	al.,	2013),	Drosophila,	mice,	and	human	(Cho	et	al.,	2013).	This	efficient	and	versatile	nuclease	can	be	turned	into	a	targeting	 system	 thanks	 to	 4	 point	mutations	 that	 inactivate	 the	 nuclease	 domain	without	 affecting	 the	 efficiency	 of	 targeting	 (dCas9)	 (Jinek	 et	 al.,	 2012;	 Qi	 et	 al.,	2013)(Qi	 et	 al.,	 2013).	 Protospacer	 adjacent	 motifs	 (PAMs)	 are	 short	 sequences	adjacent	 to	 protospacer,	 and	 they	 have	 shown	 to	 be	 critical	 for	 Cas9	 spacer	acquisition	 and	 interference	 (Mojica	 et	 al.,	 2009;	 Shah	 et	 al.,	 2013).	 Further	understanding	 about	 Protospacer	 Adjacent	 Motif	 (PAM)	 and	 single	 guide	 RNA	development	 make	 CRISPR-Cas9	 system	 efficiently	 designed	 for	 any	 target	 DNA	sequence	for	engineering.		
1.3.2	dCas9	in	gene	activation	CRISPR-Cas9	 based	 targeting	 systems	 have	 become	 the	 standard	 tool	 for	altering	gene	expression	 (Braun	et	al.,	2017;	Hilton	et	al.,	2015;	Kwon	et	al.,	2017;	Maeder	et	al.,	2013b;	Mali	et	al.,	2013b;	Morita	et	al.,	2016,	2016;	Perez-Pinera	et	al.,	2013b;	Vojta	et	al.,	2016).	Synthetic	transcriptional	activator	VP16	or	VP64	fused	to	catalytic	 dead	 Cas9	 has	 moderate	 gene	 activation	 capabilities	 with	 one	 sgRNA	guidance.	Using	multiple	sgRNAs	can	 further	 increase	activation	rates	(Konermann	et	 al.,	 2013;	 Maeder	 et	 al.,	 2013b;	 Mali	 et	 al.,	 2013b;	 Perez-Pinera	 et	 al.,	 2013b).	Epigenome	editing	using	a	fusion	between	dCas9	and	the	histone	methyltransferase	PRDM9	 increased	 H3K4me3	 and	 intercellular	 adhesion	 molecule	 1	 (ICAM1),	 Pas	association	 domain-containing	 protein	 1	 (RASSF1a)	 and	 epithelial	 cell	 adhesion	molecule	(EpCAM)	gene	expression	in	HEK293T	and	A549	cells	(Cano-Rodriguez	et	al.,	2016).	This	report	also	indicates	the	importance	of	local	chromatin	modifications	in	 altering	 gene	 expression.	 Ten-eleven	 translocation	 dioxygenases	 (TET)	 acts	 as	DNA	demethylase	also	showed	gene	activation	ability	in	conjunction	with	dCas9	(Liu	
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et	 al.,	 2016;	 Morita	 et	 al.,	 2016).	 dCas9-TET1	 fusion	 targeting	 endogenous	hypermethylated	BDNF	 gene	promoter	and	MyoD	 enhancer	 showed	demethylation	and	 gene	 activation	 in	 neurons	 and	myoblast	 respectively	 (Liu	 et	 al.,	 2016).	Using	two	 copies	 of	 bacteriophage	MS2	RNA	 elements	 as	 a	 linker	 for	 the	 TET1	 catalytic	domain	 (TET-CD)	 with	 sgRNA,	 dCas9-TET-CD	 and	 sgRNA-MS2-TET-CD	 can	significantly	 upregulate	 transcription	 in	 RANKL,	 MAGEB2	 and	 MMP2	 gene	 in	HEK293FT	and	HeLa	cells	(Xu	et	al.,	2016).	SunTag	was	reported	in	2014	which	is	a	ten	 copies	 repeating	 GCN4	 peptide	 array	 for	 recruiting	 multiple	 proteins	 by	 an	antibody	 (Tanenbaum	 et	 al.,	 2014).	With	 amplification	 effect	 by	 SunTag	 inclusion,	dCas9-TET1-CD	can	efficiently	demethylate	7	out	of	9	loci	in	ESCs,	cancer	cell	lines,	primary	neural	precursor	cells	and	mouse	 fetuses	(Morita	et	al.,	2016).	One	recent	publication	 using	 dCas9	 fused	 to	 Tet1	 successfully	 reversed	 the	 hypermethylation	within	 CGG	 repeats	 and	 the	 upstream	 promoter	 region	 of	 Fragile	 X	 syndrome	induced	Pluripotent	Stem	Cells	(iPSCs)	and	the	derived	neurons	(Figure	II.2,	Liu	et	al.,	2018).	This	correction	of	the	chromatin	state	accompanied	by	increases	of	the	FMR1	mRNA	 and	 FMRP	 upregulation	 in	 iPSC	 and	 transgenic	 mice	 as	 well	 as	electrophysiological	 abnormalities	 rescue	 by	 MEA	 assays	 in	 editing	 FXS	 neurons.	Interestingly,	the	acetyltransferase	domain	of	P300	works	more	efficiently	than	V64	to	 activate	 genes,	 and	 this	 gene	 upregulation	 ability	 bias	 only	 exists	 in	 dCas9	epigenetic	 engineering,	 not	 ZFs	nor	TALEs	 (Hilton	et	 al.,	 2015).	On	the	one	hand,	it	showed	that	histone	 acetylation	 is	 sufficient	to	activate	gene	transcription,	at	least	 in	 the	 loci	 IL1RN,	 MYOD	and	 OCT4	 in	 HEK293T	 cells	Hilton	and	colleagues	looked	at.	On	 the	 other	 hand,	 this	 also	indicates	 different	 epigenome	engineering	 tools	 have	 a	variable	 binding	 affinity	 or	
Figure II. 2. dCas9-Tet1 reactivates FMR1 gene expression. Tet1 driven by dCas9 
reverses hypermethylation in FMR1 gene and reactivates transcription in FXS iPSC. 
The FMR1 gene reactivation remains in iPSC derived FXS neuron and in vivo. 
(Derived from Liu	et	al.,	2018)	
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protein	folding	properties.	Above	all,	dCas9	can	be	used	as	an	epigenome	editing	tool	to	activate	gene	expression.		
	
1.3.3	dCas9	in	gene	silencing	dCas9	 can	 induce	 gene	 silencing	 without	 the	 help	 of	 any	 transcriptional	repressor	 in	 some	 circumstances	 due	 to	 steric	 hindrance	 (Qi	 et	 al.,	 2013).	 More	efficient	 silencing	 is	 the	 use	 of	 dCas9	 fusion	 proteins	 linked	 to	 KRAB	 or	 Mxi1,	 a	mammalian	 transcriptional	 repressor	 domain	 (Gilbert	 et	 al.,	 2013).	 CTCF	 DNA	recognition	 site	 can	 be	 methylated	 by	 dCas9	 linked	 to	 the	 de	 novo	 DNA	methyltransferase	3a	(DNMT3a)	and	further	blocked	CTCF	binding	(Liu	et	al.,	2016).	The	 SunTag-mediated	 oligomerization	 strategy	 was	 applied	 to	 dCas9-DNMT3a	 in	HEK293T	 with	 equal	 success	 (Huang	 et	 al.,	 2017).	 Unlike	 transient	 transcription	alternation	 as	 reported	 for	 KRAB,	 dCas9-DNMT3a	 can	 achieve	 long-term	 gene	silencing	 to	 25	 days	 in	 K-562	 (Amabile	 et	 al.,	 2016)	 and	 23	 days	 in	HEK293	 cells	(Vojta	et	al.,	2016).	Using	a	different	effector,	histone	deacetylase	3	(HDAC3),	dCas9	could	increase	or	decrease	the	expression	of	target	genes	in	murine	neuroblastoma	cell	 line,	 N2a	 (Kwon	 et	 al.,	 2017).	 The	 authors	 proposed	 that	 this	 be	 due	 to	 the	chromatin	context.	All	of	those	indicate	dCas9	can	be	used	to	manipulate	chromatin	structure	and	gene	silencing	by	fusing	to	chromatin	modifying	enzymes.		
1.3.4	Cas9	in	clinical	trial	and	limitation	The	 primary	 concern	 for	 translational	 application	 is	 the	 same	 as	 for	 the	 ZFs	and	TALEs:	the	off-target	effects.		sgRNAs	can	bind	genomic	locations	with	multiple	mismatches	 and	 often	 require	 delicate	 screening	 and	 optimization.	 Several	 trials	focusing	on	 targeting	 sequence	optimization	of	 the	 sgRNA,	and	modification	of	 the	Cas9	enzyme	to	better	bind	the	sgRNA	or	to	alter	PAM	requirements	as	well	as	the	use	of	Cas9	variants	or	nickase	variants	have	been	shown	to	reduce	off-target	effects	(Doench	et	al.,	2014,	2016;	Hruscha	et	al.,	2013;	Hsu	et	al.,	2013;	Kleinstiver	et	al.,	2015,	 2016;	 Mali	 et	 al.,	 2013b;	 Slaymaker	 et	 al.,	 2016).	 	 With	 the	 benefit	 of	convenient	 design	 to	 virtually	 any	 locus	 of	 interest,	 Cas9-derived	 genome	 editing	and	epigenome	engineering	has	exciting	potential	for	novel	therapeutic	approaches	in	cancers	and	neurodegenerative	diseases	(Cinesi	et	al.,	2016;	Gori	et	al.,	2015;	Kick	
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et	al.,	2017;	Lin	et	al.;	Liu	et	al.;	Long	et	al.,	2014;	Niu	et	al.,	2014;	Park	et	al.,	2015;	Pinto	et	al.,	2017).				All	the	clinical	trials,	for	now,	are	nuclease	version	Cas9,	not	the	dCas9.	Clinical	studies	using	Cas9-mediated	gene	editing	to	target	several	types	of	cancer	have	been	initiated	 in	 China,	 including	 HPV-related	 Cervical	 intraepithelial	 Neoplasial,	Leukemia	 and	Lymphoma	 (Baylis	 and	McLeod,	 2017;	Kick	 et	 al.,	 2017).	 It	 is	 likely	that	 Cas9-mediated	 treatment	 of	 two	 types	 of	 blood	 disorders,	 β-thalassemia	 and	sickle	cell	disease,	may	start	 their	clinical	 trials	 this	year	 in	Europe	and	the	United	States	(Baylis	and	McLeod,	2017).	 It	 is	still	early	to	speculate	the	outcome	of	 these	trials.	 If	Cas9	proved	to	be	efficient	and	safe	 to	apply,	 it	would	give	hope	to	cure	a	wide	range	of	devastating	diseases.		In	 conclusion,	 epigenome	 editing	 tools	 have	 been	widely	 involved	 in	 driving	chromatin	 modifying	 enzymes	 to	 specific	 genomic	 loci	 for	 gene	 regulation.	 These	targeting	tools	provide	a	convenient	way	to	tackle	the	interplay	between	chromatin	structure	and	gene	regulation	and	make	it	possible	to	manipulate	epigenome	at	will.		Thus	 far,	 the	majority	 of	 the	 studies	 use	 a	 continuous	 expression	 of	 the	 ZFs,	TALEs,	or	dCas9	 fusions.	 It	 is	 therefore	unclear	how	permanent	 the	changes	to	 the	epigenome	might	be.	The	key	 is	 to	use	 reversible	 systems,	 such	 as	many	 chemical	induced	and	light-induced	proximity	systems.		
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2.	Chemical	and	light-induced	proximity	system	
	To	gain	a	better	understanding	and	 to	manipulate	gene	expression,	 	multiple	approaches	 have	 been	 developed	 to	 control	 cell	 in	 a	 switchable	 way	 like	 light	inducible	proximity	(LIP)	and	chemical	inducible	proximity	(CIP).	The	systems	that	have	 been	 developed	 to	 alter	 gene	 expression	 are	 listed	 in	 Table	 I.1	 and	 I.2.	Invariably,	 they	 are	 composed	of	 two	 same	or	different	 components	 that	dimerize	with	 each	 other	 upon	 addition	 of	 a	 small	 molecule	 or	 by	 the	 light	 of	 a	 specific	wavelength.	 One	 component	 binds	 chromatin,	 and	 the	 other	 is	 fused	 to	 some	transcriptional	activator	or	repressor.		Light	induction	for	protein-protein	interactions	was	developed	within	the	past	ten	years	with	different	systems	using	different	wavelengths	of	light	(Kennedy	et	al.,	2010;	Levskaya	 et	 al.,	 2009;	Yazawa	et	 al.,	 2009).	The	Zhang	group	 further	 adapts	light	induced	dimerization	into	transcription	control	usage	with	TALEs	DNA	binding	motif	 fusion	 (Konermann	 et	 al.,	 2013).	 In	 Gao	 et	 al.,	 they	 compared	 the	transcriptional	 efficiency	 of	 LIP	 and	 CIP	 systems	 side	 by	 side	 and	 found	 that	 LIP	systems	 are	 less	 potent	 than	 CIP	 ones	 in	 activating	 transcription,	 reaching	 a	maximum	induction	of	126	fold	(Gao	et	al.,	2016).		CIP	 systems	 have	 been	 used	 widely	 to	 study	 transcriptional	 activation,	signaling	 transduction,	 protein-protein	 interactions,	 apoptosis,	 glycosylation,	splicing,	and	mouse	development	(Belshawl	et	al.,	1996;	Graef	et	al.,	1997;	Gruber	et	al.,	2006;	Ho	et	al.,	1996;	Holsinger	et	al.,	1995;	Kohler	and	Bertozzi,	2003;	Liu	et	al.,	2007;	 Mootz	 and	 Muir,	 2002;	 Stankunas	 et	 al.,	 2003;	 Stanton	 et	 al.,	 2018).	 The	original	 CIP	 system	 is	 the	 FK1012	 system	 (Holsinger	 et	 al.,	 1995;	 Spencer	 et	 al.,	1993).	It	involves	the	chemical	inducer	FK1012	with	two	ligand-binding	domains	of	FKBP12	 (Holsinger	 et	 al.,	 1995).	More	 recently,	 Zhang	 and	 colleagues	 produced	 a	split	Cas9	and	dCas9	 constructs	 fused	 to	FKBP	 (FK506	binding	protein)	 and	FKBP	rapamycin	 binding	 (FRB)	 domains	 and	 the	 addition	 of	 rapamycin-induced	 the	dimerization	of	a	protein	of	 interest	(POI)	 fused	to	FRB	(Zetsche	et	al.,	2015).	This	reconstruction	of	Cas9	functioned	as	a	normal	Cas9	and	enabled	the	experimenters	
	 27	
to	 restrict	 the	 activity	 to	 specific	 tissues	 by	 putting	 each	 fragment	 under	 different	tissue-specific	promoter	while	maintaining	a	low	off-target	rate.	Further	results	from	Qi	and	colleagues	showed	that	multiple	CIP	systems	could	be	combined	and	used	for	programming	 complex	 transcription	 in	 vitro	 and	 in	 vivo	 (Gao	 et	 al.,	 2016).	 Taking	advantage	 of	 the	 reversible	 properties	 of	 Frb-FKBP-Rap	 and	 Pyl1-Abi1-ABA,	targeting	 a	 truncation	 of	 heterochromatin	 protein	 1	 alpha	 (HP1α)	 to	Oct4	 in	 ESC	induced	H3K9me3-dependent	 gene	 silencing.	 This	 silencing	 remained	 for	multiple	cell	generations	after	HP1α	targeting	was	relieved	(Hathaway	et	al.,	2012).	A	recent	study	 using	 FKBP-FrB-Rap	 system	 linked	 to	 dCas9	 led	 to	 the	 recruitment	 of	mSWI/SNF	 (BAF)	 and	 activated	 bivalent	 gene	 transcription	 in	 mouse	 ESCs	 in	 a	reversible	way	(Braun	et	al.,	2017).	Frb-FKBP	dimerized	dCas9	with	HP1	and	histone	methyltransferase	 Suv39h1	 induced	 H3K9me3	 deposit,	 and	 the	 effect	 can	 be	reversed	 by	 washing	 out	 inducer	 rapamycin	 (Braun	 et	 al.,	 2017).	 As	 a	 potent	immunosuppressant,	 Rap	 inhibits	 mammalian	 target	 of	 Rap,	 mTOR,	 and	 showed	toxicity	 in	 the	 beta	 cell	 (Barlow	 et	 al.,	 2012,	 2013).	 The	 Crabtree	 lab	 developed	another	 CIP	 system	 based	 on	 abscisic	 acid	 (ABA),	 a	 phytohormone	 (Liang	 et	 al.,	2011).	ABA	 insensitive	1	 (ABI)	 can	 form	a	dimer	with	pyrabactin	 resistance	1-like	(PYL)	 in	 the	presence	of	ABA	 into	 the	cell	medium.	Here	again,	 the	dimerization	 is	reversible.	 It	 is	 non-toxic,	 and	 ABA	 is	 reasonably	 prized.	 Also,	 it	 is	 an	 entirely	exogenous	system,	reducing	the	potential	for	side	effects	in	mammalian	cells.		CIP	system	has	been	used	to	build	a	safety	switch	for	adoptive	cell	therapy	(Di	Stasi	 et	 al.,	 2011).	Human	caspase	9	 fused	 to	FK-binding	protein	became	active	by	adding	 AP1903	 in	 T	 cells	 with	 haploidentical	 stem-cell	 transplants	 patients.	 This	iCasp9	suicide	system	improved	cellular	therapies	safety	in	graft-versus-host	disease.	This	being	said,	the	spatiotemporal	characteristic	of	CIP	system	may	have	significant	benefit	for	understanding	cellular	functions	and	even	for	clinical	usage.		In	conclusion,	with	its	power	for	spatiotemporal	control	of	cellular	processes,	CIP	and	LIP	systems	may	contribute	significantly	to	the	study	of	chromatin	structure	and	gene	regulation.	To	take	one	step	further,	it	could	be	interesting	to	apply	the	CIP	system	to	one	type	of	human	diseases	to	investigate	their	molecular	mechanisms.	
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Table	I.1.	Chemical-induced	proximity	system	comparison		 Proteins	 Ligands	 Toxicity	 Receptors	in	human	
FKBP	 FRB	 Rapamycin	 Immunosuppression	(Kang	et	al.,	2008)	 mammalian	target	of	rapamycin	(mTOR)	(Kang	et	al.,	2008)	FKBP	 FKBP	 FK1012	
Immunosuppression	(Kang	et	al.,	2008)	 CaM-dependent	phosphatase	calcineurin	(CaN)	(Kang	et	al.,	2008)	
FKBP	 Calcineurin	 FK506	
FKBP	 CyP	 FKCsA	
Calcineurin	 CyP	 Cyclosporine	A	 Immunosuppression	(Kang	et	al.,	2008)	
PYL	 ABI1	 Abscisic	Acid	 Non-toxic	for	human	(Liang	et	al.,	2011)	Organ	toxicity	in	rat	(Celik	et	al.,	2007)	 No	report	GID1	 GA1	 GA	
Organ	toxicity	in	rat	(Celik	et	al.,	2007)	Teratogenic	to	Xenopus	laevis	embryos	(Boga	(Pekmezekmek	et	al.,	2009)	Gibberellin3-AM	
FKBP	F36V	 FKBP	F36V	 AP1903	 Pancytopenia	(Zhou	et	al.,	2016)	 FKBP	AP20187	 Non-toxic	(Je	et	al.,	2009)	
IAA17	 TIR1	 Auxin	 Non-toxic	(Ester	et	al.,	2009)	 No	report			 	
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Table	I.2.	Light-induced	proximity	system	comparison		 Proteins	 Ligands	 Toxicity	 Receptors	in	human	
GI	 FKF1	 450nm	blue	light	(Yazawa	et	al.,	2009)	
No	report	 No	report	CIB1	 CRY2	
488nm	blue	light	(Kennedy	et	al.,	2010)	
PhyB	 PIF3	
650nm	red	light	(Levskaya	et	al.,	2009)	750nm	red	light	(Levskaya	et	al.,	2009)					
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3.	Potential	applications	-	Trinucleotide	repeat	diseases	
	 Tandem	 repeats	 are	 common	 in	 genomes	 from	 yeast	 to	 human.	 At	 least	 20	neurological	diseases	are	caused	by	trinucleotide	repeat	(TNR)	expansion	(Table	I.3).	Since	 the	 first	 report	 of	 a	 CGG/CCG	 repeat	 expansion	 causing	 Fragile	 X	 syndrome	(FXS)	(Oberlé	et	al.,	1991;	Verkerk	et	al.,	1991),	 it	has	been	shown	that	Huntington	Disease	(HD),	Myotonic	Dystrophy	Type	1	(DM1)	and	Friedreich’s	ataxia	(FRDA)	are	due	to	CAG,	CTG,	and	GAA	expansions,	respectively	(Brook	et	al.,	1992;	Campuzano	et	al.,	1996;	MacDonald	et	al.,	1993).	Decades	of	research	focus	on	understanding	the	molecular	 mechanisms	 by	 which	 trinucleotide	 repeats	 cause	 the	 diseases.	 These	diseases	 are	 caused	 by	 the	 expression	 of	 a	 toxic	 RNA	 and/or	 a	 toxic	 protein.	Therefore,	 preventing	 their	 expression,	 for	 example	 by	 manipulating	 gene	expression,	 or	 by	 reducing	 repeat	 sizes	 may	 be	 suitable	 therapeutic	 avenues.	Currently,	the	knowledge	of	these	phenomena	is	not	well	characterized	and	prevents	the	rational	development	of	effective	treatments.	
Table I.3. Neurological disease caused by TNR expansion 
Disease name repeats Repeat location 
Huntington disease (HD) CAG Exon 
Spinocerebellar ataxia 1 (SCA1) CAG Exon 
Spinocerebellar ataxia 2 (SCA2) CAG Exon 
Spinocerebellar ataxia 3 (SCA3) CAG Exon 
Spinocerebellar ataxia 6 (SCA6) CAG Exon 
Spinocerebellar ataxia 7 (SCA7) CAG Exon 
Spinocerebellar ataxia 12 (SCA12) CAG 5’-UTR 
Spinocerebellar ataxia 17 (SCA17) CAG Exon 
Spinal and bulbar muscular atrophy (SBMA) CAG Exon 
Dentatorubral–pallidoluysian atrophy (DRPLA) CAG Exon 
Huntington disease-like 2 (HDL2) CTG 3’-UTR 
Spinocerebellar ataxia 8 (SCA8) CTG 3’-UTR 
Myotonic dystrophy 1 (DM1) CTG 3’-UTR 
Fuchs endothelial corneal dystrophy (FECD) CTG Intron 
Fragile X syndrome (FXS) CGG 5’-UTR 
Fragile X–associated tremor/ataxia syndrome (FXTAS) CGG 5’-UTR 
Fragile X–associated primary ovarian insufficiency (FXPOI) CGG 5’-UTR 
FRA7A CGG Intron 
Fragile XE mental retardation syndrome (FRAXE MR) GCC 5’-UTR 
Friedreich’s ataxia GAA Intron 
Data were obtained from (Dion and Wilson, 2009; Mirkin, 2007; Schmidt and Pearson, 
2016; Zhao and Usdin, 2015) 
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3.1	Mechanism	of	repeat	instability	
3.1.1	Trinucleotide	repeats	form	a	non-B	structure	that	causes	instability	Expanded	TNRs	are	unstable.	Below	35	units,	the	repeats	loci	tend	to	be	stable,	which	would	not	cause	disease.	However,	once	the	numbers	of	repeat	units	reach	35,	the	TNR	expansion	derived	neurological	disease	appears	(Castel	et	al.,	2010).	Worse	still,	 longer	 repeats	 cause	 more	 severe	 phenotypes	 and	 passing	 down	 unstable	expanded	repeats	 to	 the	offspring	causes	a	more	severe	disease	phenotype	and	an	earlier	 age	 of	 onset,	 a	 phenomenon	 coined	 anticipation	 (McMurray,	 2010;	Mirkin,	2007).	
	The	 subset	 of	 trinucleotide	 repeats	 can	 form	 aberrant	 secondary	 DNA	structures	 during	 transcription,	 DNA	 repair,	 and	 translation	 (Castel	 et	 al.,	 2010;	Mirkin,	2007).	The	structures	include	mismatched	hairpins,	slipped-strands,	R-loops,	G-quadruplex,	et	al.	(Mirkin,	2007;	Usdin	et	al.,	2015).	The	current	models	stipulate	that	the	DNA	repair	machinery	recognize	these	non-B	structures	as	DNA	lesions	and	initiate	repair.	The	repetitive	nature	of	the	sequences,	as	well	as	their	ability	to	form	non-B	DNA	structure,	make	the	repair	error-prone,	leading	to	instability.	One	of	the	first	observation	of	non-B	DNA	structures	formed	by	CAG/CTG	repeats	was	done	in	
vitro	 using	 chemical	 probing	 (Kohwi	 et	 al.,	 1993).	 They	 showed	 that	 even	 a	 single	AGC	 could	 form	 unusual	 DNA	 structures	 independently	 of	 flanking	 sequences.	Another	milestone	 occurred	when	McMurray	 and	 colleagues	 in	 1995	 showed	 that	CAG/CTG	and	CGG/CCG	repeats	could	 form	hairpins	 in	vitro	 in	a	 length-dependent	and	 sequence-specific	 manner	 (Gacy	 et	 al.,	 1995).	 Melting	 temperature	 profiles	revealed	that	CAG,	CGG	and	AT	repeats	could	form	stable	hairpins,	but	AAG	and	AC	cannot.	 In	vivo	evidence	came	first	 in	2010	from	the	Leffak	 lab.	They	used	 isogenic	HeLa	cells	with	CAG/CTG	multiple	repeats	 inserted	after	the	Myc	replication	origin	to	 uncover	 hairpins	 formation	 in	 102	 CAG/CTG	 repeats	 cells.	 Using	 ZFNCTG	 and	ZFNCAG,	secondary	structure	formed	cell	 lines	would	be	cleaved	and	showed	repeat	length	 change	 by	 small	 pool	 PCR	 (SP-PCR).	 Liu	 and	 colleagues	 revealed	 102	CAG/CTG	repeats	cells	formed	hairpins	but	hardly	in	12	repeats	counterpart	(Liu	et	al.,	 2010).	Moreover,	Axford	et	 al.	 showed	 that	 they	 could	precipitate	 slipped	DNA	from	 the	 expanded	 repeat	 locus	 in	 DM1	 patient-derived	 lymphoblastoid	 cell	 lines	
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(Axford	 et	 al.,	 2013).	 Similar	 hairpin	 forming	 feature	 with	 CGG	 repeat	 was	 also	observed	in	vitro	(Nadel	et	al.,	1995;	Usdin	and	Woodford,	1995).			Slipped-strand	 DNA	 (S-DNA)	 is	 also	 extensively	 studied.	 Using	 electron	microscopy	 as	 well	 as	 chemical	 and	 enzymatic	 probing	 followed	 by	 gel	electrophoresis,	slipped	strands	are	readily	visible	under	microscopy	(Pearson	et	al.,	1998,	 2002).	 R-loops	 are	 DNA:	 RNA	 hybrids	 formed	 during	 transcription.	 They	preferentially	form	at	GC	rich	sequences,	including	CAG	and	CGG	repeats	(Lin	et	al.,	2010;	Loomis	et	al.,	2014;	Reddy	et	al.,	2011,	2014).	This	structure	also	depends	on	sequence	 context	 since	 R-loops	 are	 not	 detected	 when	 AGG	 or	 AAG	 repeats	 are	studied.			
3.1.2	DNA	repair	is	involved	in	TNR	instability	through	processing	of	the	non-B	
structure	Multiple	 lines	 of	 evidence	 show	 that	 virtually	 all	 DNA	 repair	 pathways	influence	 trinucleotide	 repeat	 instability.	 The	 involvement	 of	 mismatch	 repair	(MMR),	 nucleotide	 excision	 repair	 (NER),	 and	 base	 excision	 repair	 (BER)	 has	 a	particularly	important	function	in	this	process.		
Mismatch	Repair	(MMR)	The	 primary	 substrates	 for	 the	 mismatch	 repair	 machinery	 are	 base	mismatches	and	small	DNA	loops	that	lead	to	insertion	and	deletions	(INDLs).	They	are	typically	formed	during	DNA	replication	(Kunkel	and	Erie,	2005).	Depending	on	whether	the	lesions	are	single	base	mismatches	or	loops	of	mismatched	DNA,	MMR	complexes	MutSα	 (composed	 of	 MSH2/MSH6)	 or	MutSβ	 (MSH2/MSH3)	 are	 called	into	play	respectively	to	recognize	and	bind	the	bases	and	then	recruit	MutL	proteins	to	 repair	 the	 mismatches	 with	 the	 collaboration	 of	 several	 other	 enzymes.	 The	primary	 procedure	 follows	 from	 recognition,	 intermediate	 binding,	 excision,	amplification	and	DNA	ligation.	Both	MutSα	and	MutSβ	complexes	with	components	involved	in	MutL	indicate	the	role	to	destabilize	CAG/CTG	repeats	from	E.coli,	yeast	to	HD	and	DM1	mouse	models	(Broek	et	al.,	2002;	Dandelot	and	Tomé,	2017;	Foiry	et	al.,	2006;	Jaworski	et	al.,	1995;	Manley	et	al.,	1999;	Pinto	et	al.,	2013;	Schmidt	and	Pearson,	2016;	Schweitzer	and	Livingston,	1997;	Tomé	et	al.,	2009,	2013).		
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Nucleotide	Excision	Repair	(NER)	NER	can	be	divided	into	two	sub-pathways:	transcription-coupled	repair	(TCR)	in	 transcriptionally	 active	 regions	 and	 global	 genomic	 repair	 (GGR)	 that	 can	 take	care	 of	 lesions	 in	 both	 silent	 and	 active	 loci	 (Hanawalt,	 2002).	 GGR	 proteins	 are	typically	maintained	in	a	relatively	low	abundance	(Usdin	et	al.,	2015).		In	contrast,	TCR	targets	lesions	in	the	transcribed	strands	of	genes.	The	repair	process	also	starts	with	 the	 recognition	 of	 the	 lesion,	 which	 is	 different	 between	 the	 TCR	 and	 GGR	pathways,	but	they	both	merge	at	the	level	of	TFIIH	recruitment.	The	lesion	is	then	excised,	 creating	a	DNA	gap	 that	 is	 then	 filled	 in	by	a	polymerase	and	 ligated.	The	NER	pathway	has	significant	impacts	on	repeat	instability	both	in	vivo	and	in	cells.	For	 example,	 Xpa	 knockout	 mice	 carrying	 145	 CAGs	 at	 the	 SCA1	 locus	 showed	dramatically	 reduced	 levels	of	 instability	 in	neuronal	 tissues,	but	not	 in	peripheral	organs	compared	to	Xpa+/+	mice	(Hubert	et	al.,	2011).	Besides,	RNAi	knockdown	of	XPA	 reduced	 high	 contraction	 frequencies	 in	 human	 cells	 (Lin	 et	 al.,	 2006).	Moreover,	 Lin	 et	 al.	 found	 that	 the	NER	and	MMR	pathway	 components	 appear	 to	crosstalk	 to	 cause	 contractions	 during	 a	 transcription-coupled	 NER-like	 reaction	(Lin	 et	 al.,	 2006).	 The	 same	 is	 true	 if	 ERCC1	 or	 XPG	 are	 knocked	 down	 (Lin	 and	Wilson,	 2007).	 	 RNAi	 knockdown	 of	 CSB,	 which	 recognizes	 the	 stalled	 DNA	polymerase	that	triggers	TCR,	in	human	cells	also	decreased	contraction	frequencies	(Lin	 and	 Wilson,	 2007).	 By	 contrast,	 knockdown	 of	 XPC	 in	 these	 cells	 (Lin	 and	Wilson,	 2007)	 or	 knockout	 of	 Xpc	 in	 an	 HD	 mouse	 model	 did	 not	 affect	 repeat	instability	(Dragileva	et	al.,	2009).	These	results	implicate	the	TCR	pathway	in	repeat	instability	and	suggest	that	GGR	has	only	a	minor	role	if	any.			
Base	Excision	Repair	(BER)	Base	excision	repair	(BER)	is	the	primary	pathway	that	repairs	oxidized	bases	(Banerjee	et	al.,	2011;	Zharkov,	2008).	Loss	of	OGG1,	a	glycosylase	that	excises	the	common	oxidized	base	8-oxoguanine,	decreased	somatic	expansions	in	a	transgenic	HD	mouse	model	 (Kovtun	et	al.,	2007).	This	presumably	worked	by	 increasing	 the	repair	 rates	 within	 the	 repeat	 tract.	 Moreover,	 oxidative	 stress	 induced	 by	 H2O2	treatment	 in	 human	 HD	 fibroblasts	 resulted	 in	 an	 MSH2	 enrichment	 at	 the	 CAG	repeats	 (Kovtun	 et	 al.,	 2004).	 These	 results	 indicate	 that	MMR	 and	BER	pathways	show	crosstalk	during	TNR	instability.	
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3.2	TNR	expansion	affects	chromatin	structure	and	gene	expression	One	intriguing	observation	 is	 that	changes	 in	chromatin	structure	accompany	repeat	expansion	through	mechanisms	that	remain	unclear	(Dion	and	Wilson,	2009).	Specifically,	 expansions	 tend	 to	 acquire	 heterochromatic	 marks.	 The	 first	correlations	between	long	trinucleotide	repeat	and	heterochromatic-like	chromatin	marks	were	observed	in	FXS	(Hornstra	et	al.,	1993;	Oberlé	et	al.,	1991;	Sutcliffe	et	al.,	1992).	 	Indeed,	in	FXS	patient	cells,	the	FMR1	gene	is	abnormally	methylated	at	the	DNA	 level,	 which	 is	 thought	 to	 silence	 the	 gene.	 This	 is	 not	 seen	 in	 healthy	individuals.	Meanwhile,	the	hypermethylation	in	the	FMR1	promoter	in	male	patient	cells	was	even	more	significant	than	that	observed	in	the	inactive	X	of	normal	female	cells	 (Stöger	 et	 al.,	 1997).	 ChIP	 experiments	 in	 FXS	 patient	 cells	 showed	 the	accumulation	 of	 H3K9	 methylation,	 a	 heterochromatic	 mark,	 together	 with	 a	decrease	 in	 euchromatic	 histone	marks	 H3K4me	 and	 H3K4ac	 (Coffee	 et	 al.,	 1999,	2002).	 As	 predicted	 by	 the	model	whereby	 chromatin	 structure	 changes	 decrease	FMR1	 expression,	 reversal	 of	 this	 heterochromatic	 state	 using	 histone	 deacetylase	and	DNA	methyltransferase	inhibitors	led	to	a	transient	reactivation	of	the	expanded	repeat.	(Abel	and	Zukin,	2008;	Biacsi	et	al.,	2008;	Didonna	and	Opal,	2015).			Heterochromatinization	 of	 expanded	 repeats	 is	 not	 only	 restricted	 to	 CGG	repeats.	In	DM1	patient	cells,	the	expanded	CTG	tract	is	associated	with	the	loss	of	a	DNase	 I	hypersensitive	site	 in	 the	nearby	promoter	 region	of	 the	SIX5	 gene	 (Otten	and	Tapscott,	1995).	Taking	advantage	of	methylation-sensitive	restriction	enzymes,	Steinbach	 et	 al.	 showed	 that	 abnormal	 CpG	methylation	 is	mapped	 in	 the	 flanking	sequence	 of	DMPK	 gene	 in	 DM1	 patients	 with	 the	 congenital	 form	 of	 the	 disease	(Steinbach	et	al.,	1998).	This	was	further	confirmed	by	deep	sequencing	of	bisulfite-treated	DNA	 (Barbé	 et	 al.,	 2017).	 Further	 observations	 show	 that	 in	DM1	patients	fibroblasts,	 the	 CTG	 expanded	 repeat	 region	 sees	 an	 increase	 in	 antisense	transcription,	loss	of	CTCF	binding,	decreased	H3K4	methylation,	and	an	increase	in	H3K9me	(Cho	et	al.,	2005).	Moreover,	 inserting	 arrays	 of	 CD2	 transgenes	 containing	 CTG	 or	 GAA	expansions	 in	 the	 mouse	 genome	 led	 to	 silencing	 independently	 of	 the	 site	 of	integration	 (Saveliev	 et	 al.,	 2003).	 By	 contrast,	 wild-type	 CD2	 transgene	 arrays	
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displayed	position-effect	variegation.	These	data	suggest	 that	expansions	cause	the	changes	in	chromatin	structure.		Similarly,	 FRDA	 cells	 show	 hypoacetylation	 of	 H3	 and	 H4	 and	 H3K9	hypermethylation	 (Herman	 et	 al.,	 2006a).	 Moreover,	 several	 different	 histone	deacetylase	inhibitors	could	revert	the	acetylation	loss	and	promote	FXN	expression	in	 FRDA	 derived	 cells	 (Herman	 et	 al.,	 2006a).	 FRDA	 patients	 lymphoblast	 also	underpinned	 three	 novel	 CpG	 methylations	 compare	 to	 non-affected	 patients	(Greene	et	al.,	2007).	One	of	the	three	sites	is	known	to	be	crucial	for	transcription	initiation.	 It	 provides	 further	 evidence	 that	 the	 triplet	 repeat	 is	 causing	heterochromatic	 structure	 influence	 not	 only	 transcription	 elongation	 but	 also	initiation	 (Greene	 et	 al.,	 2007).	 All	 of	 these	 tell	 us	 TNR	 tract	 can	 produce	 a	correlation	with	heterochromatic	structure	formation.		
3.3	TNR	disease	treatment	strategy	Until	now,	there	is	no	cure	for	any	of	the	expanded	repeat	diseases.	Palliative	treatments	 for	expanded	TNR	disorders	mainly	 focus	on	alleviating	 the	symptoms.	Importantly,	the	longer	the	trinucleotide	repeat	is,	the	earlier	the	age	of	onset.	This	was	noted	in	HD	patients	as	early	as	1993	(Andrew	et	al.,	1993;	Duyao	et	al.,	1993;	Lee	et	al.,	2012;	Stine	et	al.,	1993).	About	50%	variation	 in	the	age	of	onset	can	be	attributed	to	repeat	size	in	the	blood	(Holmans	et	al.,	2017).	The	rest	is	attributed	to	repeat	 interruptions	 (Goldberg	 et	 al.,	 1995),	 cis	 elements	 (Warby	 et	 al.,	 2009),	and/or	trans	acting	genetic	factors	(Genetic	Modifiers	of	Huntington’s	Disease	(GeM-HD)	Consortium,	 2015),	 all	 of	which	 could	 be	 acting	 via	 altering	 repeat	 expansion	rates.	This	association	between	age	of	onset	and	repeat	 length	 is	not	 limited	to	HD	but	has	also	been	 reported	 for	other	expanded	 repeat	disorders	 (Filla	et	 al.,	 1996;	Harley	et	al.,	1993;	Koide	et	al.,	1994;	Orr	et	al.,	1993).		 	However,	since	all	of	them	are	a	repeat-driven	problem,	would	that	be	more	effective	and	sufficient	to	focus	on	repeat	 itself?	 In	 another	 word,	 can	 removal	 of	 repeat	 expansion	 reverse	 disease	phenotype?		
3.3.1	Genome	editing	may	be	possible	to	provide	efficient	treatment	The	 most	 obvious	 approaches	 to	 reducing	 repeat	 size	 are	 either	 to	 induce	repeat	contractions	or	to	remove	the	track	altogether	using	gene	editing	tools.	The	
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Wilson	group	first	tried	this	with	ZFNs	recognizing	CAG/CTG	repeats	to	induce	DSBs.	They	 found	 that	 this	 treatment	 dramatically	 increased	 the	 frequencies	 of	contractions	 in	 a	 human	 cell	 line	 systems	 (Mittelman	 et	 al.,	 2009).	 It	was	 unclear	whether	the	cells	also	accumulated	expansions	because	the	assay	could	only	detect	contractions.	 Another	 approach	 used	 to	 contract	 the	 repeat	 tract	 in	 HD-derived	iPSCs	 was	 by	 homologous	 recombination	 using	 a	 donor	 DNA	with	 a	 short	 repeat	tract.	 Although	 the	 frequencies	 of	 correction	 were	 extremely	 low,	 corrected	 cells	showed	 improved	 cell	 survival	 and	 pathogenic	 HD	 signaling	 pathways	 recovery	(caspase	activity,	cadherin,	TGF-b,	and	BDNF).	Importantly,	the	corrected	cells	were	readily	 differentiated	 into	 neurons	 (An	 et	 al.,	 2012).	 These	 experiments	 open	 the	door	 to	a	cell-based	 therapy.	Our	 lab	has	shown	that	 targeting	 the	Cas9	nickase	 to	CAG	 repeats	 within	 a	 GFP	 reporter	 can	 induce	 contractions	 without	 a	 significant	increase	 in	 expansions	 (Cinesi	 et	 al.,	 2016).	 	 If	 targeting	 the	 Cas9	 nickase	 to	 CAG	repeats	 in	vivo	 can	also	 induce	a	bias	 towards	contraction,	 then	this	strategy	could	prove	to	be	useful	in	correcting	the	mutation	leading	to	these	devastating	diseases.		Another	possible	approach	of	correcting	expanded	TNRs	is	to	remove	the	TNR	region	 altogether.	 AAV	 virus-mediated	 Cas9,	 and	HTT	 exon1	 specific	 sgRNA	were	injected	 into	 HD140Q-KI	mice	 striatum	 at	 the	 age	 of	 3	 or	 9	months	 (Yang	 et	 al.).		They	 achieved	 permanent	 suppression	 of	 endogenous	mHTT	 expression	with	HTT	aggregates	 depletion	 and	 neuropathology	 recovery.	 A	 self-inactivating	 system,	KamiCas9,	 with	 an	 additional	 sgRNA	 to	 block	 Cas9	 translation,	 has	 been	 used	 to	suppress	mHTT	expression	and	reverse	aggregates	formation	in	Ki140CAG	HD	mice	(Merienne	et	al.,	2017).	To	tackle	the	mutated	HD	allele-specific	editing	goal,	6	SNPs	in	HTT	gene	promoter	regions	were	screened	and	applied	to	engineer	mHTT	exon	1	removal	altogether	specifically	but	not	in	normal	HTT	in	HD	patients	fibroblasts	and	Bac	HD	mice	which	 contains	modified	human	HD	allele	 and	SNPs.	Dabrowska	 and	colleagues	showed	to	use	Cas9	nickase	to	excise	all	the	CAG	repeats	from	HD	patient-derived	 fibroblasts	 can	 inactivate	 HTT	 expression	 in	 variable	 repeat	 length	 cells	(Dabrowska	et	al.,	2018).	Not	only	in	HD	system,	but	similar	Cas9	based	gene	editing	to	 repeat	 expansion	 also	 achieved	 expansion	 tract	 removal	 and	 pathological	recovery	 in	 myogenic	 capacity,	 nuclocytoplasmid	 distribution,	 RNA-binding	capability	in	DM1	patient-derived	myoblasts	cells	(van	Agtmaal	et	al.,	2017).	Taken	
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together,	 removing	 CAG/CTG	 repeats	 from	 HD	 and	 DM1	 locus	 showed	 promising	improvement	in	molecule	level	and	part	of	pathology	status.		Expanded	GAA	repeats	were	excised,	 rather	 than	contracted,	using	ZFNs	 that	flanked	 the	 expansion	 in	 FRDA	 patient	 fibroblasts	 and	 iPSC-derived	 neurons.	 The	GAA	 repeat	 in	 these	 patients	 is	 found	 within	 the	 intron	 of	 FRDA	 and	 leads	 to	silencing	 (Campuzano	 et	 al.,	 1996;	 Filla	 et	 al.,	 1996).	 Thus,	 excision	 of	 the	 repeat	region	 led	 to	 an	 increase	 in	 FRDA	 expression	 along	 with	 disease-associated	biomarkers	 normalization	 and	 aconitase	 activity	 and	 intracellular	 ATP	 levels	increase	 (Li	 et	 al.,	 2015).	 Ouellet	 and	 colleagues	 took	 advantage	 of	 Cas9	 to	 excise	GAA	repeat	expansion	from	FRDA	gene	and	increase	frataxin	gene	transcription	and	protein	level	in	YG8R	and	YG8sR	mouse	models	and	their	derived	cell	lines	(Ouellet	et	al.,	2017).		Taking	advantage	of	CRISPR/Cas9-based	gene	editing,	Park	et	al.	induced	a	DSB	within	the	expanded	CGG	repeat	of	FXS-derived	iPSCs.	In	those	clones	that	contained	a	 contraction,	 they	 saw	 an	 increase	 in	 the	 FMR1	 mRNA	 and	 the	 up-regulation	 of	FMRP.	 This	 was	 presumably	 due	 to	 the	 loss	 of	 heterochromatic	 marks	 in	 the	promoter	of	FMR1	(Park	et	al.,	2015).		Thus,	it	is	becoming	feasible	to	precisely	edit	the	repeat	region.	It	remains	to	be	seen	 whether	 these	 approaches	 will	 work	 in	 vivo	 and	 when	 during	 disease	development	they	would	be	efficient	and	safe	to	use.			
3.3.2	Epigenome	editing	may	also	provide	a	potential	treatment	As	discussed	previously,	 chromatin	 structure	 changes	have	been	observed	 in	TNR	expansion	causing	diseases	mice	models,	and	patients	derived	cells	(Dion	and	Wilson,	2009).	It	would	be	logical	to	suspect	chromatin	modifying	enzymes	may	take	action	during	disease	onset	and	progression	based	on	those	observations.	Moreover,	here	 histone	 deacetylases	 and	 DNA	 methyltransferases	 involvement	 in	 TNR	disorders	will	be	discussed.	
3.3.2.1	Histone	deacetylases	(HDACs)	HDACs	appear	to	play	a	central	role	in	neurodegeneration	and	thus	have	been	considered	 for	 treatment	 of	 multiple	 expanded	 TNR	 disorders	 (Butler	 and	 Bates,	
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2006;	Soragni	and	Gottesfeld,	2016).	For	instance,	HDAC	inhibitors,	TSA	and	SAHA,	have	 been	 shown	 to	 reduce	 cell	 death	 and/or	 neurodegeneration	 in	mouse	motor	neuron-neuroblastoma	 fusion	 cell	 lines	 (MN-1),	 Drosophila,	 and	 transgenic	Huntington	mouse	model	R6/2	(Hockly	et	al.,	2003;	McCampbell	et	al.,	2001;	Steffan	et	 al.,	 2001).	 HDAC3	 selective	 inhibitor,	 RGFP966,	 can	minimize	 cognitive	 defects	and	 suppress	 somatic	 repeat	 expansion	 in	HdhQ111	 transgenic	mice	 (Suelves	 et	 al.,	2017).	 FRDA	 is	 another	 prime	 candidate	 for	 HDAC	 inhibition	 treatment.	 As	described	 previously,	 FRDA	 is	 an	 autosomal	 recessive	 neurodegenerative	 disease	due	to	GAA	triplet	expansion	located	in	the	first	intron	of	FXN	gene,	which	ends	up	with	 declined	 frataxin	 production	 (Yandim	 et	 al.,	 2013).	 Gottesfeld	 and	 colleagues	demonstrated	 that	 one	 specific	 HDAC	 inhibitor,	 a	 2-aminobenzamide	 derived	compound,	can	increase	levels	of	frataxin	mRNA	and	protein	in	lymphoblastoid	and	primary	 lymphocytes	 (Herman	 et	 al.,	 2006b).	 Another	 HDAC	 inhibitor,	 109,	 also	showed	 to	 lead	 an	 increase	 in	 chromatin	 accessibility	 and	 FXN	 transcription	production	 (Chutake	 et	 al.,	 2016).	 All	 these	 promising	 HDACi	 as	 drug	 treatment	share	a	slow-on/slow-off	kinetic	profile	and	target	class	I	HDAC	primarily	(Soragni	and	Gottesfeld,	2016).	Compound	109	has	been	 tested	 in	FRDA	patient	 fibroblasts,	iPSCs,	 and	 neurons	 and	 proved	 successful	 in	 increasing	 frataxin	 expression	 at	concentrations	that	were	not	significantly	toxic	(Soragni	et	al.,	2014).	In	the	context	of	 DM1,	 a	 new	 flow	 cytometry-based	 screening	 in	 Hela	 cells	 revealed	 two	 more	HDAC	inhibitors,	ISOX,	and	vorinostat,	that	can	dramatically	increase	MBNL1	mRNA	level	(Zhang	et	al.,	2017).	MBNL1	is	a	splicing	factor	that	gets	sequestered	by	mRNAs	with	an	expanded	CUG	repeat,	leading	to	mis-splicing	of	mRNAs	in	trans	(Echeverria	and	Cooper,	2012).	The	two	HDAC	inhibitors	also	up-regulated	MBNL1	protein	levels	and	partially	reversed	the	splicing	defect	in	DM1	patient-derived	fibroblasts	(Zhang	et	al.,	2017).			From	all	of	these	losses	of	function	approaches,	they	failed	to	answer	whether	HDACs	work	locally	to	affect	TNR	or	affect	other	protein	transcription	in	trans.	(Jia	et	al.,	2016).		
3.3.2.2	DNA	methyltransferase	(DNMTs)	There	are	 five	paralogues	of	DNA	methyltransferases	 (DNMTs)	 in	 the	human	genome,	DNMT1,	DNMT2,	DNMT3a,	DNMT3b,	 and	DNMT3L	 (Lyko,	2018).	DNMT1,	
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3a,	 and	 3b	 are	 cytosine-5	 DNMTs,	 which	 catalyze	 and	maintain	 DNA	methylation.	Their	action	closely	tracks	with	gene	silencing.	By	contrast,	Dnmt2	targets	RNA	(Goll	et	al.,	2006)	and	Dnmt3L	(Bourc’his	et	al.,	2001)	does	not	possess	catalytic	activity.	Aberrant	DNA	methylation	and,	by	extension,	DNMTs	activity,	are	 found	 in	several	expanded	 TNR	 diseases.	 	 For	 instance,	 as	 early	 as	 1993,	 Knight	 et	 al.	 described	aberrant	CpG	island	hypermethylation	at	the	FRAXE	mental	retardation	locus	upon	CGG	expansion	(Knight	et	al.,	1993).	The	Usdin	group	found	three	hypermethylated	CpG	 residues	 in	 the	 FXN	gene	promoter	 region	 only	 in	 FRDA	patient-derived	 cells	(Greene	et	al.,	2007).	They	also	showed	that	expanded	GAA	repeats	could	influence	transcription	 initiation	 (Kumari	 et	 al.,	 2011;	 Punga	 and	 Bühler,	 2010).	 CpG	hypermethylation	was	also	found	around	the	CTG	expansion	in	DM1	cells,	where	it	correlates	with	the	congenital	form	of	the	disease	(Barbé	et	al.,	2017).		In	a	knock-in	mouse	model	of	SCA1,	CpG	methylation	levels	at	three	sites	around	the	CAG	repeat	tract	were	found	to	be	sensitive	to	DNMT1	levels.	Although	there	was	a	correlation	between	high	levels	of	CpG	methylation	at	these	sites	and	instability	in	the	germlines,	there	did	not	seem	to	be	a	drastic	effect	on	the	pathogenesis	of	the	disease	(Dion	et	al.,	2008).				Treating	 patients	 with	 HDAC	 inhibitors	 and/or	 DNMT	 inhibitors	 is	 likely	 to	lead	to	serious	side	effects	given	that	HDACs	and	DNMTs	are	involved	in	regulating	gene	 expression	 genome-wide.	 A	more	 precise	 approach,	 therefore,	will	 be	 to	 use	epigenome	editing.	However,	as	seen	above,	the	chromatin	context	can	influence	the	efficiency	 of	 epigenome	 editing	 and	 expanded	 repeats	 come	 with	 an	 altered	chromatin	state.	Thus,	 it	 is	 crucial	 to	understand	how	repeat	expansion	affects	 the	ability	of	chromatin	modifying	enzymes	to	modify	gene	expression	locally.	
	
3.4	How	to	study	TNRs	with	an	inducible	targeting	system	To	 understand	 how	 sequence	 contexts	 affecting	 epigenome	 editing,	 it	 is	necessary	to	be	able	to	target	chromatin	modifies	to	a	locus	that	differs	only	by	the	size	of	 the	repeat	 tract.	Classically	 targeting	systems	have	used	bacterial	operators	like	LacO,	TetO,	and	LexA.	For	instance,	inserting	arrays	of	LacOs	allows	visualizing	chromatin	 dynamics,	 gene	 expression,	 and	 chromatin	 structure	 (Belmont,	 2001;	Carpenter	 et	 al.,	 2005;	 Rafalska-Metcalf	 and	 Janicki,	 2007;	 Verschure	 et	 al.,	 2005).	
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However,	 the	 LacO	 array	 is	 prone	 to	 breakage	 (Jacome	 and	 Fernandez-Capetillo,	2011)	 and	 a	 repetitive	 sequence	 inserted	 near	 a	 CAG	 repeat	 may	 influence	 the	latter’s	stability	(Blackwood	et	al.,	2010).	Thus,	we	concluded	that	a	repetitive	array,	like	 LacO	 or	 TetO,	 would	 not	 be	 ideal	 as	 a	 targeting	 system	 to	 study	 expanded	CAG/CTG	repeats.			The	Bystricky	 lab	 described	 a	 non-repetitive	 alternative	 in	 2014	 (Saad	 et	 al.,	2014).	It	involves	a	chromosome	partitioning	system	form	B.	cenocepacia,	in	which	a	sequence	 of	 roughly	 1kb,	 INT,	 that	 contains	 four	 binding	 sites	 for	 dimers	 of	 ParB	(Dubarry	et	al.,	2006).	This	 initial	binding	 initiates	 the	oligomerization	of	 the	ParB	protein,	leading	to	the	recruitment	of	up	to	200	molecules,	at	least	in	vitro	(Khare	et	al.,	 2004).	 After	 optimization	 for	 usage	 in	 yeast,	 INT-ParB	 system	 was	 used	 to	monitor	DSB	repair	in	live	cells	(Saad	et	al.,	2014).	The	authors	found	no	increase	in	fragility	 and	 no	 effect	 on	 gene	 expression.	 We	 concluded	 that	 this	 was	 a	 better	system	to	use	for	our	purpose.			The	problem	remained	that	directly	comparing	the	overexpression	of	a	protein	to	 a	 constitutive	 targeting	 at	 the	 expanded	 repeat	would	 require	 two	 independent	cell	lines.	This	is	not	ideal	and	can	be	overcome	by	the	use	of	a	CIP	system.		We	opted	for	the	exogenous	ABA-based	CIP	(Liang	et	al.,	2011).		Finally,	 we	 needed	 an	 efficient	 and	 scalable	 way	 of	 monitoring	 the	 effect	 of	targeting	 chromatin	modifying	 enzymes	on	 gene	 expression	 and	 repeat	 instability.	One	 of	 the	main	 challenges	when	working	with	 expanded	 repeats	 is	 to	 size	 them	accurately	and	rapidly.	The	gold	standard,	but	tedious,	a	method	to	determine	repeat	length	 is	 small-pool	 polymerase	 chain	 reaction	 (SP-PCR)	 (Monckton	 et	 al.,	 1995).	Since	PCR	amplification	 is	biased	 towards	 shorter	 repeats,	 in	 SP-PCR	 the	 template	DNA	 is	 diluted	 to	 just	 a	 few	 genomes	 per	 reaction.	 Since	many	 reactions	 are	 then	necessary	to	have	a	following	number	of	allele	measured,	this	is	not	an	efficient	way	of	 screening	 the	 effect	 of	 chromatin	 modifiers.	 More	 recently,	 new	 long-read	sequencings	methods	have	been	applied	to	tandem	repeats	(Bustos	et	al.,	2016;	Liu	et	al.,	2017;	Loomis	et	al.,	2013;	McFarland	et	al.,	2015;	Tsai	et	al.,	2017).		However,	
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the	number	 of	 quantifiable	 events	 remains	 low	and	 the	 cost	 high.	 Thus	 this	 is	 not	suitable	for	our	purposes.		Some	plasmid-based	 instability	 assays	 exist	 that	 are	 average	 throughput	 and	labor-intensive	 (Claassen	 and	 Lahue,	 2007;	 Cleary	 and	 Pearson,	 2003;	 Farrell	 and	Lahue,	 2006).	 These	would	 have	 the	 added	 issues	 that	 they	 cannot	measure	 both	expansions	and	contractions	at	the	same	time	and	that	the	chromatin	structure	may	be	entirely	different	than	if	the	sequence	is	integrated	stably	in	the	genome.	A	better	approach,	therefore,	is	to	use	a	chromosomal	reporter	developed	by	the	Wilson	lab.	The	first	generation	was	based	on	the	observation	that	inserting	a	large	CAG	repeat	within	the	intron	of	selectable	genes	like	APRT	and	HPRT	decreased	their	expression	(Gorbunova	et	al.,	2003;	Lin	et	al.,	2006).	This	works	because	the	CAG	repeat	acts	as	an	alternative	exon	whose	strength	depends	on	the	size	of	the	repeat,	which	acts	as	a	splicing	enhancer	(Blencowe,	2000;	Elrick	et	al.,	1998;	Hong	and	Li,	2002;	Yeakley	et	al.,	1996).	When	this	CAG	exon	is	included,	it	also	includes	38bp	downstream	of	the	repeat	 tract	 that	 throws	 off	 the	 reading	 frame.	 Thus,	 starting	 with	 a	 large	 repeat	tract,	 and	 thus	an	 inactive	gene,	massive	 contractions	 can	be	 readily	quantified	by	selecting	for	the	activity	of	the	selectable	marker.		Here	again,	one	caveat	is	that	the	assay	 only	 measures	 one	 class	 of	 events,	 in	 this	 case,	 rare	 massive	 contractions.	Attempts	 to	 modify	 the	 assay	 such	 that	 expansions	 can	 be	 detected	 had	 limited	impact	and	was	impractical	(Lin	et	al.,	2005).			The	 latest	 generation	 of	 the	 assay	 is	 GFP-based.	 It	 contains	 an	 inducible	promoter,	and	a	GFP	split	 into	 two	exons	with	 the	 intron	of	 the	mouse	Pem1	gene	inserted	in	between	(Santillan	et	al.,	2014).	It	was	initially	designed	as	a	contraction	assay,	but	our	lab	has	shown	that	it	can	monitor	both	expansions	and	contractions	at	the	 same	 time	 within	 only	 a	 few	 days	 (Cinesi	 et	 al.,	 2016).	 The	 system	 will	 be	introduced	in	detail	in	Chapter	III	Results.		The	goal	 of	 this	 thesis	was	 to	build	 an	 inducible	 targeting	 assay	 to	 study	 the	effect	of	repeat	expansion	on	epigenome	editing.	I	describe	herein	the	engineering	of	the	 system	 and	 the	 use	 of	 this	 synthetic	 biology	 approach	 for	 uncovering	 novel	mechanisms	by	which	chromatin	modifiers	affect	gene	expression.		
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Plasmids	The	plasmids	used	to	make	the	cell	lines	or	transient	transfection	are	found	in	Table	II.1.		
	
Cell	culture	conditions	The	majority	of	the	cell	lines,	including	all	the	parental	lines,	used	(Table	II.1)	were	 genotyped	 by	 Microsynth,	 AG	 (Switzerland)	 and	 found	 to	 be	 HEK293.2sus.	They	were	 free	 of	mycoplasma	 as	 assayed	 by	 the	Mycoplasma	 check	 service	 from	GATC	Biotech.	The	cells	were	maintained	 in	DMEM	containing	10%	FBS,	penicillin,	and	 streptomycin,	 as	 well	 as	 the	 appropriate	 selection	 markers	 at	 the	 following	concentrations	15	µg	ml-1	 blasticidin,	 1µg	ml-1	puromycin,	150µg	ml-1	hygromycin,	400	µg	ml-1	G418,	400	µg	ml-1	zeocin	at	37	°C	with	5%	CO2.	The	ABA	concentration	used	was	500	µM,	unless	otherwise	indicated.	Dox	was	used	at	a	concentration	of	2	µg	ml-1			
Cell	line	construction	A	schematic	of	cell	 line	construction	is	 found	in	Figure	III.	7	and	the	 lines	are	listed	 in	 Table	 S1.	 For	 each	 line,	 single	 clones	 were	 picked	 and	 verified	 for	expression	 of	 ParB-ABI	 and	 PYL-fusions	 by	 western	 blotting	 using	 the	 protocol	described	 before	 (Cinesi	 et	 al.,	 2016).	 Proteins	were	 extracted	 in	 RIPA	Buffer	 and	scrapped	 from	 the	 plate.	 Centrifugation	 removed	 the	 cell	 debris.	 The	 supernatant	was	 collected	 and	 further	 quantified	 using	 the	 Pierce	 BCA	 Protein	 Assay	 Kit	(ThermoScientific).	 	 Proteins	were	 then	mixed	with	 loading	 buffer	 and	 run	 onto	 a	Tris-glycine	 10%	 SDS	 PAGE	 gels.	 The	 proteins	 were	 then	 transferred	 to	nitrocellulose	 membrane	 (Axonlab).	 The	 membranes	 were	 blocked	 using	 the	Blocking	 Buffer	 for	 Fluorescent	 Western	 Blotting	 (Rockland)	 and	 then	 primary	antibodies	were	added	overnight.	Membranes	were	 then	washed	with	PBS	+	0.1%	Tween	 at	 room	 temperature	 followed	 by	 the	 addition	 of	 the	 secondary	 antibody	(1:2000).	 After	 washing	 with	 PBS,	 the	 fluorescent	 signal	 was	 detected	 using	 an	Odyssey	 Imaging	 System	 (Li-CoR).	 All	 antibodies	 used	 are	 found	 in	 Table	 II.2.	Besides,	repeat	sizes	were	verified	using	oVIN-0459	and	oVIN-0460	with	the	UNG-based	PCR	reaction	described	before	(Aeschbach	and	Dion,	2017)	and	then	Sanger-sequenced	by	Microsynth	AG	(Switzerland).		
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	PaB-ABI	 (pBY-008),	 PYL	 (pAB-NEO-PYL),	 PYL-DNMT1	 (pAB(EXPR-PYL-DNMT1-NEO)),	 PYL-HDAC5	 (pAB(EXPR-PYL-HDAC5-NEO))	 and	 PYL-HDAC3	(pAB(EXPR-PYL-HDAC3-NEO))	were	 randomly	 inserted.	The	GFP-reporter	 cassette	was	 inserted	 using	 the	 Flp-mediated	 method	 as	 the	 manufacturer's	 instructions	(https://www.thermofisher.com/ch/en/home/references/protocols/proteins-expression-isolation-and-analysis/protein-expression-protocol/flp-in-system-for-generating-constitutive-expression-cell-lines.html#prot3	 Thermo	 Scientific).	 Single	colonies	were	picked	and	screened	for	zeocin	sensitivity	to	ensure	that	the	insertion	site	was	correct.			
Targeting	assays	For	 targeting	 assays	 involving	 transient	 transfections,	 cells	were	 plated	 onto	poly-D-lysine-coated	 12	 well	 plates	 with	 600'000	 per	 well	 on	 the	 first	 day.	Constructs	 were	 transfected	 using	 Lipofectamine	 2000	 or	 Lipofectamine	 3000	(Thermofisher	 Scientific)	 with	 1	 µg	 per	 well	 on	 the	 same	 day.	 6	 hours	 after	transfection,	the	medium	was	replaced	with	one	containing	dox	and	ABA	or	DMSO.	48h	 after	 the	 transfection,	 the	 cells	 were	 split,	 and	 dox	 with	 ABA	 or	 DMSO	were	added	again.	On	 the	 fifth	day,	 samples	were	detached	 from	 the	plate	with	PBS	+	1	mM	EDTA	for	flow	cytometry	analysis.		In	 the	 case	of	 stable	 cell	 lines,	 cells	were	 seeded	 at	 a	 density	 of	 400'000	per	well	in	12-well	plates.	The	media	includes	dox	and	ABA	or	DMSO.	The	medium	was	changed	48	hours	later,	and	the	cells	were	resuspended	in	500µl	PBS	+	1	mM	EDTA	for	Accuri	(BD)	flow	cytometry	analysis	with	12517	events	recorded.			For	 dCas9	 targeting,	 CIT0	 and	 CIT40	 cells	 were	 seeded	 into	 coated	 12	 well	plates	to	a	density	of	600’000	cells	per	well.	dCas9-KRAB	(pBY-040),	dCas9-HDAC5	NT	(pBY-038),	or	dCas9-HDAC5	CD	(pBY-039)	were	transfected	using	Lipofectamine	2000	 (Life	 technology)	 together	with	 the	 sgRNAs	 in	 a	 1:1	 ratio.	 6	 hours	 later,	 the	medium	was	changed	for	one	containing	dox.	The	medium	was	changed	again	on	the	third	day,	and	fresh	dox	was	added.	The	cells	were	then	recovered	and	analyzed	by	flow	cytometry.		
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Flow	cytometry	and	analysis	We	used	an	Accuri	C6	flow	cytometer	from	BD	and	measured	the	fluorescence	in	at	least	12517	events	for	each	treatment.	The	raw	data	was	exported	as	FCS	files	and	analyzed	using	FlowJo	version	10.0.8r1.	The	statistical	analysis	was	done	using	R	studio	version	3.4.0.	All	R	scripts	are	attached	in	the	Appendix.	
	
Chromatin	immunoprecipitation	For	chromatin	immunoprecipitation,	CIT	cells	were	treated	as	for	the	targeting	experiments	 except	 that	 the	 number	 of	 cells	 used	was	 10	 times	 higher	 and	 10cm	plates	 were	 used.	 At	 the	 end	 of	 the	 five	 days,	 formaldehyde	 was	 added	 to	 the	medium	 to	 a	 final	 concentration	 of	 1%	 and	 incubated	with	 gentle	 shaking	 for	 10	minutes	at	room	temperature.	The	samples	were	then	quenched	with	0.125M	PBS-glycine	 for	 5	 minutes	 at	 room	 temperature.	 Samples	 were	 then	 centrifuged,	 the	supernatant	was	discarded,	and	the	cell	pellets	were	washed	with	ice-cold	PBS	twice.	The	samples	were	split	into	10	million	cells	per	aliquot	and	either	used	immediately	or	stored	-75	°C	for	later	use.		Sonication	was	done	using	a	Bioruptor	in	1	ml	of	cell	lysis	buffer	(10	mM	Tris-HCl	pH	8.0,	200mM	NaCl,	1mM	EDTA,	0.5	mM	EGTA,	0.1%	Na-Deoxycholate,	0.25%	Sodium	lauroyl	sarcosinate,	protease	inhibitor	Complete	EDTA	free	(Roche))	for	25	to	 30	 min.	 DNA	 shearing	 was	 visualized	 by	 agarose	 gel	 electrophoresis	 after	crosslink	reversal	and	RNase	treatment.		20%	of	sonicated	supernatant	was	used	per	IP	with	3	μg	anti-Flag	(M2,	Sigma),	anti-PAN	acetylated	H3	(Merck),	or	anti-IgG	(3E8,	Santa	Cruz	Biotechnology)	in	800	μl	IP	dilution	buffer	(1.25%	Triton-X,	1	mM	EDTA	pH	 8.0,	 0.5	 mM	 EGTA,	 16.25	 mM	 Tris-HCl,	 137.5	 mM	 NaCl,	 1x	 protease	 inhibitor	Complete	EDTA	free	(Roche))	with	50	µl	blocked	50%	slurry	of	Protein	G	Sepharose	4	Fast	 Flow	beads	 (GE	healthcare).	 The	 samples	were	 incubated	 at	 4	 °C	 overnight	and	then	washed	with	progressively	more	stringent	conditions	(wash	1:	0.1%	SDS,	1%	 Trition,	 20mM	 Tris-HCl,	 2mM	 EDTA,	 300mM	 NaCl;	 wash	 2:	 0.1%	 SDS,	 1%	Trition,	 20mM	 Tris-HCl,	 2mM	 EDTA,	 500mM	 NaCl;	 wash3:	 1%	 NP-40,	 1%	 Na-deoxycholate,	 10mM	 Tris-HCl,	 1mM	 EDTA,	 250mM	 LiCl;	 wash4:	 10mM	 Tris-HCl,	
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1mM	 EDTA).	 After	 the	 IP,	 the	 samples	 were	 de-crosslinked	 and	 purified	 using	 a	QIAquick	PCR	purification	kit	(Qiagen)	and	analyzed	using	a	qPCR.		
Quantitative	PCR	qPCR	was	performed	with	the	FastStart	Universal	SYBR	Green	Master	(Roche)	using	 a	 7900HT	Fast	 Real-Time	PCR	 System	 in	 a	 384-Well	 Block	Module	 (Applied	Biosystems™).	 Primers	 used	 to	 detect	 enrichment	 at	 the	 INT	 sequence	 and	ACTA1	gene	are	listed	below	and	in	Table	S3.		oVIN-0969	(INT)	5’	TGAATACCATGCGCTCTA	oVIN-0970	(INT)	5’	GCCGTTCGTGGCAGAGAT	oVIN-1075	(ACTA1)	5’	AGCGCGGCTACAGCTTCAC	oVIN-1076	(ACTA1)	5’	CAGCCGTGGCCATCTCTT			Ct	 values	 were	 analyzed	 using	 the	 SDS	 Software	 v2.4.	 The	 reported	enrichments	were	obtained	using	the	ΔCt	method:		ΔCt[normalized	ChIP]	=	(Ct[ChIP]-	(Ct[input]	–	log2(input	dilution	factor))		%	input	=	2-	ΔCt[normalized	ChIP]		ΔΔCt[ABA	PYL	INT	ChIP]	=	Ct[	normalized	ABA	PYL	INT	ChIP]	-	Ct[	normalized	DMSO	PYL	INT	ChIP]		Fold	difference	=	2-	ΔΔCt[ABA	PYL	INT	ChIP]		
	
	
Small-pool	PCR	
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CIT40BYH5	and	CIT89BYD	cells	were	treated	as	for	the	targeting	experiments	but	 split,	 and	 the	 medium	 replaced	 every	 three	 days	 for	 one	 month.	 Cells	 were	harvested,	 and	 genomic	DNA	was	 extracted	 using	NucloSpin	Tissue	Kit	 (Macherey	Nagel).			Small	Pool	PCR	was	performed	as	previously	described	(Aeschbach	and	Dion,	2017).	Seven	PCR	reactions	per	sample,	plus	one	negative	control,	were	set	up	using	the	 Phusion	 U	 Green	 Hot	 Start	 DNA	 Polymerase	 kit	 (Thermo	 Fisher	 Scientific)	 as	follow:	 1X	 reaction	 buffer,	 0.2mM	dNTP	mix	 (without	 dTTP),	 0.4mM	dUTP,	 0.5μM	oVIN-460,	0.5μM	oVIN-1425,	3%	DMSO,	0.1U	Uracil-DNA	N-Glycosylase	heat	 labile	(Roche	#11775367001),	0.4U	Phusion	Taq,	1ng	of	DNA,	and	H2O	to	10μL.	The	PCR	program	used	consist	of	20°C	 for	10	min,	95°C	 for	7	min,	 followed	by	35	cycles	at	95°C	for	30	s,	60°C	for	30	s,	and	72°C	for	1	min	30	s,	at	the	end	a	final	extension	of	72°C	for	10	min.	After	the	PCR	run	finish,	100μg	ml-1	of	Proteinase	K	was	added	to	each	reaction	and	incubated	at	37°C	for	1	hour.		PCR	products	were	separated	on	a	2%	agarose	gel.	The	gel	was	washed	twice	for	 20	 min	 in	 alkaline	 transfer	 buffer	 (0.4M	 NaOH,	 1M	 NaCl).	 The	 gel	 was	 then	transferred	 overnight	 onto	 a	 charged	membrane	 (Zeta-Probe	 GT	 Genomic	 Tested,	Bio-Rad)	 using	 capillary	 action	 in	 alkaline	 transfer	 buffer.	 After	 transfer,	 the	membrane	was	washed	with	a	neutralization	buffer	(1.5M	NaCl,	0.5M	Tris	base,	pH	7.4)	 for	 5	 min,	 and	 added	 into	 a	 hybridization	 cylinder	 along	 with	 pre-warmed	Ultrahyb	 buffer	 (Thermo	 Scientific).	 Salmon	 sperm	 DNA	 was	 added	 and	 the	membrane,	which	was	then	incubated	for	at	least	one	hour	at	52°C.		The	 probe	 for	 hybridization	 was	 prepared	 using	 T4	 PNK	 (New	 England	BioLabs)	as	follow:	1X	Reaction	buffer,	50pmol	of	oVIN-100,	10mM	[γ-32P]	ATP,	10U	T4	PNK,	and	H20	to	25μL.	The	probe	was	incubated	at	37°C	for	1	hour,	followed	by	10	 minutes	 at	 65°C.	 The	 probe	 was	 then	 added	 directly	 to	 the	 membrane	 and	incubated	 at	 52°C	 for	 2	 hours.	 After	 incubation,	 the	 membrane	 was	 washed	 four	times	for	20	min	with	a	washing	buffer	(0.5X	SSC,	0.1%	SDS).	Finally,	the	membrane	was	washed	with	 2X	 SSC,	 exposed	 to	 a	 phosphoscreen	 for	 24	 hours,	 and	 revealed	with	a	Typhoon	scannersphoimager.		
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Cas9	T7E1	test		CIT40	cells	were	seeded	into	coated	12	well	plates	to	a	density	of	600’000	cells	per	well.	Cas9	(pcDNA3.3-TOPO-hCas9)	with	sgRNAs	were	transfected	in	a	1:1	ratio	using	Lipofectamine	2000	(Life	technology)	for	6h	followed	after	which	the	medium	was	 changed	 and	 included	 dox.	 Cells	 were	 harvest	 72h	 after	 transfection,	 and	genomic	 DNA	 was	 extracted	 using	 the	 NucloSpin	 Tissue	 Kit	 (Macherey	 Nagel).	Genomic	regions	targeted	by	the	sgRNAs	were	amplified	with	oVIN-0755	and	oVIN-0970,	which	listed	in	Table	II.3.	PCR	products	were	purified	with	the	NucloSpin	Gel	and	PCR	Clean-up	Kit	(MN)	and	quantified	using	the	Nanodrop	spectrophotometer.	200ng	 of	 purified	 PCR	 product	 was	mixed	with	 NEB	 buffer	 2	 and	 ddH2O	 to	 19µl,	followed	 by	 5	 min	 95°C,	 then	 a	 slow	 2°C	 per	 second	 decrease	 from	 95	 to	 85	 °C	followed	by	0.1°C	per	second	decrease	in	temperatures	to	25°C	and	then	paused	at	15°C.	The	reaction	mix	was	incubated	with	1µl	of	T7	endonuclease	I	(NEB)	for	15min	at	37	°C.	Treated	samples	were	visualized	on	a	1%	agarose	gel.		
Statistics	When	 analyzed	 flow	 cytometry	 data	 between	 ABA	 and	 DMSO	 treatment,	 we	could	not	be	certain	they	were	normally	distributed.	I	performed	paired	Student's	t-test	for	all	the	mean	values	of	each	sample.	The	same	statistics	analysis	was	applied	to	 different	 repeat	 length	POI	 cell	 lines	 comparison.	All	 the	 statistical	 analysis	 has	been	done	in	R	studio	3.4.0.	We	used	p-value	<	0.05	as	significant	difference	exist.					 	
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Table	II.2.	Antibodies	used		 Epitope	 Company	 Catalog	number	 Dilution	 Assay	FLAG	 Sigma-Aldrich	 F1804-5MG	 3	μg	per	IP	1:1000	 ChIP	WB	IgG	 Santa	Cruz	Biotechnology	 sc-69786	 3	μg	per	IP	 ChIP	Pan-acetylation	of	H3	 Merck	 #06-599	 3	μg	per	IP	 ChIP	HA	 Roche	 11	867	423	001	 1:1000	 WB	Histone	H3	 Abcam	 ab1791	 3	μg	per	IP	 ChIP	Actin	 Sigma-Aldrich	 A2066-.2ML	 1:2000	 WB	PolII	 Abcam	 ab26721	 3	μg	per	IP	 ChIP		
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Table	II.3.	Primers	used		 Name	 Sequence	 Locus	 Purpose	 Reference	oVIN-0969	 5’-	TGAATACCATGCGCTCTA-3’	 INT	 ChIP-Q-PCR	 This	study	oVIN-0970	 5’-	GCCGTTCGTGGCAGAGAT-3’	 INT	 ChIP-Q-PCR	 This	study	oVIN-1075	 5’-	AGCGCGGCTACAGCTTCAC-3’	 Actin	 ChIP-Q-PCR	 This	study	oVIN-1076	 5’-	CAGCCGTGGCCATCTCTT-3’	 Actin	 ChIP-Q-PCR	 This	study	oVIN-0459	 5’-	AAGAGCTTCCCTTTACACAACG-3’	 GFP	reporter	 CAG	repeat	amplification	 (Cinesi	et	al.,	2016)	oVIN-0460	 5’-	TCTGCAAATTCAGTGATGC-3’	 GFP	reporter	 CAG	repeat	amplification	 (Cinesi	et	al.,	2016)	oVIN-1425	 5’-GACCTCATACGAAGATAGGCTT-3’	 GFP	reporter	 CAG	repeat	amplification	 This	study	oVIN-0100	 5’-AGCAGCAGCAGCAGCAGCAGCAGCAGCAGC-3’	 GFP	reporter	 CAG	repeat	probe	 This	study	oVIN-0755	 5’-GACCTCATACGAAGATAGGCTT-3’	 GFP	reporter	 INT	amplification	 This	study	oVIN-0970	 5’-GCCGTTCGTGGCAGAGAT-3’	 GFP	reporter	 INT	amplification	 This	study		
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1.	Targeting	system	design	and	construction		The	 inducible	 targeting	 system	 can	 be	 divided	 into	 three	 major	 parts.	 It	contains	 a	GFP	 reporter	 assay	 to	monitor	CAG	 repeat	 instability	 and	 expression,	 a	ParB-INT	 protein-DNA	 binding	 system	 and	 the	 ABA-induced	 proximity	 system	(Figure	 III.	 1	 A-C).	 Each	 component	was	 engineered	 in	 vitro	and	 stably	 integrated	into	Flp-in	T-REX	(HEK293)	cells.														 			 	Figure III. 1. Three components of the inducible targeting system. A. Abscisic acid (ABA)-inducible proximity system. PYL can bind to ABI when ABA is present. 
B. ParB-INT protein DNA binding assay. Bacteria-derived ParB can 
bind to INT in a sequence-dependent manner and nucleate the 
oligomerization of ParB at the locus. 
C. GFP reporter. Doxycycline addition can induce transcription along 
the locus and thus GFP expression. 
D. Illustration of the CIT system structure. INT sequence is integrated 
into GFP reporter intron where ParB could bind. PYL forms a 
dimer with ParB-ABI fusion protein when ABA is present in the 
system. 
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We	took	advantage	of	the	GFP-based	reporter	assay	published	by	Santillan	and	colleagues	in	2014	and	further	broadened	its	usage	to	monitor	CAG	repeat	instability	(Cinesi	et	al.,	2016;	Santillan	et	al.,	2014)	(Figure	III.	2).	This	GFP	reporter	consists	of	a	TetO2	CMV	 inducible	promoter	with	a	mouse	Pem1	 intron	 flanked	by	 two	exons	coding	 for	 GFP.	 One	 DM1	 patient-derived	 CTG	 repeats	 containing	 fragment	 was	cloned	into	the	Pem1	intron	in	the	CAG	orientation,	including	72	bp	upstream	and	93	bp	downstream	of	patient-derived	material.		As	being	a	splicing	signal	enhancer,	CA	dinucleotide	 influence	GFP	splicing	with	a	reverse	correlation	between	CAG	repeat	length	 and	GFP	expression	 (Tacke	 and	Manley,	 1999).	A	 similar	 strategy	based	on	the	HPRT	mini-gene	 showed	 that	 as	CAG	 repeats	 increase	 in	 length,	 they	promote	the	 inclusion	of	 an	 alternative	 ‘CAG	exon’	 that	 contains	 the	 repeat	 tract	minus	 the	first	CAG	and	38bp	downstream	of	the	CAG	repeat.	mRNAs	containing	the	CAG	exon	are	degraded,	presumably	via	nonsense-mediated	decay	(Gorbunova	et	al.,	2003).	In	conclusion,	 GFP	 intensity	 can	 act	 as	 a	 readout	 of	 CAG	 repeats	 instability	 and/or	expression	and	is	easily	detected	by	flow	cytometry.		 	
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Figure III. 2. GFP reporter. The report contains an inducible CMV TetO2 
promoter (black box) and a split GFP gene (exons in green, the intron in 
grey) with a varying repeat size (orange). 
A. After the induction of transcription by the addition of dox, the short 
repeat construct produces high levels of GFP. 
B. Expanded CAG repeats tend to be included into mRNA during 
transcription. This CAG repeat containing transcript would end up 
with degradation. The longer the CAG repeat, the lower the amount 
of GFP produced. 
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To	 build	 an	 inducible	 targeting	 system	 with	 as	 little	 interference	 with	 the	repeat	 tract	 as	 possible,	 we	 opted	 for	 a	 non-repetitive	 bacterial-derived	 system	developed	 by	 the	 Saad	 et	 al.	 in	 yeast	 (Saad	 et	 al.,	 2014)	 and	 adapted	 it	 here	 for	mammalian	 use.	 	 This	 system	 (Figure	 III.	 1B),	 called	 ParB-INT,	 was	 first	 used	 to	visualize	 the	 dynamics	 in	 double-strand	 break	 resection.	 Initially,	 P31	 from	
Burkholderia	 cenocepacia	 J231	 binds	 to	 chromosome	 2	 via	 a	 parS	 DNA	 motif	 to	activate	mitotic	 segregation	 in	bacteria	 (Dubarry	et	al.,	2006).	Saad	and	colleagues	named	the	optimized	DNA	binding	sequence	INT	and	DNA	binding	protein	as	ParB.	ParB	 initially	 binds	 to	 4	 nucleation	 sites	 within	 INT	 and	 leads	 to	 oligomerization	beyond	 INT	 itself	 such	 up	 to	 two	 hundred	 ParB	 molecules	 can	 be	 recruited	 to	 a	single	site	 in	vitro	 (Khare	et	al.,	2004).	The	relatively	small	size	of	 INT	(<	1kb)	and	the	 absence	 of	 fragility	 seen	 in	 yeast	 or	 toxicity	 make	 ParB-INT	 ideal	 for	 our	purposes	(Mariamé	et	al.,	2018).			We	 chose	 sequence	 optimized	 ParBc2	 for	 use	 in	 human	 cells.	 	 The	 INT	fragment	was	cloned	in	the	intron	of	the	GFP	reporter	construct	289	bp	downstream	of	 the	 first	 GFP	 exon	 and	 308	 bp	 upstream	 of	 the	 CAG	 repeat.	 Using	 the	 Flp-in	integration	method,	we	 generated	 stable	 cell	 lines	 in	 Flp-in	 T-Rex	 (HEK293)	 cells,	called	 chromatin	 Inducible	 Targeting	 (CIT),	 harboring	 the	 GFP-INT	 construct	containing	varying	numbers	of	CAG	repeats.		To	test	the	effect	of	inserting	the	INT	sequencing	within	the	Pem1	intron	of	the	GFP	 construct,	we	monitored	GFP	 expression	 in	GFP(CAG)0,	which	do	not	 have	 an	INT	sequence,	 and	CIT0	cells	by	 flow	cytometry.	This	was	done	 in	 the	presence	of	dox	 to	 activate	 transcription	 of	 the	 reporter.	We	 found	 that	 there	 was	 a	 minimal	effect	(Figure	III.	3)	and	conclude	that	INT	sequence	insertion	has	a	minor	effect,	 if	any,	on	GFP	expression.			 	
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Figure III. 3. INT has a minor effect on GFP expression. Comparison 
between GFP(CAG)0 and CIT0 cells.  
A. Illustration of GFP constructs with and without the INT sequence. 
INT sequence (blue) is located in GFP reporter intron (grey) in 
CIT0 cell line. 
B. Density plot of GFP in cells with and without INT. Black: 
GFP(CAG)0 cells, blue:  CIT0 cells. The x-axis indicates log10 
scale GFP intensity. Y-axis is normalized cell count.  
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We	 next	 tested	 whether	 the	 ParB-ABI	 fusion	 by	 itself	 interfered	 with	 GFP	expression.	 We,	 therefore,	 have	 transfected	 plasmid	 expressing	 the	 fusion	 in	GFP(CAG)0	and	GFP(CAG)101	cells	and	measured	GFP	produced	five	days	later	in	the	presence	of	dox.	We	found	that	ParB-ABI	had	no	detectable	effect	on	GFP	expression	in	the	conditions	(Figure	III.	4ABC).	However,	when	both	the	INT	sequence	and	the	ParB-ABI	proteins	are	stably	integrated	into	the	cells'	genome	to	create	CITnB,	which	n	is	the	number	of	repeats,	GFP	expression	decreased	with	increasing	amount	of	the	fusion.	This	 is	evidence	 that	ParB-ABI	 is	 indeed	binding	 to	 the	 INT	 in	human	cells.	However,	the	effect	on	expression	suggests	that	ParB-ABI	binding	to	INT	may	block	transcription	or	alter	splicing,	which	is	in	contrast	to	what	was	found	in	yeast	(Saad	et	al.,	2014).					 	
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Figure III. 4. ParB expression and its effect on GFP expression. 
A. Illustration of ParB-INT targeting. ParB-ABI fusion proteins 
(brown and orange) bind to INT sequence (blue). 
B-C. Transient transfection of the ParB-ABI constructs to GFP(CAG)0 
(B), GFP(CAG)101 (C) hardly affects GFP intensity compare to the 
transfection of empty vectors.  
D.     Cell line construction. Flp-in T-REX cells were stably transfected 
with GFP-INT reporter in a site-specific manner to construct CIT0 
cell lines. CIT0 cell line was further stably transfected with the 
ParB-ABI construct to achieve CIT0B cell line. 
E.   ParB-ABI expression level in CIT0B clones. Numbers below 
CIT0B indicate clone numbers. 
F-J. Stably expressed ParB-ABI construct in CIT0 induces GFP 
intensity shift. As ParB-ABI expression levels shown in E, clones 
with more ParB-ABI expression show greater GFP intensity 
difference compare to CIT0 control. 
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Since	showed	ParB-INT	binding	could	affect	GFP	 intensity,	 it	was	essential	 to	determine	whether	any	further	effect	was	seen	upon	targeting	of	a	control	protein.	Given	that	the	presence	of	ABA	drives	the	targeting,	we	first	tested	whether	ABA	by	itself	 modified	 GFP	 expression.	 We	 found	 that	 adding	 up	 to	 500µM	 of	 ABA	 to	GFP(CAG)0	 and	GFP(CAG)101	 cells	 did	 not	 affect	GFP	 expression	 (Figure	 III.	 5).	We	used	 500µM	 of	 ABA	 in	 all	 our	 experiments	 because	 we	 found	 that	 this	 induced	dimerization	 by	 co-immunoprecipitation	 (not	 shown)	 and	 is	 in	 line	 with	 the	concentrations	used	by	Liang	et	al.	(Liang	et	al.,	2011).			 	
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Figure III. 5. ABA does not affect GFP expression.  
A. Cartoon of CIT. The fusion of ABI (brown) with ParB (orange) 
make CIP system and ParB-INT system into inducible. The 
presence of ABA brings PYL to INT sequence showing on the 
right. 
B. Schematics of ABA-induced dimerization and the tags found on 
ParB-ABI and PYL-fusions. 
C-D.ABA titration test in GFP(CAG)0 (C) and GFP(CAG)101 (D). 
None of the ABA concentration tested change GFP intensity 
compare to the untreated group. 
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Next,	we	 introduced	PYL	alone	or	PYL	 fusion	proteins	 (all	 containing	3	FLAG	tags	and	an	NLS)	 into	 the	genome	of	HEK293	T-Rex	FlpIN	cells	already	containing	ParB-PYL	 (HEKB	cells)	 to	 generate	HEKBY	cells.	To	 these,	we	 introduced	 the	GFP-INT	constructs	with	either	16	CAGs	or	an	expanded	repeat	(CITnBY	cells	–	Figure	III.	6A).	This	was	done	in	collaboration	with	Alicia	Borgeaud.	This	strategy	allows	us	to	compare	the	effect	on	targeting	next	to	different	repeat	lengths	directly.	We	used	the	same	 strategy	 to	 generate	 PYL-HDAC5	 (CITnBYH5),	 PYL-HDAC3	 (CITnBYH3)	 and	PYL-DNMT1	 (CITnBYD)	 expressing	 cells.	 All	 cell	 lines	 were	 verified	 with	 western	blot	for	ParB-ABI	and	PYL	levels,	the	repeat	tract	was	sequenced,	and	the	cells	were	tested	 for	Zeocin	 sensitivity	 to	 ensure	 that	 the	 integration	 site	was	 correct	 for	 the	Flp-IN	insertions.	All	stable	cell	lines	generated	are	listed	in	Table	II.1	and	Figure	III.	7.			 	
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Figure III. 6. Cell line construction with protein expression analysis. 
A.  CIT cell lines construction. ParB-ABI, PYL/PYL-protein of interest 
and GFP reporter constructs are stably transfected into Flp-in T-
REX cells in a sequential manner. 
B.  HEKB clones and their levels of ParB-ABI. Actin is shown as a 
loading control. The chosen clone is shown with a red box. 
C.  PYL expression in HEKBY clones. Actin is shown as a loading 
control. The chosen clone is shown with a red box. 
D.  PYL-HDAC5 expression in HEKBYH5 clones. Actin is shown as a 
loading control. The chosen clone is shown with a red box.  
E.  PYL-HDAC3 expression in HEKBYH3 cells. Actin is shown as a 
loading control. The chosen clone is shown with a red box.  
F. PYL-DNMT1 expression in HEKBYD cells. Actin is shown as a 
loading control. The chosen clone is shown with a red box. 
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Figure III. 7. Stable cell line generation process with example cell line 
cartoons. 
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2.	PYL	targeting	does	not	change	GFP	expression	in	CIT	system	I	next	determined	the	effect	of	targeting	PYL	alone	to	the	INT	locus	(Figure	III.	8A).		The	working	procedure	is	showing	in	Figure	III.	8B.	We	found	that	there	was	no	significant	effect	on	 the	amount	of	GFP	produced	with	or	without	ABA	 in	CIT40BY	cells.	As	expected,	PYL	was	efficiently	 recruited	 to	 the	 INT	sequence	by	ChIP	upon	addition	of	ABA	by	over	nine-fold	in	CIT40BY	cells	but	remained	unchanged	and	at	deficient	 levels	 at	 the	 ACTA1	 locus,	 showing	 the	 specificity	 and	 robustness	 of	 the	targeting	(Figure	III.	9).	These	results	led	me	to	conclude	that	targeting	of	PYL	does	not	interfere	further	with	GFP	expression.				Due	to	unforeseen	issues,	the	PYL	control	cells	with	16	CAG	and	89	CAG	are	on-going	as	of	this	writing.	Therefore,	I	use	below	CIT40BY	cells	as	a	comparison.			 	
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Figure	III.	8.	Transient	transfection	of	PYL	does	not	change	GFP	
intensity	upon	targeting	in	CIT0B	and	CIT40B	cells.	A. Illustration	of	PYL	targeting.	With	ABA	addition,	PYL	(blue)	forms	 a	 dimer	 with	 ParB-ABI	 protein	 (brown	 and	 orange)	and	further	target	to	INT	sequence	in	GFP	reporter.	With	no	ABA	presence,	the	PYL	targeting	would	not	occur.	B. Experimental	 design.	 Cells	 were	 transfected	 with	 PYL	construct	and	drugs	being	added.	After	48	hours,	drugs	were	changed	 with	 cell	 medium.	 On	 the	 fifth	 day,	 cells	 passed	through	the	flow	cytometer	and	GFP	intensity	was	recorded.	C-D.	PYL	targeting	showed	no	GFP	intensity	shift	in	CIT0B	(C)	and	CIT40B	(D)	cell	lines	compared	to	DMSO–treated	cells.		
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Figure III. 9. PYL targeting in CITnBY cells do not affect GFP 
expression. 
A. Cell line construction. ParB-ABI, PYL and GFP reporter 
constructs are stably transfected into Flp-in T-REX cells in a 
sequential manner. 
B.   Protein expression pattern in the cells.  
C. ChIP-qPCR experiment at INT and Actin locus upon ABA 
addition or not using an antibody against PYL construct. N=4. 
Error bars stand for standard error. 
D. Illustration of PYL targeting and non-targeting scenarios. 
E.   Typical flow cytometry profile for targeting of PYL. 
F-G Quantification of data in E for CIT40BY cells treated with ABA or 
DMSO. N=4. The error bars represent the standard error and the 
mean.  
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3.	 Histone	 deacetylase	 5	 (HDAC5)	 targeting	 decreases	 GFP	
expression	HDAC5	was	found	to	promote	CAG	repeat	expansion	in	a	plasmid-based	assay	for	 repeat	 instability	 in	 immortalized	 astrocytes	 (Gannon	 et	 al.,	 2012).	 The	mechanism	of	action	remains	unclear,	and	Gannon	et	al.	postulated	that	it	might	not	be	 because	 of	 local	 changes	 in	 chromatin	 structure.	 CIT	 is	 ideal	 to	 test	 this	hypothesis	directly.	If	indeed	targeting	of	HDAC5	acts	locally,	we	expected	to	find	a	shoulder	on	the	dark	side	of	the	GFP	curve	that	corresponds	to	expansions	(Cinesi	et	al.,	2016).	We	first	tested	the	hypothesis	by	transient	transfection	of	PYL-HDAC5	in	CIT40B	cells	(Figure	III.	10A).	We	found	that	a	bulge	appears	in	the	GFP	distribution	upon	ABA	addition	(Figure	III.	10D),	which	prompted	us	to	sort	individual	cells	with	less	 GFP,	 expecting	 to	 find	 expansions.	 However,	 all	 clones	 generated	 in	 this	experiment	had	40	repeats.	Besides,	we	found	that	the	culture	lost	the	characteristic	shoulder,	as	expected	if	this	effect	depended	on	expansions	when	the	targeting	was	released,	and	the	GFP	was	degraded	over	a	time	course	of	3	weeks	(Alicia	Borgeaud	Master	Thesis).	Together	these	results	suggest	that	the	GFP	intensity	decrease	seen	upon	targeting	HDAC5	is	not	due	to	CAG	instability.				 To	 control	 for	 efficient	 HDAC5	 targeting	 efficiency	 when	 adding	 ABA,	 I	performed	ChIP-qPCR	after	transient	transfection	to	determine	if	the	INT	sequence	is	enriched.	Unfortunately,	 I	 could	never	manage	 to	achieve	ChIP-qPCR	signal	over	background	 level	or	co-immunoprecipitating	PYL	and	ParB-ABI	 in	these	conditions		(data	not	shown).	This	is	likely	due	to	a	low	abundance	of	HDAC5	being	introduced	into	the	cell	by	transient	transfection.			 	
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Figure III. 10. Transient transfection and targeting of PYL-HDAC5 
downregulate GFP expression.  
A. Illustration of PYL-HDAC5 targeting. With ABA addition, PYL-
HDAC5 (blue and purple) forms dimer with ParB-ABI protein (brown 
and orange) and further target to INT sequence in GFP reporter. With 
no ABA presence, the PYL-HDAC5 targeting would not occur. 
B. Experimental design. Cells were transfected with PYL-HDAC5 
construct and drugs being added. After 48 hours, drugs were changed 
with cell medium. On the fifth day, cells passed through the flow 
cytometer and GFP intensity was recorded. 
C. Effect of targeting PYL-HDAC5 on GFP expression in CIT0B. 
D. Effect of targeting PYL-HDAC5 on GFP expression in CIT40B cells. 
Arrowhead indicates the change in expression seen upon targeting. 
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To	 overcome	 some	 of	 the	 limitations	 of	 transient	 transfections,	 I	 generated	CIT16BYH5	and	CITBY59H5	stable	cell	lines	(Figure	III.	11AB).					 			 	
Figure III. 11. CITnBYH5 stable cell line making. 
A. Cell line construction. ParB-ABI, PYL-HDAC5 and GFP reporter 
constructs are stably transfected into Flp-in T-REX cells in a 
sequential manner. 
B. Transgene expression in CITnBYH5 cells.  
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In	CIT16BYH5	cells,	I	found	a	robust	enrichment	of	39	fold	in	targeting	of	PYL-HDAC5	upon	addition	of	ABA	by	ChIP-qPCR	(Figure	III.	12B).	This	was	specific	to	the	INT	locus	because	the	levels	of	PYL-HDAC5	remained	unchanged	at	the	ACTA1	locus.	We	conclude	that	PYL-HDAC5	is	robustly	targeted	upon	ABA	addition	in	our	stable	cell	lines.			To	 test	 the	effect	of	PYL-HDAC5	 targeting	on	GFP	expression,	 I	 added	dox	as	well	as	ABA	or	DMSO	to	CIT16BYH5	cells	(Figure	III.	12C).	I	found	over	a	three-fold	decrease	 in	expression	upon	ABA	addition	compared	 to	DMSO	controls	 (Figure	 III.	12DE	–	P	<	0.01).			The	HDAC5	targeting	dependent	silencing	I	observed	may	occur	due	to	HDAC5	deacetylase	 activity.	 To	 test	 this	 hypothesis,	 I	 quantified	 acetylated	 histone	 H3	locally	 at	 the	 INT	 insertion	 using	 ChIP-qPCR,	 using	 an	 antibody	 recognizing	 pan-acetylated	 histone	 H3	 in	 CIT16BYH5	 cells,	 I	 found	 a8n	 eight-fold	 decrease	 in	 the	acetylation	 levels	 upon	 ABA	 addition.	 ChIP	 using	 an	 antibody	 against	 histone	 H3	indicated	that	this	acH3	enrichment	was	not	due	to	changes	in	H3	levels	at	this	locus	(Figure	 III.	 12F).	 This	 indicates	 that	 targeting	 HDAC5	 to	 the	 INT	 sequence	 led	 to	deacetylation	of	H3	and	suggested	that	the	PYL-HDAC5	construct	is	functional.				 	
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Figure III. 12. PYL-HDAC5 silencing of GFP expression in 
CIT16BYH5 cells. 
A. Cartoon of CIT16BYH5 with and without ABA. 
B. ChIP-qPCR experiment at INT and Actin locus in CIT16BYH5 cell 
line upon ABA addition or not using the antibody against PYL-
HDAC5 construct. N=4. Error bars stand for standard error.  
C. Experimental design. 
D. Typical flow cytometry profile for targeting in CIT16BYH5 cells. 
E. Quantification of the data shown in D. N=4 for each condition. 
Error bars stand for standard deviation. 
F. ChIP-qPCR experiment at INT and Actin locus in CIT16BYH5 cell 
line upon ABA addition or not using the antibody against acH3 
(N=2) and and H3 (N=1). Error bars stand for standard error.  
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Interestingly,	 the	 results	 upon	 targeting	 PYL-HDAC5	 in	 CIT59BYH5	 cells	suggested	 a	 repeat-size-dependent	 effect	 on	GFP	 expression.	 	 I	 first	 quantified	 the	shift	 in	 GFP	 expression	 upon	 PYL-HDAC5	 targeting	 	 (Figure	 III.	 13C).	 I	 found	 that	HDAC5	targeting	in	this	cell	line	led	to	a	two-fold	decrease	in	expression,	which	was	significantly	less	than	the	threefold	seen	in	CIT16BYH5	cells	(Figure	III.	12E,	P<0.01).	This	was	not	due	to	differences	in	protein	levels	between	the	two	cell	 lines	(Figure	III.	11B)	or	differences	in	targeting	efficiencies	(Figure	III.	13E).	ChIP	efficiency	was	higher	 in	 the	cell	 line	with	 the	 longer	CAG	 tract	 (Figure	 III.	12B,	13E).	 	These	data	suggest	 that	 the	 efficiency	 of	 HDAC5	 deacetylation	 is	 dependent	 on	 the	 sequence	context.	To	test	 this	directly,	 I	ChIPed	acetylated	H3	 in	CIT59BYH5	cells	and	found	that	 the	decrease	was	only	two-fold,	 i.e.,	not	as	dramatic	as	 the	sevenfold	decrease	seen	in	CIT16BYH5	cells	(Figure	III.	12F,	13F).	Here	again,	my	H3	ChIP	indicates	the	acH3	 enrichment	 difference	 was	 not	 due	 to	 H3	 default	 level	 (Figure	 III.	 13F).	 In	another	word,	the	addition	of	a	129	bp	(59	CAG	vs	16	CAG)	can	significantly	induce	local	chromatin	modifications	and	affect	how	HDAC5	deacetylates	its	target.		 	
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Figure III. 13. PYL-HDAC5 targeting reduces GFP expression.  
A. Experimental design.  
B. Typical flow cytometry profile for targeting in CIT59BYH5 cells. 
C. Quantification of the data shown in B. N=4 for each condition. 
D. The ratio of the mean comparison of the targeting effect in 
CIT16BYH5 and CIT59BYH5 cells. 
E. ChIP-qPCR of PYL-HDAC5 in CIT59BYH5. N=4 
F. ChIP-qPCR of acH3 (N=2) and H3 (N=1) in CIT59BYH5. 
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There	 is	 still	 a	 possibility	 that	 the	 effect	 we	 observed	 is	 not	 due	 to	 the	dimerization	 of	 ParB-ABI	 and	 PYL-HDAC5	 at	 the	 INT	 sequence.	 To	 test	 this	possibility,	 I	generated	cell	 lines	without	an	INT	sequence	but	expressing	ParB-ABI	stably:	 GFP(CAG)0B	 and	 GFP(CAG)101B	 cells	 (Figure	 III.	 14A).	 I	 then	 transiently	transfected	PYL-HDAC5	into	GFP(CAG)0B	cells	and	GFP(CAG)101B	cells	and	measured	GFP	intensity	after	five	days	culture	with	dox	and	ABA	or	DMSO	(Figure	III.	14B).	I	found	no	change	in	GFP	expression	(Figure	III.	14CD)	in	contrast	to	what	was	seen	in	CIT40B	cells	(Figure	III.	10D).			Overall,	 our	 results	 suggest	 that	 HDAC5	 deacetylation	 activity	 depends	 on	sequence	context.			 	
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Figure III. 14. The effect of PYL-HDAC5 targeting on GFP expression 
depends on the presence of the INT sequence.   
A. Cell line construction. GFP reporter and ParB-ABI constructs are 
stably transfected into Flp-in T-REX cells in a sequential manner. 
B.    Experimental design.  
C-D. Representative flow cytometry profiles for GFP(CAG)0B (C) and 
GFP(CAG)101B (D) cells. 
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N-terminal	of	HDAC5	may	be	responsible	for	gene	silencing	To	gain	further	insights	into	the	mechanisms	of	action	of	HDAC5,	we	sought	to	determine	 which	 domains	 are	 necessary	 and/or	 sufficient	 for	 silencing.	 We,	therefore,	 constructed	 a	 series	 of	 truncation	 mutants	 and	 transfected	 them	 into	CIT40B	cells.	We	 found	 that	 the	HDAC5	N-terminus	 is	 sufficient	 for	decreasing	 the	expression	of	the	GFP	reporter,	whereas	targeting	the	catalytic	domain	alone	did	not	have	 an	 effect.	 Indeed,	 using	 mutants	 in	 the	 catalytic	 domain	 that	 dramatically	improves	acetylation	 levels	or	entirely	abolish	 them	did	not	have	an	effect	on	GFP	expression	 upon	 targeting.	 This	 is	 not	 entirely	 unexpected	 given	 that	 HDAC5,	 like	other	types	IIa	HDACs,	is	thought	to	function	by	recruiting	other	factors	rather	than	carrying	out	the	deacetylation	itself	(Fischle	et	al.,	2002;	Kao	et	al.,	2000;	Lahm	et	al.,	2007).	Further	truncation	of	the	N-terminus	suggests	that	the	coiled-coil	domain	of	HDAC5	 responsible	 for	 homo-	 and	 heterodimerization	 (Backs	 et	 al.,	 2008),	 is	essential	 for	 the	 function	 of	 HDAC5.	 These	 experiments	 show	 that	 our	 targeting	system	 is	 highly	 useful	 in	 gaining	 significant	 insights	 into	 the	mechanism	 of	 gene	silencing.			 	
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Figure III. 15. Targeting of the N-terminal of HDAC5 is sufficient to 
shift the expression of GFP. (Adapted from Alicia Borgeaud Master 
Thesis) 
A. HDAC5 mutant constructs. The HDAC5 catalytic domain is shown 
in orange. All the truncation forms have amino acid sizes indicated 
on the left and names on the right.   
B. Experimental design.  
C. Data quantification for GFP intensity differences in ABA or DMSO 
in CIT40B cells transfected with PYL-HDAC5 truncations. N=4. 
Error bars indicate standard deviation. 
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4.	HDAC3	targeting	promotes	local	gene	expression	HDAC5	is	thought	to	recruit	Class	I	HDACs,	including	HDAC3.	HDAC3	is	part	of	the	 nuclear	 co-repressor	 complexes	 Nco-R	 and	 SMRT	 and	 acts	 as	 the	 deacetylase	(You	 et	 al.,	 2013).	 Moreover,	 both	 HDAC3	 and	 HDAC5	 were	 shown	 to	 promote	trinucleotide	 repeat	 expansion	 in	 human	 astrocyte	 cells	 by	 Lahue’s	 laboratory	(Debacker	et	al.,	2012;	Gannon	et	al.,	2012).	Thus,	I	expected	that	targeting	HDAC3	would	have	a	similar	effect	to	HDAC5	targeting.	Transient	 transfection	 of	 PYL-HDAC3	 in	 CITnB	 cells	 (Figure	 III.	 16A),	 unlike	PYL-HDAC5,	changed	GFP	expression	in	neither	CIT0B	nor	CIT40B	cells	(Figure	III.	16BC).			 	
Figure III. 16. The PYL-HDAC3 transient expression did not change 
GFP intensity upon targeting. 
A. Experimental design. 
B. Typical flow cytometry profile for targeting of PYL-HDAC3 in 
CIT0B cells. 
C. Typical flow cytometry profile for targeting of PYL-HDAC3 in 
CIT40B cells. 
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Since	the	effect	we	saw	with	HDAC5	was	dramatically	smaller	than	that	seen	in	stable	cell	lines,	we	build	CITnBYH3	cells	that	were	isogenic	except	for	the	size	of	the	repeat	tract	in	the	GFP-INT	reporter	(Figure	III.	17AB,	Table	1).			 				 	
Figure III. 17. CITnBYH3 stable cell line making. 
A. Cell line construction. ParB-ABI, PYL-HDAC3 and GFP reporter 
constructs are stably transfected into Flp-in T-REX cells in a 
sequential manner. 
B. Transgenes expression in CITnBYH3 cells.  
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I	found	that	PYL-HDAC3	was	robustly	recruited	to	INT	with	a	four-fold	increase	when	ABA	was	added	to	the	media	for	five	days	compared	to	DMSO	alone	(Figure	III.	18A).			Surprisingly,	 PYL-HDAC3	 targeting	 in	 CIT16BYH3	 cells	 showed	 a	 slight	 but	significant	 shift	 towards	 more	 GFP	 expression	 as	 measured	 after	 five	 days	 of	targeting	using	flow	cytometry	(Figure	III.	18	CD).	This	is	surprising,	but	HDAC3	was	shown	to	bind	preferentially	to	promoters	of	highly	expressed	genes,	and	targeting	it	with	a	catalytically	null	Cas9	had	locus-specific	effects	that	are	currently	unexplained	(Kwon	et	al.,	2017;	Wang	et	al.,	2009).			To	test	whether	PYL-HDAC3	targeting	affected	histone	H3	acetylation,	I	ChIPed	acetylated	 H3	 in	 CIT16BYH3	 cells.	 	 After	 five	 day-treatment	 with	 either	 ABA	 or	DMSO,	 I	 found	 that	 the	 INT	 sequence	 showed	 significant	 2.5	 fold	 enrichment	 of	acetylated	H3	upon	targeting	(Figure	III.	18E).	H3	ChIP	excluded	the	possibility	that	acH3	 increased	 because	 of	 an	 increase	 in	 H3	 (Figure	 III.	 18E).	 The	 ACTA1	 locus	remained	 unaltered	 by	 these	 treatments,	 showing	 that	 the	 targeting	 was	 specific.	The	increase	in	acH3	upon	targeting	explains	well	the	concomitant	increase	in	GFP	expression.	Why	HDAC3	 targeting	would	 increase	 acH3	 is	 not	 clear,	 and	 it	will	 be	further	speculated	about	in	the	Discussion	section.			 	
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Figure III. 18.  PYL-HDAC3 targeting increases GFP expression. 
A. ChIP-qPCR experiment at INT and Actin locus in CIT16BYH3 cell 
line upon ABA addition or not using the antibody against PYL-
HDAC3 construct. N=4. Error bars stand for standard error.  
B. Experimental design.  
C. Typical flow cytometry profile for targeting in CIT16BYH3 cells. 
D. Quantification of the data shown in C. N=4 for each condition. 
Error bars stand for standard deviation. 
E. ChIP-qPCR experiment at INT and Actin locus in CIT16BYH3 cell 
line upon ABA addition or not using the antibody against acH3 and 
H3. Error bars stand for standard error. N=4 
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To	 determine	 whether	 HDAC3,	 like	 HDAC5,	 had	 a	 repeat-length	 dependent	effect	on	gene	expression,	I	performed	the	ChIP	and	flow	cytometry	experiments	in	isogenic	CIT89BYH3	cells.	 	The	cells	were	cultured	 for	 five	days	 in	 the	presence	of	dox	 as	 well	 as	 either	 ABA	 or	 DMSO	 (Figure	 III.	 19A).	 I	 found	 that	 PYL-HDAC3	targeting	in	this	context	also	increased	GFP	expression	significantly	(Figure	III.	19BC	–	P<0.01).	To	determine	whether	HDAC3	acts	differently	when	the	repeat	tract	is	in	the	 normal	 or	 the	 expanded	 range,	 I	 performed	 a	 statistical	 analysis	 on	 the	expression	 results	 of	 CIT16BYH3	 and	 CIT89BYH3	 cells.	 I	 found	 that	 PYL-HDAC3	targeting	increased	slightly	from	a	1.2	fold	effect	in	CIT16BYH3	cells	to	a	1.5	fold	in	CIT89BYH3	 cells,	 but	 this	 increase	was	 not	 statistically	 different.	 (p-value	 =	 0.07)	(Figure	 III.	 19D).	Thus,	 unlike	HDAC5,	which	had	a	 repeat-length-dependent	 effect	on	gene	expression,	HDAC3	did	not.			HDAC3	targeting	and	functionality	were	also	tested	by	ChIP-qPCR	of	the	fusion	protein	 to	 INT	 and	 by	 the	 levels	 of	 acH3	 and	 H3	 ChIP-qPCR	 in	 CIT89BYH3.	 The	results	 were	 similar	 to	 those	 with	 the	 shorter	 repeat	 tract:	 PYL	 pull	 down	 was	enriched	3.2	fold	when	cultured	in	the	presence	of	ABA	compared	to	the	untargeted	DMSO	 (Figure	 III.	 19E).	 Concomitantly,	 the	 levels	 of	 acetylation	were	 increased	by	2.1	fold,	while	the	H3	levels	did	not	change	(Figure	III.	18F).	It	may	be	useful	to	test	whether	the	catalytic	activity	of	HDAC3	is	required	using	specific	HDAC3	inhibitors.		
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Figure III. 19. PYL-HDAC3 targeting increases GFP expression 
independently of repeat size.  
A. Experimental design.  
B. Typical flow cytometry profile for targeting in CIT89BYH5 cells. 
C. Quantification of the data shown in C. N=4 for each condition.  
D. Comparison of the effect of targeting on GFP expression in 
CIT16BYH3 and CIT89BYH3 cells. 
E. ChIP-qPCR of PYL-HDAC3 in CIT89BYH3. N=4 
F. ChIP-qPCR of acH3 and H3 in CIT89BYH3.  N=4 
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As	it	was	the	case	with	PYL-HDAC5	targeting,	I	found	that	transient	expression	of	PYL-HDAC3	in	GFP(CAG)0B	and	GFP(CAG)101B		cells	(Figure	III.	20A)	did	not	affect	gene	 expression	 (Figure	 III.	 20BC).	 I	 conclude	 that	 local	 targeting	 of	 PYL-HDAC3	increases	acetylated	H3	and	GFP	expression	regardless	of	repeat	size.		
	 	
Figure III. 20. The effect of PYL-HDAC5 targeting on GFP expression 
depends on the presence of the INT sequence.  
A.     Experimental design.  
B-C. Representative flow cytometry profiles for GFP(CAG)0B (B) and 
GFP(CAG)101B (C)cells expressing PYL-HDAC3. 
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5.	DNA	methyltransferase	1	targeting	increases	GFP	expression	in	a	
repeat-size-dependent	manner	DNA	methyltransferase	1	 (DNMT1)	has	been	shown	 to	 stabilize	an	expanded	repeat	 in	SCA1	mice	and	human	cells	 (Dion	et	al.,	2008).	The	mechanism	of	action	remains	 unclear.	We,	 therefore,	 tested	whether	DNMT1	 had	 a	 local	 effect	 on	DNA	methylation	 to	 affect	 instability	 as	 suggested	by	Dion	et	 al.,	 or	 through	an	 indirect	effect.	 I,	 therefore,	built	CITnBYD	cells	that	express	stably	PYL-DNMT1	and	contain	the	GFP-INT	reporter	with	either	16	or	89	CAGs		(Figure	III.	21A	and	Table	1).	The	two	isogenic	cell	 lines	had,	as	expected,	similar	levels	of	ParB-ABI	and	PYL-DNMT1	(Figure	III.	21B).		 	 	
Figure III. 21. CITnBYD stable cell line making. 
A. Cell line construction. ParB-ABI, PYL-Dnmt1 and GFP reporter 
constructs are stably transfected into Flp-in T-REX cells in a 
sequential manner. 
B. Transgene expression in CITnBYD cells.  
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ChIP-qPCR	experiments	confirmed	PYL-DNMT1	recruitment	when	adding	ABA.	The	 recruitment	 was	 significant	 with	 a	 19	 fold	 increase	 in	 the	 presence	 of	 ABA	compared	to	when	DMSO	was	used	in	CIT16BYD	cells	and	26	fold	in	CIT89BYD	cells	(Figure	 III.	 22A,	 Figure	 III.	 23A).	 Recruitment	 to	 actin	 was	 low	 and	 remained	unchanged,	suggesting	that	the	targeting	is	both	specific	and	efficient.			I	then	determined	whether	PYL-DNMT1	targeting	in	CIT16BYD	and	CIT89BYD	influenced	GFP	expression	 (Figure	 III.	 22CD	and	23BC).	 In	both	 cases,	 there	was	a	significant	decrease	in	GFP	intensity	of	2	fold	and	1.6	fold	(P	=	0.003	and	P	=	0.0005,	respectively).	 By	 contrast,	 transient	 transfection	 and	 targeting	 of	 PYL-DNMT1	 in	GFP(CAG)0B	 and	 GFP(CAG)101B	 cells	 did	 no	 show	 changes	 in	 GFP	 expression,	suggesting	that	the	silencing	observed	is	due	to	direct	binding	of	DNMT1	to	the	INT	sequence	(Figure	III.	24BC).			Interestingly,	 like	 in	 the	 case	 of	 PYL-HDAC5,	 PYL-DNMT1	 targeting	 led	 to	 a	significant	 allele-length	 dependent	 silencing	 of	 the	 reporter	 (P=	 0.04).	We	will	 be	able	 to	 give	 a	 conclusion	 about	 DNMT1	 influence	 DNA	 methylation	 and/or	chromatin	modification	after	bisulfate	sequencing,	and	acH3	ChIP	finished.	However,	the	 simplest	 explanation,	 in	 this	 case,	 is	 that	 PYL-DNMT1	 targeting	 was	 more	efficient	in	the	context	of	a	longer	repeat	tract.		 	
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Figure III. 22. PYL-DNMT1 targeting silences GFP expression. 
A. ChIP-qPCR experiment at INT and Actin locus in CIT16BYD cell 
line upon ABA addition or not using the antibody against PYL-
Dnmt1 construct. N=4. Error bars stand for standard error.  
B. Experimental design. 
C. Typical flow cytometry profile for targeting in CIT16BYD cells. 
D. Quantification of the data shown in C. N=4 for each condition. 
Error bars stand for standard deviation. 
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Figure III. 23. The effect of PYL-DNMT1 targeting on GFP expression 
is repeat-length dependent. 
A. ChIP-qPCR of PYL-DNMT1 in CIT89BYD. N=4 
B. Typical flow cytometry profile for targeting in CIT89BYD cells. 
C. Quantification of the data shown in B. N=4 for each condition. 
Error bars stand for standard deviation. 
D. Comparison of the effect of targeting on GFP expression in 
CIT16BYD and CIT89BYD cells. Error bars stand for standard 
deviation. 
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Figure III. 24. The effect of PYL-DNMT1 targeting depends on the 
presence of the INT sequence.   
A.  Experimental design.  
B-C. Typical flow cytometry profile for targeting in PYL-DNMT1 in 
GFP(CAG)0B (B) and GFP(CAG)101B (C)cells.  
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6.	GFP	expression	changes	are	not	due	to	CAG	repeat	instability	The	GFP	assay	was	designed	to	 look	for	repeat	 instability	(Cinesi	et	al.,	2016;	Santillan	et	al.,	2014).	Moreover,	we	constructed	CIT	to	test	the	hypothesis	that	local	recruitment	 of	 chromatin	 modifiers	 enzymes	 is	 sufficient	 to	 drive	 CAG	 repeat	instability.	However,	given	that	the	reporter	requires	transcription	and	that	there	is	an	 alternative	 CAG	 exon,	 our	 system	 can,	 in	 principle,	 monitor	 three	 processes	simultaneously:	 instability,	 transcription,	 and	 splicing.	 I,	 therefore,	 tested	 the	hypothesis	 that	 targeting	of	HDAC5,	HDAC3,	or	DNMT1	may	be	due	 to	CAG	repeat	expansion	 or	 contraction.	 To	 do	 so,	 Oscar	 Rodriguez	 Lima	 and	 I	 collaborated	 to	perform	small	pool	PCR	(SP-PCR)	to	detect	CAG	repeats	length	change	(Method).	SP-PCR	 is	 a	 gold-standard	method	 to	 detect	 CAG	 repeats	 variability.	 Briefly,	 genomic	DNA	is	diluted	down	to	only	a	few	genomes	per	PCR,	and	multiple	reactions	are	set	up	for	a	single	sample.	This	minimizes	the	bias	towards	amplifying	shorter	repeats.	Because	 the	 yield	 is	 weak	 because	 of	 a	 limited	 number	 of	 templates,	 Southern	blotting	 is	necessary.	To	maximize	 the	chances	of	detecting	changes	 in	CAG	repeat	instability,	 I	 prepared	 the	 genomic	 DNA	 samples	 after	 four	 weeks	 of	 continuous	culturing	in	the	presence	of	ABA	or	DMSO	and	compared	the	flow	cytometry	results	(Figure	III.	25A).			We	first	tested	HDAC5	and	DNMT1	given	that	they	had	the	most	exciting	effects	on	GFP	expression.	We	saw	no	significant	changes	in	CAG	repeat	instability	between	the	 ABA	 and	 DMSO	 treated	 samples	 	 (Figure	 III.	 25BC).	 This	 result	 indicates	 the	silencing	events	when	targeting	HDAC5	or	DNMT1	in	the	CIT	system	may	not	due	to	CAG	instability.	It	remains	possible	that	the	frequencies	of	instability	are	too	low	for	SP-PCR	to	detect	and	that	waiting	longer	would	reveal	then.				
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Figure III. 25. GFP intensity change may not due to CAG repeat 
instability in one-month treatment.  
A. Experimental design. Compare to the typical flow cytometry 
experiment timeline, samples for small pool PCR analysis are 
treated for 1 month.  
B. Southern blot for CIT40BYH5. Arrowhead indicates the original 
repeat number fragment. 
C. Southern blot for CIT89BYD. Arrowhead indicates the original 
repeat number fragment. 
	 96	
7.	An	alternative	 targeting	 strategy	 to	 test	HDAC5	direct	 effect	 on	
gene	transcription	and/or	silencing	Epigenome	editing	is	increasingly	done	via	dCas9	fusions.	We,	therefore,	tested	whether	we	 could	 reproduce	 the	 results	 found	here	with	dCas9	 fusion.	 To	build	 a	dCas9-dependent	 targeting	 of	 HDAC5,	 I	 used	 CITn	 cells	 	 (Figure	 III.	 26A).	 The	experimental	 design	 was	 to	 have	 dCas9	 fused	 to	 a	 protein	 of	 interest,	 guided	 by	single	 guide	 RNA	 to	 the	 GFP	 locus	 to	 achieve	 targeting.	 There	 were	 significant	challenges	 to	 overcome	 to	 achieve	 this.	 First,	 the	 molecular	 weight	 of	 dCas9	 is	limiting,	and	a	dCAS9-HDAC5	fusion	protein	would	be	280kDa,	which	is	not	practical	to	work	with.	Besides,	since	ParB	oligomerizes,	there	is	a	large	number	of	molecules	of	ParB	that	get	recruited,	which	is	not	necessarily	the	case	for	dCas9.				We	first	designed	seven	different	sgRNAs	targeted	to	the	GFP	locus	as	showed	in	Figure	III.	26B	with	one	control	sgRNA	being	used.	To	test	how	well	they	worked	in	 cells,	 I	 transfected	wild-type	Cas9	with	 seven	 sgRNAs	 separately	 into	 the	CIT40	cells	for	three	days.	Cells	were	then	harvested,	and	genomic	DNA	was	extracted	for	PCR	amplification.	 If	 a	 sgRNA	successfully	 targeted	Cas9	 to	 its	 target	 site,	 cleavage	will	produce	indels.	The	PCR	product	of	the	region	after	transfection	is	then	mixed	in	equal	 molar	 ratios	 with	 the	 same	 PCR	 but	 from	 the	 untransfected	 cells.	 	 After	denaturation	 and	 slow	 annealing,	 fragments	 will	 form	 mismatches	 due	 to	 on-targeting	cleavage	and	indel	formation.	The	T7	endonuclease	I	is	then	used	to	digest	mismatched	fragment,	given	multiple	bands	on	an	agarose	gel.	Figure	III.	26C	shows	that	at	 least	sgVIN-006	had	a	second	band	after	T7endoI	treatment.	 I	also	included	sgRNAs	 targeting	 the	 repeat	 tract	 itself,	 sgRNA	sgVIN-050	and	 sgVIN-052,	because	they	 have	 been	 shown	 to	 bring	 the	 Cas9	 nickase	 to	 the	 repeat	 tract	 (Cinesi	 et	 al.,	2016).	I	also	included	these	two	sgRNAs	even	though	they	did	not	show	an	evident	T7endoI	endonuclease	cleavage	(Figure	III.	26C).			 	
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Figure III. 26.  dCas9 targeting using sgRNAs in CIT0 and CIT40 
cells. 
A. Cell lines construction. GFP reporter is stably integrated into Flp-in 
T-REX cells. 
B. Short lines indicate sgRNA localization within the GFP transgene 
along with their identifying numbers. 
C. T7endI test for editing efficiency. 
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I	 used	 the	 dCas9-KRAB	 fusion	 construct	 first	 to	 see	 whether	 targeting	 of	 a	silencing	 factor	 to	 the	 INT	sequence,	which	 is	 several	kb	away	 from	 the	promoter,	could	silence	it.			The	control	is	an	empty	vector	construct	called	pPN10	that	does	not	encode	a	targeting	sequence.	sgVIN-006	was	used	to	target	the	INT	sequence.	I	found	that	dCas9-KRAB	targeting	to	INT	had	no	significant	effect	on	the	expression	of	the	GFP	compared	to	dCas9	expression	without	a	sgRNA	(Figure	III.	27B).	The	same	was	true	in	CIT40	cells	(Figure	III.	27C).	As	a	further	control,	I	targeted	a	blue	fluorescent	protein	(BFP)	fused	to	dCas9.	As	expected,	no	GFP	intensity	change	was	seen	for	this	construct	 (Figure	 III.	 27DE).	 dCas9	 to	 bring	 transcription	 silencing	 factor	KRAB	 to	INT	sequence	could	induce	minor	GFP	decrease	in	CIT	cells	with	0	CAG	and	40	CAGs.			 	
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Figure III. 27. dCas9-KRAB and dCas9-BFP targeting in CIT0 and 
CIT40 cells. 
A. Experimental design.  
B. Typical flow cytometry profile for targeting in dCas9-KRAB in 
CIT0 cells. 
C. Typical flow cytometry profile for targeting in dCas9-KRAB in 
CIT40 cells. 
D. Typical flow cytometry profile for targeting in dCas9-BFP in CIT0 
cells. 
E. Typical flow cytometry profile for targeting in dCas9-BFP in 
CIT40 cells. 
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Considering	the	size	of	the	dCas9-HDAC5	fusion	protein,	we	opted	to	use	only	the	N-terminal	based	on	our	results	with	transient	transfection	(Figure	III.	15).		The	 dCas9-HDAC5	 truncation	 constructs	 with	 sgRNAs	 were	 transiently	transfected	 into	 CIT0	 and	 CIT40	 cells.	 	 I	 found	 that	 the	 dCas9-HDAC5	 N	 terminal	domain	(dCas9-HDAC5NT)	fusion	protein	did	not	affect	GFP	intensity	shift	whether	the	sgRNA	against	INT	was	included	or	not	(Figure	III.	28B).	Furthermore,	the	dCas9	fused	to	an	HDAC5	catalytic	domain	(dCas9-HDAC5	CD)	seemed	to	narrow	the	GFP	intensity	peak	in	sgVIN-006-transfected	compare	to	pPN10-transfected	cells.	(Figure	III.	 28C).	 The	 same	 experiment	 with	 dCas9-HDAC5NT	 in	 CIT40	 cells	 seemed	 to	increase	 GFP	 expression	 slightly	 when	 the	 sgRNA	 against	 the	 INT	 sequence	 was	included,	whereas	dCas9-HDAC5	CD	did	not	have	any	effect	(Figure	III.	28DE).		It	is	possible	that	this	lack	of	significant	effects	on	GFP	expression	of	the	dCas9-construct	reflects	 the	 requirement	 to	 recruit	 silencers	 closer	 to	 the	 promoter	 (Gilbert	 et	 al.,	2014)	or	that	there	is	not	enough	HDAC5	recruited	to	the	INT	sequence	when	dCas9	is	 used	 compared	 to	 ParB.	 Indeed,	 many	 silencing	 proteins	 appear	 as	 foci	 in	 the	nucleus	 that	 correspond	 to	 several	 hundred	 molecules	 and	 may	 work	 via	 liquid	phase	 separation	 (Larson	 et	 al.,	 2017;	 Strom	 et	 al.,	 2017).	 This	 interpretation	 has	significant	 implications	 when	 it	 comes	 to	 designing	 epigenome	 editing	 strategies	with	dCas9.			 	
	 101	
		 	
	
	
	 	
Figure III. 28. dCas9-HDAC5 truncation targeting in CIT0 and CIT40 
cells. 
A. Experimental design.  
B–I. Typical flow cytometry profiles for targeting of dCas9-HDAC5 
truncations.   
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Chapter	IV	
	
Discussion	 	
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Here	 we	 present	 the	 chromatin	 inducible	 targeting	 (CIT)	 system	 and	 its	application	 to	 understanding	 how	 chromatin	 modifying	 enzymes	 affect	 gene	regulation.	 CIT	 uses	 cell	 lines	with	 a	 stable	 transgene	 integration	 that	 is	 carefully	designed	to	make	transgenes	comparable	to	each	other.	We	designed	it	to	make	up	for	 what	 loss-of-function	 approaches	 could	 not	 tackle:	 whether	 the	 effect	 of	 any	given	chromatin	modifying	enzyme	is	direct	or	is	due	to	changes	in	gene	expression	
in	trans.	We	used	it	to	investigate	the	effect	of	HDAC5,	HDAC3	and	DNMT1	targeting	on	 either	 silencing	 or	 promoting	 gene	 expression.	 CIT	 can	 be	 integrated	 into	 any	genome	locus,	not	restricted	to	usage	we	showed	here.	Furthermore,	it	may	have	an	extensive	usage	for	screening.	
	
1.	The	advantages	of	CIT			
	
1.1	Protein-DNA	targeting	system	-	ParB-INT	Targeting	 systems	 have	 been	 used	 widely	 for	 tethering	 specific	 protein	 to	specific	locus	and	induces	diverse	cellular	functions	(Waryah	et	al.,	2018).	What	we	have	here	 is	a	 targeting	strategy	with	a	bacteria	derived	ParB-INT	system	fused	 to	plant	hormone	ABA-induced	proximity	system.	The	feature	of	the	ParB-INT	system	is	 its	efficient	 targeting	rate	(up	 to	44	 fold),	 insensitive	 to	 the	DNA	contexts	 tested	here	and	can	attract	multiple	molecules	to	the	target	DNA	sequence.		A	characteristic	of	significant	importance	for	targeting	systems	is	the	tethering	efficiency.	 Indeed,	 one	 concern	 is	 that	 large	 fusion	 proteins	may	 not	 be	 recruited	efficiently.	Here,	however,	we	found	that	four	different	POIs	ranging	from	26	kDa	to	196	 kDa,	 achieved	 robust	 targeting	 efficiency	 upon	 ABA	 addition,	 up	 to	 44-fold	increase	 compared	 to	 DMSO	 alone,	 in	 PYL	 as	 well	 as	 PYL-HDAC5,	 PYL-HDAC3	 or	PYL-DNMT1,	 based	 on	 the	 validation	 from	 ChIP-qPCR.	 We	 conclude	 that	 the	targeting	efficiency	within	the	system	is	robust	regardless	of	the	size	of	the	proteins	targeted,	at	least	within	the	range	that	we	tested.		Chromatin	context	could	also	affect	targeting	efficiently.	This	is	the	case	within	other	 existing	 targeting	 systems.	 TALEs	 can	 be	 impaired	 by	 condensed	 chromatin	
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(Bultmann	 et	 al.,	 2012;	 Chen	 et	 al.,	 2013)	 and	 dCas9	 binds	 poorly	 to	hypermethylated	CpG	islands	(Cano-Rodriguez	et	al.,	2016;	Qi	et	al.,	2013).	Targeting	efficiency	for	ParB-INT,	by	contrast,	was	unaffected	by	the	presence	of	an	expanded	CAG	tract.	 	Expanded	TNRs	correlate	with	altered	chromatin	structure	and	make	 it	more	 heterochromatic	 (Dion	 and	 Wilson,	 2009;	 Nageshwaran	 and	 Festenstein,	2015),	suggesting	that	 targeting	of	ParB-INT	is	 independent	of	changes	brought	by	an	expanded	CAG	tract.	 In	CIT59BYH5	DMSO	condition,	acetylated	histone	3	 levels	dropped	to	below	50%	compared	to	CIT16BYH5	in	DMSO.	With	active	transcription	marks	significantly	decreased,	HDAC5	still	shows	30-fold	PYL	pull	down	enrichment	upon	ABA	addition	in	59	CAG	samples	and	40-fold	when	CIT16BYH5	cells	were	used.	Until	 now,	 we	 observed	 no	 impairment	 of	 targeting	 by	 expanded	 trinucleotide	repeats	at	the	GFP	reporter.					Last	but	not	 least,	 is	 the	 feature	of	 the	ParB-INT	 targeting	 that	multiple	ParB	molecules	are	recruited	to	 the	 INT	sequence.	This	may	explain	why	CIT	and	dCas9	system	 give	 different	 results	 with	 the	 same	 POI	 domain	 treatment.	 Clearly,	 in	contrast	to	CIT,	dCas9-HDAC5	N	terminal	in	our	system	did	not	show	direct	silencing	effect.	We	hypothesize	 that	 this	might	be	due	 to	 local	protein	 concentration.	 Since	ParB	 has	 been	 reported	 to	 accumulate	 100-200	 proteins	 targeting	 to	 INT	 in	 vitro	(Saad	 et	 al.,	 2014),	 this	may	provide	 a	 dramatic	 difference	with	 having	 one	dCas9	bringing	 one	 HDAC5	 molecule	 to	 the	 same	 locus.	 Of	 course,	 there	 are	 other	possibilities	like	the	steric	hindrance	or	that	HDAC5NT	fusion	to	dCas9	prevents	its	efficient	targeting.	To	test	this,	I	may	perform	a	dCas9-HDAC5NT	ChIP-qPCR	to	test	the	 targeting	 efficiency.	 Unlike	 the	 dCas9	 targeting	 approach,	 CIT	 system	multiple	molecules	binding	enlarges	POI	signal,	and	it	may	help	to	fish	out	some	weaker	effect	using	this	system.		 	
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1.2	Chemical-induced	proximity	system	-	ABA	system	It	is	important	to	note	that	different	levels	of	the	PYL	fusions	between	cell	lines	with	different	repeat	length	would	have	prevented	us	from	making	the	conclusions	found	herein.	Indeed,	we	took	care	to	design	CIT	such	that	PYL	fusions	are	integrated	into	the	genome	before	adding	the	GFP	reporter	with	differing	repeat	sizes.	The	FLP-In	system	further	allows	us	to	integrate	the	reporter	at	a	specific	single	locus.	Thus,	we	can	make	the	comparisons	directly,	yet	not	between	the	lines	with	different	PYL	fusions.		We	chose	the	ABI-PYL	system	among	several	CIP	systems	(Liang	et	al.,	2011).	This	was because	it	did	not	show	evident	toxicity	to	human	and	animals	proved	by	our	 regular	 vegetable	 consumption	 (Stanton	 et	 al.,	 2018).	 Compared	 to	 ABA,	 the	commonly	 used	 FKBP-rapamycin	 system	 contains	 endogenous	 proteins	 receptors	(Kang	et	al.,	2008).	Overexpression	of	FKBP	may	disturb	in	vivo	signal	transduction	and	make	 it	 less	 ideal	 for	our	purpose.	On	 the	other	hand,	 the	 trivial	 addition	and	removal	of	ABA	to	induce	or	reverse	proximity	provide	a	convenient	way	to	control	the	process.	The	light-induced	dimerization	systems	also	show	some	advantages	in	spatiotemporal	protein-protein	 interaction	studies	 (Kennedy	et	al.,	2010;	Levskaya	et	al.,	2009;	Yazawa	et	al.,	2009).	Compared	to	expose	cell	culture	under	blue	light,	which	 requires	 LEDs	 and	 black	 box,	 ABA	 system	 would	 be	 more	 efficient	 to	 be	applied	in	our	application	and	more	efficiently	to	be	implemented	by	merely	adding	ABA	to	cell	medium.	In	conclusion,	including	ABA-inducible	proximity	system	in	the	CIT	system	gives	well-controlled	POI	local	effect	and	is	trivial	to	use	in	daily	research.		
1.3	 Convenient	 reporter	 assay	 to	 measure	 transcription	 and	
splicing	alternation	-	GFP	reporter	A	 widely	 used	 detection	 for	 transcription	 and/or	 splicing	 change	 is	quantitative	 PCR.	 Instead	 of	 using	 qPCR	 as	 the	 readout	 on	 a	 daily	 basis,	 I	 took	advantage	of	our	lab	common	tool,	a	GFP	minigene	reporter,	as	a	fast	and	sensitive	readout	 of	 gene	 expression.	 It	 can	 detect	 repeat	 instability	 (Cinesi	 et	 al.,	 2016;	Santillan	 et	 al.,	 2014),	 changes	 in	 alternative	 splicing	 and	 transcription,	making	 it	ideal	for	a	wide	array	of	purposes.	
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	Five	 days	 of	 treatment	with	 Cas9	 nickase	 and	 chromatin	modifying	 enzymes	leads	to	significant	GFP	intensity	shift	shown	in	previous	publications	from	our	lab	and	others	(Cinesi	et	al.,	2016).	This	indicates	that	a	short	time	frame	treatment	with	GFP	 reporter	 is	 enough	 to	 reveal	 GFP	 intensity	 difference	 after	 local	 genome	 or	epigenome	 editing.	 It	 can	 also	 detect	 GFP	 expression	 up-regulation	 and	 down-regulation	result	at	the	same	time.	This	would	be	very	informative	for	researches	on	gene	regulation	and/or	repeat	instability.			
2.	Testing	chromatin	modifying	enzymes	effect	using	CIT		
	The	 first	 group	 of	 proteins	 we	 tested	 with	 CIT	 were	 HDAC5,	 HDAC3	 and	DNMT1.	HDAC5	and	HDAC3	affect	 local	chromatin	modification	and	further	 impact	on	gene	regulation	and	trinucleotide	repeat	instability(Debacker	et	al.,	2012;	Gannon	et	 al.,	 2012;	 Suelves	 et	 al.,	 2017).	 DNMT1	 is	 responsible	 for	 maintaining	 DNA	methylation	 and	 shows	 its	 role	 also	 in	 trinucleotide	 repeat	 instability	 (Dion	 et	 al.,	2008;	Robert	et	al.,	2003).			Making	 of	 some	 additional	 control	 cell	 lines	 is	 still	 ongoing	 due	 to	 unseen	technical	 delay.	 It	would	 be	 better	 to	 include	 PYL	 control	 cell	 lines	 (CIT16BY	 and	CIT89BY)	 with	 the	 same	 CAG	 repeat	 length	 as	 being	 used	 in	 HDACs	 and	 DNMT1	work.	 Hopefully,	 this	 part	 of	 the	 experiment	 will	 be	 finished	 before	 my	 defense.	Another	ongoing	work	is	HDAC5,	HDAC3	and	DNMT1	bisulfite	sequencing	for	 local	gene	DNA	methylation	test.	We	would	be	able	to	tell	the	change	of	DNA	methylation	upon	POI	targeting	soon.		
2.1	The	role	of	HDAC5	N-terminus	in	local	silencing		Targeting	PYL-HDAC5	has	a	silencing	effect	in	CIT.	As	a	class	IIa	HDAC,	HDAC5	possesses	a	poor	deacetylase	activity	(Fischle	et	al.,	2002;	Lahm	et	al.,	2007).	While	in	the	CIT	system	with	16	CAG	and	59	CAG	GFP	reporter,	HDAC5	targeting	induces	clear	deacetylation	of	histone	H3	without	changing	the	levels	of	H3	locally.	Whether	the	gene	silencing	 is	due	to	HDAC5	deacetylase	activity	or	HDAC5	binding	to	other	
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endogenous	 HDACs	 and/or	 silencing	 complex	 could	 be	 an	 interesting	 topic	 to	discuss.		We	 first	 tested	 whether	 the	 catalytic	 activity	 is	 responsible	 for	 HDAC5	targeting	dependent	silencing.	One	advantage	of	CIT	is	that	we	can	target	truncations	and	mutants	 to	 understand	 the	mechanism	 of	 action.	 For	 instance,	 we	 found	 that	HDAC5	 mediated	 silencing	 was	 independent	 of	 its	 catalytic	 activity.	 However,	HDAC5	 truncations	 revealed	 that	 the	N	 terminal	 appears	 responsible	 for	 silencing	activity.	 How	 the	 HDAC5	 N	 terminal	 induces	 gene	 silencing	 is	 not	 clear.	 One	possibility	 is	 that	by	recruiting	other	HDACs	that	would	deacetylate	the	 locus.	This	could	 be	 done	 via	 the	 coiled-coil	 domain	 in	 the	 N-terminal,	 which	 forms	heterodimers	and	homodimers	with	HDAC4	and	HDAC5,	 respectively	 (Backs	et	al.,	2008).	To	test	this	directly,	I	would	perform	immunoprecipitation	on	HDAC5-coiled	coil	 truncation	 targeting	 samples	 and	 look	 for	 endogenous	 HDAC4	 and	 HDAC5	presence	by	western	blot.		Current	models	 of	 silencing	 complex	 suggest	 that	 HDAC5	 recruits	 HDAC3	 as	part	 of	 the	 N-CoR/SMRT	 complex	 to	 deacetylate	 histones	 and	 to	 promote	 gene	silencing	 (Fischle	et	al.,	2002;	Kao	et	al.,	2000;	You	et	al.,	2013).	 In	support	of	 this	model,	 the	 C-terminal	 of	 HDAC5	 interacts	 with	 the	 SMRT	 component	 SMRT	repression	 domain	 3	 (SRD3)	 (Kim	 et	 al.,	 2015).	 Given	 that	 HDAC3	 and	 HDAC5	targeting	leads	to	different	outcomes	in	CIT,	I	propose	that	HDAC5-dependent	gene	silencing,	at	least	in	some	contexts,	does	not	function	via	SMRT	recruitment.	To	test	this	directly,	pulling	down	PYL-HDAC5	in	CITnBYH5	cells	and	looking	for	SRD3	may	give	 the	 answer.	These	 results	would	 challenge	 the	 current	model	 on	how	HDAC5	promotes	gene	silencing.				One	 significant	 finding	 is	 that	 HDAC5	 promotes	 gene	 silencing	 in	 a	 repeat-length	dependent	manner.	In	this	case,	we	could	rule	out	that	the	effect	was	due	to	different	 targeting	 efficiencies.	 A	 simpler	 model,	 therefore,	 could	 be	 that	 59	 CAG	repeats	 are	 sufficient	 to	 induce	 the	 accumulation	 of	 heterochromatic	 marks,	 like	H3K9me2/3	 and	 the	 loss	 of	 acetylated	 H3.	 As	 a	 result,	 HDAC5	 would	 have	 less	
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substrate	to	work	with	and	therefore	exhibit	a	less	pronounced	silencing	effect	than	that	in	the	context	of	16	CAG	repeats.			Overall,	 HDAC5	 in	 CIT	 uncovered	 its	 direct	 role	 in	 local	 gene	 silencing.	 This	silencing	 acts	 differently	 depending	 on	 sequence	 contexts.	 Even	 though	 I	 did	 not	observe	 any	 CAG	 repeat	 expansion	 or	 contraction,	 my	 data	 suggests	 an	 SMRT-independent	role	of	HDAC5	in	gene	silencing	that	will	be	interesting	to	understand	further.		
2.2	 PYL-HDAC3	 targeting	 increases	 local	 histone	 acetylation	 and	
gene	expression.		We	chose	to	study	HDAC3	along	with	HDAC5,	because	of	their	roles	to	promote	CAG	repeat	expansion	in	human	cells	(Debacker	et	al.,	2012).	Moreover,	HDAC3	was	recently	 shown	 to	 influence	 Huntington’s	 disease	 pathology	 which	 marks	 its	potential	 for	 clinical	 application	 (Jia	 et	 al.,	 2015,	 2016;	 Suelves	 et	 al.,	 2017).	Therefore,	we	asked	whether	HDAC3	has	a	direct	role	on	CAG	repeats	and/or	gene	regulation	 in	 the	 CIT	 system.	 Stable	 CITnBYH3	 cells	 showed	 that	 PYL-HDAC3	targeting	promoted	GFP	expression	regardless	of	the	size	of	the	repeat	tract,	because	HDAC3,	as	a	histone	deacetylase,	is	thought	to	promote	silencing.	For	the	first	time,	we	show	that	HDAC3	targeting	increases	acH3	levels	 locally	upon	targeting.	This	is	unlikely	due	to	an	inactive	PYL-HDAC3	fusion.	With	its	overexpression	via	transient	transfection,	non-targeting	PYL-HDAC3	sample	decreased	GFP	intensity	compare	to	not	 transfected	 control.	 This	 suggests	 a	 genome-wide	 effect	 in	 gene	 silencing	 as	expected	(data	not	shown)	and	this	 is	the	evidence	that	PYL-HDAC3	fusion	may	be	functional.				How	 does	 HDAC3	 targeting	 increases	 gene	 expression?	 One	 ChIP-seq	 study	shows	 that	 HDAC3	 co-localizes	 with	 histone	 acetyltransferases	 (HATs)	 at	 highly	transcribed	regions	instead	of	at	the	expected	heterochromatin	(Wang	et	al.,	2009).	HDACs	 are	 associated	 with	 active	 gene	 and	 are	 positively	 correlated	 with	transcription.	Whereby,	they	proposed	a	model	that	HDAC3	and	HATs	work	together	to	influence	gene	transcription	dynamics	(Wang	et	al.,	2009).	In	this	system,	HDAC3	associates	at	genes	also	enriched	by	several	HATs,	suggesting	that	they	may	keep	a	
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balance	between	activation	and	repression	at	any	given	locus.	In	addition,	Rpd3	and	Hos2	in	yeast	associate	with	highly	transcribed	genes	(Kurdistani	et	al.,	2002;	Wang	et	 al.,	 2002).	The	observation	 further	 supports	 this	 that	dCas9-HDAC3	 targeting	 in	MC3T3-e1	pre-osteoblasts	induced	MecP2	mRNA	up-regulation	(Kwon	et	al.,	2017).	Another	 overlapping	 model	 (Greer	 et	 al.,	 2015)	 is	 that	 HDACs	 promote	 gene	transcription	 by	 inhibiting	 negative	 elongation	 factor	 (NELF)	 and	 by	 limiting	acetylation	in	gene	body	and	intergenic	regions,	less	acetylation	within	gene	bodies	preventing	cryptic	transcription	and	facilitating	transcription	elongation.	This	model	is,	however,	not	supported	by	ChIP-seq	data	showing	that	HDAC3	associates	mostly	with	the	promoter	region	of	highly	transcribed	genes	(Wang	et	al.,	2009).			Our	 data	 are	 consistent	 with	 the	 idea	 that	 HDAC3	 targeting	 promotes	 gene	expression.	However,	it	would	not	do	so	by	deacetylating	histones	in	gene	body	since	its	 targeting	 increases	 acetylation.	 This	 raises	 the	 question	 of	 the	 necessity	 of	 the	deacetylase	activity	of	HDAC3.	The	next	step	 is	 to	 test	whether	the	HDAC3	specific	inhibitor	 RGFP966	 (Malvaez	 et	 al.,	 2013)	 can	 minimize	 the	 increase	 in	 gene	expression	upon	targeting.	Our	speculative	model	is	that	HDAC3	targets	non-histone	proteins	(Glozak	et	al.,	2005;	Spange	et	al.,	2009)	which	would	act	as	inhibitors	for	gene	 expression.	 Those	 proteins,	 when	 being	 acetylated,	 tend	 to	 dissociate	 from	chromatin,	 allowing	 transcription	 to	 go	 through	 and	 enabling	 HATs	 to	 access	 the	locus	 better.	 Alternatively,	 deacetylation	 of	 those	 proteins	 could	 activate	 some	transcription	 factor	 or	 some	 remodeling	 enzyme	 that	 promotes	 transcription	elongation	and/or	 initiation.	 If	 this	model	were	 correct,	 the	deacetylase	 activity	of	HDAC3		would	be	required	for	overexpression.		IP-Mass	 spec	 using	 HDAC3	 as	 bait	 has	 been	 reported	 with	 some	 unusual	potential	 factors	 for	 us	 to	 work	 on	 (Armour	 et	 al.,	 2017).	 Besides	 the	 known	interactors	 such	as	NCoR,	Armour	and	colleagues	also	 found	proteins	essential	 for	development	 as	 well	 as	 several	 transcription	 factors.	 These	 candidates	 could	 be	knockout,	and	their	effect	on	HDAC3-dependent	gene	activation	will	be	determined.		One	 possibility	 is	 that	 HDAC3	 brings	 in	 HATs	 that	 target	 histones	 for	acetylation.	 This	 model	 predicts	 that	 HDAC3	 has	 a	 structural	 role	 and	 does	 not	
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require	its	deacetylase	activity.	If	this	model	is	correct,	we	may	be	able	to	detect:	1.	accumulation	 of	 HATs	 around	 the	 GFP	 locus	 upon	 PYL-HDAC3	 targeting;	 2.	 the	recruitment	of	a	HAT	should	be	indispensable	to	have	the	same	effect	as	HDAC3	and	should	no	longer	depend	on	HDAC3;	3.	HDAC3-targeting	in	HAT	knockouts	would	be	predicted	not	to	affect	gene	expression.		
2.3	DNMT1	has	a	direct	effect	on	gene	silencing	Similar	 to	 HDAC5,	 PYL-DNMT1	 stable	 integration	 into	 the	 CIT	 system	 gives	direct	evidence	that	DNMT1	targeting	to	gene	body	can	induce	further	silencing	of	a	strongly	 expressed	 gene	 in	 human	 cells.	 Unlike	 promoter	 regions	 with	 low	 CpG	methylation,	gene	body	usually	 is	highly	methylated	and	correlates	positively	with	the	transcriptional	output	(Jones,	1999,	2012).	Evidence	comes	from	human	active	X	chromosome	and	inactive	X	chromosome	DNA	methylation	profiles,	in	which	Xa	has	at	 least	 two	 times	 more	 allele-specific	 methylation	 than	 Xi	 (Hellman	 and	 Chess,	2007).	 The	 methylation	 pattern	 concentrates	 on	 gene-bodies	 in	 Xa.	 A	 shotgun	genomic	 bisulfite	 sequencing	 in	 plants	 and	 animals	 also	 shows	 the	 same	hypermethylation	 in	 the	 gene	 body	 (Feng	 et	 al.,	 2010).	 The	 role	 of	 gene-body	methylation	is	highly	debated,	however,	mainly	because	of	the	correlational	nature	of	the	experiments.	Nevertheless,	it	is	reported	that	DNMT	inhibition	in	HCT116	cells	reduces	DNA	methylation	in	the	gene	body,	which	leads	to	alleviated	overexpression	of	tumor-suppressor	genes	and	helps	reactivation	of	oncogenes	like	c-Myc.	(Yang	et	al.,	 2014).	 This	 complicated	 relationship	 suggests	 that	 gene-body	 methylation	regulates	gene	expression,	but	the	mechanisms	remain	unknown.			CIT	 would	 be	 ideal	 to	 tackle	 the	 mechanism	 of	 gene	 body	 methylation-dependent	gene	expression.	For	instance,	if	bisulfite	sequencing	reveals	that	DNMT1	targeting	leads	to	an	increase	in	DNA	methylation,	it	would	be	interesting	to	see	how	DNMT1	effect	get	around	classic	understanding	about	gene	body	methylation.	If	local	DNA	methylation	 increased	after	DNMT1	targeting,	what	can	be	done	 is	 to	make	a	DNMT1	catalytic	dead	mutant	and	test	whether	the	mutant	construct	is	still	able	to	induce	 DNA	 hypermethylation	 or	 not.	 This	 may	 indicate	 that	 DNMT1	 targeting	dependent	 silencing	 is	 due	 to	 its	 catalytic	 activity	 or	 other	 factors	 like	DNMT3a/b	recruited	by	DNMT1	(Kim	et	al.,	2002)	to	perform	methylation.	
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	One	critical	observation	was	that	targeting	PYL-DNMT1	to	INT	led	to	a	repeat-dependent	silencing	of	the	GFP	reporter.	The	first	potential	explanation	may	be	the	large	size	of	the	fusion	with	a	molecular	weight	of	196	kDa.	Long	CAG	repeats	may	induce	heterochromatic	markers	accumulation	and	lower	DNA	accessibility	(Cho	et	al.,	2005).	This	may	influence	the	efficiency	of	a	big	fusion	protein	binding	to	the	GFP	intron	like	DNMT1.	We	also	have	stable	cell	lines	with	a	relatively	big	size	(147kDa)	protein	 expression,	 FANCI,	 and	 targeting	 FANCI	 does	 not	 reproduce	 the	 silencing	effect	 observed	 in	 HDAC5	 and	 DNMT1.	 This	 may	 indicate	 the	 size	 of	 the	 fusion	protein	is	not	the	main	reason	for	repeat	dependent	silencing.		Secondly,	 this	 short	 repeat	 specific	 silencing	 may	 merely	 due	 to	 the	 GFP	intensity	detection	 limitation.	As	 the	GFP	reporter	with	16	CAG	repeats	has	higher	baseline	intensity	after	transcription	than	the	89	ones,	the	silencing	effect	difference	of	DNMT1	targeting	compares	to	non-targeting	can	be	less	evident	in	long	repeat	cell	lines.	To	test	this	hypothesis,	GFP	reporter	mRNA	qPCR	may	give	a	better	resolution.	If	the	suspect	is	correct,	we	may	observe	similar	fold	difference	between	CIT16BYD	and	 CIT89BYD	 in	 ABA	 versus	 DMSO	 dataset.	 Polymerase	 II	 ChIP	 can	 also	 provide	insight	about	local	transcription.				Local	DNA	methylation	may	also	affect	splicing.	 It	has	been	shown	that	exons	tend	to	have	more	CpG	methylation	than	introns	in	hESC	(Chodavarapu	et	al.,	2010;	Laurent	 et	 al.,	 2010;	 Shukla	 et	 al.,	 2011).	 Sharp	 methylation	 level	 differences	 on	exon-intron	boundaries	indicate	the	potential	correlation	between	DNA	methylation	and	splicing.	The	higher	the	methylation	is,	the	more	likely	the	gene-body	fragment	gets	 involved	 (Laurent	 et	 al.,	 2010;	 Shukla	 et	 al.,	 2011).	 So	 if	 DNMT1	 targeting	 is	inducing	 DNA	 methylation	 increase	 locally,	 it	 may	 result	 in	 the	 inclusion	 of	hypermethylated	INT-CAG	intron.		Our	GFP	reporter	is	a	splicing	driven	assay.	The	longer	the	CAG	repeats	are	in	the	intron,	the	more	likely	GFP	mRNA	will	be	included	the	CAG	repeat	as	part	of	an	alternative	 exon,	 resulting	 in	 lower	 GFP	 intensity	 in	 CIT89BYD	 cells	 than	 in	CIT16BYD	 cells.	 If	 the	 hypothesis	 is	 correct,	 that	 DNMT1	 targeting	 ends	 up	 with	
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more	 intron	 inclusion	 into	 mRNA,	 GFP	 expression	 should	 show	 further	 silencing	compare	to	non-targeted	cell	samples.				Furthermore,	the	observed	allele	specificity	may	also	due	to	DNA	methylation	level.	 With	 more	 heterochromatic	 structure	 property	 for	 expanded	 CAG/CTG	repeats,	DNA	methylation	starting	rate	in	CIT89BYD	cells	may	be	higher	than	that	in	CIT16BYD	 cells.	 DNMT1	 targeting	 in	 expanded	 CAG	 repeat	 cell	 lines	 would	 have	fewer	substrates	available	to	catalyze.	It	could	explain	why	the	reporter	with	16	CAG	repeats	is	more	sensitive	to	DNMT1	targeting	than	89	repeats.		CpG	 methylation	 and	 heterochromatic	 marks	 increase	 upon	 TNR	 expansion,	regardless	of	the	type	of	repeat	(Dion	and	Wilson,	2009).	It	has	been	widely	accepted	that	 DNA	 methylation	 interplays	 with	 histone	 modifications	 like	 methylation	 and	acetylation	(Fuks	et	al.,	2000;	Robert	et	al.,	2003).	If	the	hypothesis	proves	to	be	true,	that	 in	 extended	 CAG	 repeat-containing	 GFP	 locus	 has	 a	 different	 level	 of	 DNA	methylation,	it	can	be	interesting	to	determine	whether	heterochromatic	marks	like	H3K9me2/H3K9me3	appear	upon	PYL-DNMT1	targeting	versus	non-targeting.	This	observation	can	provide	insights	into	whether	DNA	methylation	is	indispensable	to	recruit	histone	modifiers,	or	whether	histone	marks	affect	DNA	methylation.			DNMT1	 has	 been	 shown	 to	 cooperate	 with	 other	 DNA	 methyltransferases	(DNMTs),	histone	methyltransferases	(HMTs),	histone	deacetylases	(HDACs)	(Fuks,	2005;	Fuks	et	al.,	2000;	Robert	et	al.,	2003).	Considering	that	DNMT1	directly	affects	gene	 silencing	 with	 low	 repeat	 specificity,	 I	 would	 imagine	 its	 working	 model	 by	which	 DNMT3a/b	 and	 HDAC1	 and	 2	 involved.	 DNMT3a/b	 are	 responsible	 for	establishing	 CpG	 methylation	 and	 DNMT1	 maintains	 DNA	 methylation	 after	replication	 (Robert	 et	 al.,	 2003).	 If	 our	 bisulfate	 sequencing	 data	 shows	 that	 local	DNA	 methylation	 increases	 upon	 PYL-DNMT1	 targeting,	 it	 may	 indicate	 that	DNMT3a/b	are	attracted	by	DNMT1	to	the	gene	and	catalyze	CpG	methylation,	which	further	 results	 in	 gene	 silencing.	 DNMT1	 catalytic	 dead	mutant	 targeting	 can	 also	provide	 the	 correlation	 between	 DNMT1	 catalytic	 activity	 and	 gene	 silencing.	HDAC1/2	 are	 also	DNMT1	working	 partners	 for	 removing	 acetylation	marks	 from	histone	 proteins	 and	 cause	 heterochromatic	 structure	 formation	 and	 gene	 down-
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regulation	 (Fuks	 et	 al.,	 2000).	 We	 can	 perform	 DNMT1	 targeting	 combined	 with	HDAC	 inhibitor-like	 TSA	 to	 see	 whether	 silencing	 effect	 disappears	 or	 not.	 If	 the	answer	is	yes,	it	indicates	that	PYL-DNMT1	targeting	induces	silencing	in	an	HDAC-dependent	manner.	Above	all,	DNMT1	targeting	dependent	silencing	works	in	a	DNA	context-sensitive	 manner.	 This	 provides	 insight	 into	 the	 DNMT1	 function	 in	 gene	regulation.		
3.	Further	applications	of	CIT	
	
3.1	CIT	can	be	used	in	other	sequence	contexts		Other	 apparent	 applications	 of	 CIT	 include	 replacing	 CAG	 repeat	 expansion	with	any	sequence	of	interest,	for	instance,	Friedreich’s	Ataxia's	GAA	repeats	or	the	CGG	repeats	seen	in	Fragile	X	syndrome	or	even	random	sequence	from	the	genome.	If	 targeting	 POI	 induces	 GFP	 intensity	 change	 comparable	 to	 the	 DMSO	 group,	 it	suggests	that	POI	has	a	direct	effect	on	the	targeting	region.	In	conclusion,	CIT	can	be	transplanted	to	any	locus	of	 interest,	promising	more	extensive	applications	of	this	inducible	chromatin	targeting	system	to	test	protein	working	mechanism	in	any	loci.	
	
3.2	Screening	of	expanded	allele	silencers	using	CIT	Here	we	use	a	GFP	reporter	with	different	 lengths	of	CAG	repeats	 to	uncover	novel	roles	of	chromatin	modifying	enzymes	in	gene	regulation	at	a	disease-relevant	locus.		Patients	with	CAG	repeat	expansions	are	generally	heterozygous	and	harbor	a	normal	allele	that	is	important	for	function	(Orr	and	Zoghbi,	2007;	Ross	and	Tabrizi,	2011).	This	 system	will	be	particularly	useful	 to	 find	 factors	 that	 could	 silence	 the	expanded	allele	specifically.			The	PYL	 construct	designed	here	 is	 amenable	 to	 large-scale	 studies	 since	we	can	 use	 a	 simple	 Gateway	 cloning	 reaction	 to	 fuse	 any	 protein	 of	 interest	 to	 PYL	using	currently	available	cDNA	libraries	(Katzen,	2007).	Here	we	can	take	advantage	of	 a	 ready-to-use	 database	 of	 epigenetic	modifiers	 (Nanda	 et	 al.,	 2016)	 and	 clone	them	into	PYL	construct	for	transfection.	After	transfected	into	CITnB	cells,	positive	transfected	 ones	will	 be	 selected	 by	 proper	 selection	marker.	 Then	 these	 samples	
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will	pass	through	flow	cytometry	and	western	blot	to	further	confirm	their	effect	on	the	 local	 gene	 expression.	 This	 large-scale	 chromatin	 modifiers	 screening	 will	provide	 a	 further	 understanding	 of	 chromatin	modifiers	 and	 disease-causing	 TNR	expansion	interplay.	
	
4.	Conclusion	
	In	 conclusion,	 the	 whole	 project	 goal	 was	 to	 build	 an	 inducible	 chromatin	targeting	system.	I	achieved	this	successfully	and	tested	the	effect	of	three	chromatin	modifying	enzymes	on	gene	expression	and	partially	repeat	instability	(HDAC5	and	DNMT1).	CIT	system	can	be	further	transplanted	for	mechanistic	studies.		My	results	challenge	 current	 models	 of	 how	 these	 proteins	 affected	 gene	 expression	 and	clarified	their	indirect	role	in	repeat	instability.	Moreover,	the	system	can	be	used	for	further	mechanistic	studies	and	to	uncover	novel	therapeutic	targets	for	devastating	expanded	repeat	disorders.		
	
	 	
	 115	
	
	
	
	
	
	
	
	
Chapter	V	
	
References	 	
	 116	
Abel,	 T.,	 and	 Zukin,	 R.S.	 (2008).	 Epigenetic	 targets	 of	 HDAC	 inhibition	 in	neurodegenerative	and	psychiatric	disorders.	Curr	Opin	Pharmacol	8,	57–64.	Aeschbach,	 L.,	 and	 Dion,	 V.	 (2017).	 Minimizing	 carry-over	 PCR	 contamination	 in	expanded	CAG/CTG	repeat	instability	applications.	Scientific	Reports	7,	18026.	van	Agtmaal,	E.L.,	André,	L.M.,	Willemse,	M.,	Cumming,	S.A.,	van	Kessel,	I.D.G.,	van	den	Broek,	 W.J.A.A.,	 Gourdon,	 G.,	 Furling,	 D.,	 Mouly,	 V.,	 Monckton,	 D.G.,	 et	 al.	 (2017).	CRISPR/Cas9-Induced	 (CTG⋅CAG)n	 Repeat	 Instability	 in	 the	 Myotonic	 Dystrophy	Type	1	Locus:	Implications	for	Therapeutic	Genome	Editing.	Molecular	Therapy	25,	24–43.	Amabile,	A.,	Migliara,	A.,	Capasso,	P.,	Biffi,	M.,	Cittaro,	D.,	Naldini,	L.,	and	Lombardo,	A.	(2016).	 Inheritable	 Silencing	 of	 Endogenous	 Genes	 by	 Hit-and-Run	 Targeted	Epigenetic	Editing.	Cell	167,	219-232.e14.	An,	 M.C.,	 Zhang,	 N.,	 Scott,	 G.,	 Montoro,	 D.,	 Wittkop,	 T.,	 Mooney,	 S.,	 Melov,	 S.,	 and	Ellerby,	 L.M.	 (2012).	 Genetic	 correction	 of	 Huntington’s	 disease	 phenotypes	 in	induced	pluripotent	stem	cells.	Cell	Stem	Cell	11,	253–263.	Andrew,	S.E.,	Goldberg,	Y.P.,	Kremer,	B.,	Telenius,	H.,	Theilmann,	J.,	Adam,	S.,	Starr,	E.,	Squitieri,	 F.,	 Lin,	 B.,	 Kalchman,	 M.A.,	 et	 al.	 (1993).	 The	 relationship	 between	trinucleotide	 (CAG)	 repeat	 length	 and	 clinical	 features	 of	 Huntington’s	 disease.	Nature	Genetics	4,	398.	Armour,	 S.M.,	 Remsberg,	 J.R.,	 Damle,	M.,	 Sidoli,	 S.,	 Ho,	W.Y.,	 Li,	 Z.,	 Garcia,	 B.A.,	 and	Lazar,	M.A.	(2017).	An	HDAC3-PROX1	corepressor	module	acts	on	HNF4α	to	control	hepatic	triglycerides.	Nature	Communications	8,	549.	Axford,	M.M.,	Wang,	Y.-H.,	Nakamori,	M.,	Zannis-Hadjopoulos,	M.,	Thornton,	C.A.,	and	Pearson,	 C.E.	 (2013).	Detection	of	 slipped-DNAs	at	 the	 trinucleotide	 repeats	 of	 the	myotonic	dystrophy	type	I	disease	locus	in	patient	tissues.	PLoS	Genet.	9,	e1003866.	Backs,	 J.,	 Backs,	 T.,	 Bezprozvannaya,	 S.,	 McKinsey,	 T.A.,	 and	 Olson,	 E.N.	 (2008).	Histone	 Deacetylase	 5	 Acquires	 Calcium/Calmodulin-Dependent	 Kinase	 II	Responsiveness	 by	Oligomerization	with	Histone	Deacetylase	 4.	Mol.	 Cell.	 Biol.	28,	3437–3445.	Banerjee,	 D.,	 Mandal,	 S.M.,	 Das,	 A.,	 Hegde,	 M.L.,	 Das,	 S.,	 Bhakat,	 K.K.,	 Boldogh,	 I.,	Sarkar,	 P.S.,	Mitra,	 S.,	 and	Hazra,	 T.K.	 (2011).	 Preferential	 Repair	 of	 Oxidized	Base	Damage	in	the	Transcribed	Genes	of	Mammalian	Cells.	J.	Biol.	Chem.	286,	6006–6016.	Barbé,	 L.,	 Lanni,	 S.,	 López-Castel,	 A.,	 Franck,	 S.,	 Spits,	 C.,	 Keymolen,	 K.,	 Seneca,	 S.,	Tomé,	S.,	Miron,	I.,	Letourneau,	J.,	et	al.	(2017).	CpG	Methylation,	a	Parent-of-Origin	Effect	 for	Maternal-Biased	 Transmission	 of	 Congenital	Myotonic	 Dystrophy.	 Am.	 J.	Hum.	Genet.	100,	488–505.	Barlow,	 A.D.,	 Xie,	 J.,	Moore,	 C.E.,	 Campbell,	 S.C.,	 Shaw,	 J.	 a.	M.,	 Nicholson,	M.L.,	 and	Herbert,	T.P.	 (2012).	Rapamycin	 toxicity	 in	MIN6	cells	 and	 rat	 and	human	 islets	 is	mediated	by	 the	 inhibition	of	mTOR	complex	2	 (mTORC2).	Diabetologia	55,	 1355–1365.	
	 117	
Barlow,	 A.D.,	 Nicholson,	 M.L.,	 and	 Herbert,	 T.P.	 (2013).	 Evidence	 for	 rapamycin	toxicity	in	pancreatic	β-cells	and	a	review	of	the	underlying	molecular	mechanisms.	Diabetes	62,	2674–2682.	Baylis,	 F.,	 and	 McLeod,	 M.	 (2017).	 First-in-human	 Phase	 1	 CRISPR	 Gene	 Editing	Cancer	Trials:Are	We	Ready?	Curr	Gene	Ther	17,	309–319.	Beerli,	 R.R.,	Dreier,	 B.,	 and	Barbas,	 C.F.	 (2000).	 Positive	 and	negative	 regulation	 of	endogenous	genes	by	designed	transcription	factors.	Proc.	Natl.	Acad.	Sci.	U.S.A.	97,	1495–1500.	Belmont,	 A.S.	 (2001).	 Visualizing	 chromosome	 dynamics	 with	 GFP.	 Trends	 in	 Cell	Biology	11,	250–257.	Belshawl,	 P.J.,	 Spencer,	 D.M.,	 Crabtree,	 G.R.,	 and	 Schreiber,	 S.L.	 (1996).	 Controlling	programmed	 cell	 death	 with	 a	 cyclophilincyclosporin-based	 chemical	 inducer	 of	dimerization.	Chemistry	&	Biology	3,	731–738.	Beltran,	 A.,	 Parikh,	 S.,	 Liu,	 Y.,	 Cuevas,	 B.D.,	 Johnson,	 G.L.,	 Futscher,	 B.W.,	 and	Blancafort,	P.	(2007).	Re-activation	of	a	dormant	tumor	suppressor	gene	maspin	by	designed	transcription	factors.	Oncogene	26,	2791–2798.	Beltran,	 A.S.,	 Sun,	 X.,	 Lizardi,	 P.M.,	 and	 Blancafort,	 P.	 (2008).	 Reprogramming	epigenetic	 silencing:	 artificial	 transcription	 factors	 synergize	 with	 chromatin	remodeling	 drugs	 to	 reactivate	 the	 tumor	 suppressor	 mammary	 serine	 protease	inhibitor.	Mol	Cancer	Ther	7,	1080–1090.	Biacsi,	R.,	Kumari,	D.,	and	Usdin,	K.	(2008).	SIRT1	Inhibition	Alleviates	Gene	Silencing	in	Fragile	X	Mental	Retardation	Syndrome.	PLoS	Genet	4.	Blackwood,	 J.K.,	 Okely,	 E.A.,	 Zahra,	 R.,	 Eykelenboom,	 J.K.,	 and	 Leach,	 D.R.F.	 (2010).	DNA	tandem	repeat	instability	in	the	Escherichia	coli	chromosome	is	stimulated	by	mismatch	repair	at	an	adjacent	CAG·CTG	 trinucleotide	repeat.	Proc.	Natl.	Acad.	Sci.	U.S.A.	107,	22582–22586.	Blancafort,	 P.,	 Steinberg,	 S.V.,	 Paquin,	 B.,	 Klinck,	 R.,	 Scott,	 J.K.,	 and	 Cedergren,	 R.	(1999).	 The	 recognition	 of	 a	 noncanonical	 RNA	base	 pair	 by	 a	 zinc	 finger	 protein.	Chem.	Biol.	6,	585–597.	Blencowe,	B.J.	(2000).	Exonic	splicing	enhancers:	mechanism	of	action,	diversity	and	role	in	human	genetic	diseases.	Trends	in	Biochemical	Sciences	25,	106–110.	Boch,	J.,	Scholze,	H.,	Schornack,	S.,	Landgraf,	A.,	Hahn,	S.,	Kay,	S.,	Lahaye,	T.,	Nickstadt,	A.,	and	Bonas,	U.	(2009).	Breaking	the	Code	of	DNA	Binding	Specificity	of	TAL-Type	III	Effectors.	Science	326,	1509–1512.	Boga	 (Pekmezekmek,	 A.,	 Binokay,	 S.,	 and	 Sertdemir,	 Y.	 (2009).	 The	 toxicity	 and	teratogenicity	 of	 gibberellic	 acid	 (GA	 3	 )	 based	 on	 the	 frog	 embryo	 teratogenesis	assay-Xenopus	(FETAX).	Turkish	Journal	of	Biology	33.	
	 118	
Bourc’his,	D.,	Xu,	G.L.,	Lin,	C.S.,	Bollman,	B.,	and	Bestor,	T.H.	(2001).	Dnmt3L	and	the	establishment	of	maternal	genomic	imprints.	Science	294,	2536–2539.	Braun,	S.M.G.,	Kirkland,	J.G.,	Chory,	E.J.,	Husmann,	D.,	Calarco,	J.P.,	and	Crabtree,	G.R.	(2017).	 Rapid	 and	 reversible	 epigenome	 editing	 by	 endogenous	 chromatin	regulators.	Nature	Communications	8,	560.	Broek,	 V.D.,	 A,	 W.J.A.,	 Nelen,	 M.R.,	 Wansink,	 D.G.,	 Coerwinkel,	 M.M.,	 te	 Riele,	 H.,	Groenen,	 P.J.T.A.,	 and	 Wieringa,	 B.	 (2002).	 Somatic	 expansion	 behaviour	 of	 the	(CTG)n	 repeat	 in	 myotonic	 dystrophy	 knock-in	 mice	 is	 differentially	 affected	 by	Msh3	and	Msh6	mismatch–repair	proteins.	Hum	Mol	Genet	11,	191–198.	Brook,	 J.D.,	 McCurrach,	 M.E.,	 Harley,	 H.G.,	 Buckler,	 A.J.,	 Church,	 D.,	 Aburatani,	 H.,	Hunter,	 K.,	 Stanton,	 V.P.,	 Thirion,	 J.-P.,	Hudson,	 T.,	 et	 al.	 (1992).	Molecular	 basis	 of	myotonic	 dystrophy:	 Expansion	 of	 a	 trinucleotide	 (CTG)	 repeat	 at	 the	 3′	 end	 of	 a	transcript	encoding	a	protein	kinase	family	member.	Cell	68,	799–808.	Bultmann,	S.,	Morbitzer,	R.,	Schmidt,	C.S.,	Thanisch,	K.,	Spada,	F.,	Elsaesser,	J.,	Lahaye,	T.,	 and	 Leonhardt,	 H.	 (2012).	 Targeted	 transcriptional	 activation	 of	 silent	 oct4	pluripotency	 gene	 by	 combining	 designer	 TALEs	 and	 inhibition	 of	 epigenetic	modifiers.	Nucleic	Acids	Res	40,	5368–5377.	Bustos,	 A.D.,	 Cuadrado,	 A.,	 and	 Jouve,	 N.	 (2016).	 Sequencing	 of	 long	 stretches	 of	repetitive	DNA.	Scientific	Reports	6,	36665.	Butler,	R.,	and	Bates,	G.P.	(2006).	Histone	deacetylase	inhibitors	as	therapeutics	for	polyglutamine	disorders.	Nature	Reviews	Neuroscience	7,	784.	Campuzano,	 V.,	 Montermini,	 L.,	 Moltò,	 M.D.,	 Pianese,	 L.,	 Cossée,	 M.,	 Cavalcanti,	 F.,	Monros,	 E.,	 Rodius,	 F.,	 Duclos,	 F.,	 Monticelli,	 A.,	 et	 al.	 (1996).	 Friedreich’s	 Ataxia:	Autosomal	Recessive	Disease	Caused	by	an	Intronic	GAA	Triplet	Repeat	Expansion.	Science	271,	1423–1427.	Cano-Rodriguez,	 D.,	 Gjaltema,	 R.A.F.,	 Jilderda,	 L.J.,	 Jellema,	 P.,	 Dokter-Fokkens,	 J.,	Ruiters,	 M.H.J.,	 and	 Rots,	 M.G.	 (2016).	 Writing	 of	 H3K4Me3	 overcomes	 epigenetic	silencing	in	a	sustained	but	context-dependent	manner.	Nat	Commun	7,	12284.	Carpenter,	A.E.,	Memedula,	S.,	Plutz,	M.J.,	and	Belmont,	A.S.	(2005).	Common	effects	of	 acidic	 activators	 on	 large-scale	 chromatin	 structure	 and	 transcription.	Mol.	 Cell.	Biol.	25,	958–968.	Castel,	A.L.,	Cleary,	 J.D.,	and	Pearson,	C.E.	(2010).	Repeat	 instability	as	the	basis	 for	human	diseases	and	as	a	potential	target	for	therapy.	Nat	Rev	Mol	Cell	Biol	11,	165–170.	Celik,	 I.,	 Tuluce,	 Y.,	 and	 Isik,	 I.	 (2007).	 Evalution	 of	 toxicity	 of	 abcisic	 acid	 and	gibberellic	acid	in	rats:	50	days	drinking	water	study.	 Journal	of	Enzyme	Inhibition	and	Medicinal	Chemistry	22,	219–226.	
	 119	
Chang,	 N.,	 Sun,	 C.,	 Gao,	 L.,	 Zhu,	 D.,	 Xu,	 X.,	 Zhu,	 X.,	 Xiong,	 J.-W.,	 and	 Xi,	 J.J.	 (2013).	Genome	editing	with	RNA-guided	Cas9	nuclease	in	Zebrafish	embryos.	Cell	Research	
23,	465–472.	Chen,	S.,	Oikonomou,	G.,	Chiu,	C.N.,	Niles,	B.J.,	Liu,	 J.,	Lee,	D.A.,	Antoshechkin,	 I.,	and	Prober,	 D.A.	 (2013).	 A	 large-scale	 in	 vivo	 analysis	 reveals	 that	 TALENs	 are	significantly	 more	 mutagenic	 than	 ZFNs	 generated	 using	 context-dependent	assembly.	Nucleic	Acids	Res	41,	2769–2778.	Cho,	D.H.,	 Thienes,	 C.P.,	Mahoney,	 S.E.,	 Analau,	 E.,	 Filippova,	G.N.,	 and	Tapscott,	 S.J.	(2005).	 Antisense	 transcription	 and	 heterochromatin	 at	 the	 DM1	 CTG	 repeats	 are	constrained	by	CTCF.	Mol.	Cell	20,	483–489.	Cho,	S.W.,	Kim,	S.,	Kim,	 J.M.,	 and	Kim,	 J.-S.	 (2013).	Targeted	genome	engineering	 in	human	cells	with	the	Cas9	RNA-guided	endonuclease.	Nature	Biotechnology	31,	230–232.	Chodavarapu,	R.K.,	Feng,	S.,	Bernatavichute,	Y.V.,	Chen,	P.-Y.,	Stroud,	H.,	Yu,	Y.,	Hetzel,	J.A.,	 Kuo,	 F.,	 Kim,	 J.,	 Cokus,	 S.J.,	 et	 al.	 (2010).	 Relationship	 between	 nucleosome	positioning	and	DNA	methylation.	Nature	466,	388–392.	Chutake,	Y.K.,	Lam,	C.C.,	Costello,	W.N.,	Anderson,	M.P.,	and	Bidichandani,	S.I.	(2016).	Reversal	 of	 epigenetic	 promoter	 silencing	 in	 Friedreich	 ataxia	 by	 a	 class	 I	 histone	deacetylase	inhibitor.	Nucleic	Acids	Res	44,	5095–5104.	Cinesi,	C.,	Aeschbach,	L.,	Yang,	B.,	and	Dion,	V.	(2016).	Contracting	CAG/CTG	repeats	using	the	CRISPR-Cas9	nickase.	Nature	Communications	7,	13272.	Claassen,	 D.A.,	 and	 Lahue,	 R.S.	 (2007).	 Expansions	 of	 CAG·CTG	 repeats	 in	immortalized	human	astrocytes.	Hum.	Mol.	Genet.	16,	3088–3096.	Cleary,	 J.D.,	 and	 Pearson,	 C.E.	 (2003).	 The	 contribution	 of	 cis-elements	 to	 disease-associated	repeat	instability:	clinical	and	experimental	evidence.	Cytogenet.	Genome	Res.	100,	25–55.	Coffee,	 B.,	 Zhang,	 F.,	 Warren,	 S.T.,	 and	 Reines,	 D.	 (1999).	 Acetylated	 histones	 are	associated	with	FMR1	in	normal	but	not	fragile	X-syndrome	cells.	Nat	Genet	22,	98–101.	Coffee,	 B.,	 Zhang,	 F.,	 Ceman,	 S.,	 Warren,	 S.T.,	 and	 Reines,	 D.	 (2002).	 Histone	Modifications	 Depict	 an	 Aberrantly	 Heterochromatinized	 FMR1	 Gene	 in	 Fragile	 X	Syndrome.	The	American	Journal	of	Human	Genetics	71,	923–932.	Cong,	 L.,	 Zhou,	 R.,	 Kuo,	 Y.,	 Cunniff,	 M.,	 and	 Zhang,	 F.	 (2012).	 Comprehensive	interrogation	 of	 natural	 TALE	DNA-binding	modules	 and	 transcriptional	 repressor	domains.	Nature	Communications	3,	968.	Cong,	L.,	Ran,	F.A.,	Cox,	D.,	Lin,	S.,	Barretto,	R.,	Habib,	N.,	Hsu,	P.D.,	Wu,	X.,	 Jiang,	W.,	Marraffini,	 L.A.,	 et	 al.	 (2013).	 Multiplex	 genome	 engineering	 using	 CRISPR/Cas	systems.	Science	339,	819–823.	
	 120	
Dabrowska,	 M.,	 Juzwa,	 W.,	 Krzyzosiak,	 W.J.,	 and	 Olejniczak,	 M.	 (2018).	 Precise	Excision	of	the	CAG	Tract	from	the	Huntingtin	Gene	by	Cas9	Nickases.	Front	Neurosci	
12.	Dandelot,	E.,	and	Tomé,	S.	(2017).	Genetic	Modifiers	of	CAG.CTG	Repeat	Instability	in	Huntington’s	Disease	Mouse	Models.	Debacker,	K.,	Frizzell,	A.,	Gleeson,	O.,	Kirkham-McCarthy,	L.,	Mertz,	T.,	and	Lahue,	R.S.	(2012).	Histone	Deacetylase	Complexes	Promote	Trinucleotide	Repeat	Expansions.	PLOS	Biol	10,	e1001257.	Deng,	D.,	Yan,	C.,	Pan,	X.,	Mahfouz,	M.,	Wang,	J.,	Zhu,	J.-K.,	Shi,	Y.,	and	Yan,	N.	(2012).	Structural	Basis	for	Sequence-Specific	Recognition	of	DNA	by	TAL	Effectors.	Science	
335,	720–723.	Di	Stasi,	A.,	Tey,	S.-K.,	Dotti,	G.,	Fujita,	Y.,	Kennedy-Nasser,	A.,	Martinez,	C.,	Straathof,	K.,	Liu,	E.,	Durett,	A.G.,	Grilley,	B.,	et	al.	(2011).	Inducible	Apoptosis	as	a	Safety	Switch	for	Adoptive	Cell	Therapy.	New	England	Journal	of	Medicine	365,	1673–1683.	Didonna,	 A.,	 and	 Opal,	 P.	 (2015).	 The	 promise	 and	 perils	 of	 HDAC	 inhibitors	 in	neurodegeneration.	Ann	Clin	Transl	Neurol	2,	79–101.	Dion,	 V.,	 and	Wilson,	 J.H.	 (2009).	 Instability	 and	 chromatin	 structure	 of	 expanded	trinucleotide	repeats.	Trends	in	Genetics	25,	288–297.	Dion,	V.,	Lin,	Y.,	Hubert,	L.,	Waterland,	R.A.,	and	Wilson,	J.H.	(2008).	Dnmt1	deficiency	promotes	CAG	repeat	expansion	in	the	mouse	germline.	Hum.	Mol.	Genet.	17,	1306–1317.	Doench,	J.G.,	Hartenian,	E.,	Graham,	D.B.,	Tothova,	Z.,	Hegde,	M.,	Smith,	I.,	Sullender,	M.,	 Ebert,	 B.L.,	 Xavier,	 R.J.,	 and	 Root,	 D.E.	 (2014).	 Rational	 design	 of	 highly	 active	sgRNAs	 for	 CRISPR-Cas9–mediated	 gene	 inactivation.	 Nature	 Biotechnology	 32,	1262–1267.	Doench,	J.G.,	Fusi,	N.,	Sullender,	M.,	Hegde,	M.,	Vaimberg,	E.W.,	Donovan,	K.F.,	Smith,	I.,	 Tothova,	 Z.,	 Wilen,	 C.,	 Orchard,	 R.,	 et	 al.	 (2016).	 Optimized	 sgRNA	 design	 to	maximize	 activity	 and	 minimize	 off-target	 effects	 of	 CRISPR-Cas9.	 Nature	Biotechnology	34,	184–191.	Dragileva,	 E.,	 Hendricks,	 A.,	 Teed,	 A.,	 Gillis,	 T.,	 Lopez,	 E.T.,	 Friedberg,	 E.C.,	Kucherlapati,	 R.,	 Edelmann,	 W.,	 Lunetta,	 K.L.,	 MacDonald,	 M.E.,	 et	 al.	 (2009).	Intergenerational	and	striatal	CAG	repeat	instability	in	Huntington’s	disease	knock-in	mice	involve	different	DNA	repair	genes.	Neurobiol.	Dis.	33,	37–47.	Dubarry,	N.,	Pasta,	F.,	and	Lane,	D.	(2006).	ParABS	Systems	of	the	Four	Replicons	of	Burkholderia	 cenocepacia:	 New	 Chromosome	 Centromeres	 Confer	 Partition	Specificity.	J.	Bacteriol.	188,	1489–1496.	Duyao,	M.,	Ambrose,	C.,	Myers,	R.,	Novelletto,	A.,	Persichetti,	F.,	Frontali,	M.,	Folstein,	S.,	Ross,	C.,	Franz,	M.,	Abbott,	M.,	et	al.	(1993).	Trinucleotide	repeat	length	instability	and	age	of	onset	in	Huntington’s	disease.	Nature	Genetics	4,	387.	
	 121	
Echeverria,	 G.V.,	 and	 Cooper,	 T.A.	 (2012).	 RNA-binding	 proteins	 in	 microsatellite	expansion	disorders:	mediators	of	RNA	toxicity.	Brain	Res.	1462,	100–111.	Egger,	G.,	Liang,	G.,	Aparicio,	A.,	and	Jones,	P.A.	(2004).	Epigenetics	in	human	disease	and	prospects	for	epigenetic	therapy.	Eisenstein,	 M.	 (2012).	 Sangamo’s	 lead	 zinc-finger	 therapy	 flops	 in	 diabetic	neuropathy.	Elrick,	L.L.,	Humphrey,	M.B.,	Cooper,	T.A.,	and	Berget,	S.M.	(1998).	A	Short	Sequence	within	 Two	 Purine-Rich	 Enhancers	 Determines	 5′	 Splice	 Site	 Specificity.	Mol.	 Cell.	Biol.	18,	343–352.	Elrod-Erickson,	M.,	Rould,	M.A.,	Nekludova,	L.,	and	Pabo,	C.O.	(1996).	Zif268	protein-DNA	 complex	 refined	 at	 1.6	A:	 a	model	 system	 for	 understanding	 zinc	 finger-DNA	interactions.	Structure	4,	1171–1180.	Ester,	K.,	Ćurković-Perica,	M.,	and	Kralj,	M.	(2009).	The	Phytohormone	Auxin	Induces	G1	Cell-Cycle	Arrest	of	Human	Tumor	Cells.	Planta	Med	75,	1423–1426.	Fairall,	L.,	Schwabe,	J.W.,	Chapman,	L.,	Finch,	J.T.,	and	Rhodes,	D.	(1993).	The	crystal	structure	 of	 a	 two	 zinc-finger	 peptide	 reveals	 an	 extension	 to	 the	 rules	 for	 zinc-finger/DNA	recognition.	Nature	366,	483–487.	Falahi,	F.,	Huisman,	C.,	Kazemier,	H.G.,	Vlies,	P.	van	der,	Kok,	K.,	Hospers,	G.A.P.,	and	Rots,	M.G.	(2013).	Towards	Sustained	Silencing	of	HER2/neu	in	Cancer	By	Epigenetic	Editing.	Mol	Cancer	Res	11,	1029–1039.	Farrell,	B.T.,	 and	Lahue,	R.S.	 (2006).	CAG*CTG	repeat	 instability	 in	cultured	human	astrocytes.	Nucleic	Acids	Res.	34,	4495–4505.	Feinberg,	A.P.	(2007).	Phenotypic	plasticity	and	the	epigenetics	of	human	disease.	Feng,	 S.,	 Cokus,	 S.J.,	 Zhang,	 X.,	 Chen,	 P.-Y.,	 Bostick,	 M.,	 Goll,	 M.G.,	 Hetzel,	 J.,	 Jain,	 J.,	Strauss,	 S.H.,	 Halpern,	 M.E.,	 et	 al.	 (2010).	 Conservation	 and	 divergence	 of	methylation	patterning	in	plants	and	animals.	PNAS	107,	8689–8694.	Filla,	A.,	De	Michele,	G.,	Cavalcanti,	F.,	Pianese,	L.,	Monticelli,	A.,	Campanella,	G.,	and	Cocozza,	S.	(1996).	The	relationship	between	trinucleotide	(GAA)	repeat	length	and	clinical	features	in	Friedreich	ataxia.	Am	J	Hum	Genet	59,	554–560.	Fischle,	W.,	Dequiedt,	F.,	Hendzel,	M.J.,	Guenther,	M.G.,	Lazar,	M.A.,	Voelter,	W.,	 and	Verdin,	E.	 (2002).	Enzymatic	Activity	Associated	with	Class	 II	HDACs	 Is	Dependent	on	 a	Multiprotein	 Complex	 Containing	HDAC3	 and	 SMRT/N-CoR.	Molecular	 Cell	9,	45–57.	Foiry,	 L.,	 Dong,	 L.,	 Savouret,	 C.,	 Hubert,	 L.,	 Riele,	 H.	 te,	 Junien,	 C.,	 and	 Gourdon,	 G.	(2006).	 Msh3	 is	 a	 limiting	 factor	 in	 the	 formation	 of	 intergenerational	 CTG	expansions	in	DM1	transgenic	mice.	Hum	Genet	119,	520–526.	
	 122	
Fuks,	F.	 (2005).	DNA	methylation	and	histone	modifications:	 teaming	up	 to	silence	genes.	Curr.	Opin.	Genet.	Dev.	15,	490–495.	Fuks,	F.,	Burgers,	W.A.,	Brehm,	A.,	Hughes-Davies,	L.,	and	Kouzarides,	T.	(2000).	DNA	methyltransferase	 Dnmt1	 associates	 with	 histone	 deacetylase	 activity.	 Nature	Genetics	24,	88–91.	Gacy,	 A.M.,	 Goellner,	 G.,	 Juranić,	 N.,	 Macura,	 S.,	 and	 McMurray,	 C.T.	 (1995).	Trinucleotide	repeats	that	expand	in	human	disease	form	hairpin	structures	in	vitro.	Cell	81,	533–540.	Gannon,	 A.-M.M.,	 Frizzell,	 A.,	 Healy,	 E.,	 and	 Lahue,	 R.S.	 (2012).	MutSβ	 and	 histone	deacetylase	complexes	promote	expansions	of	trinucleotide	repeats	in	human	cells.	Nucl.	Acids	Res.	40,	10324–10333.	Gao,	 Y.,	 Xiong,	 X.,	 Wong,	 S.,	 Charles,	 E.J.,	 Lim,	 W.A.,	 and	 Qi,	 L.S.	 (2016).	 Complex	transcriptional	modulation	with	orthogonal	and	inducible	dCas9	regulators.	Nature	Methods	13,	1043–1049.	Genetic	 Modifiers	 of	 Huntington’s	 Disease	 (GeM-HD)	 Consortium	 (2015).	Identification	of	Genetic	Factors	that	Modify	Clinical	Onset	of	Huntington’s	Disease.	Cell	162,	516–526.	Gilbert,	L.A.,	Larson,	M.H.,	Morsut,	L.,	Liu,	Z.,	Brar,	G.A.,	Torres,	S.E.,	Stern-Ginossar,	N.,	 Brandman,	 O.,	 Whitehead,	 E.H.,	 Doudna,	 J.A.,	 et	 al.	 (2013).	 CRISPR-Mediated	Modular	RNA-Guided	Regulation	of	Transcription	in	Eukaryotes.	Cell	154,	442–451.	Gilbert,	 L.A.,	 Horlbeck,	 M.A.,	 Adamson,	 B.,	 Villalta,	 J.E.,	 Chen,	 Y.,	 Whitehead,	 E.H.,	Guimaraes,	 C.,	 Panning,	 B.,	 Ploegh,	 H.L.,	 Bassik,	 M.C.,	 et	 al.	 (2014).	 Genome-Scale	CRISPR-Mediated	Control	of	Gene	Repression	and	Activation.	Cell	159,	647–661.	Glozak,	 M.A.,	 Sengupta,	 N.,	 Zhang,	 X.,	 and	 Seto,	 E.	 (2005).	 Acetylation	 and	deacetylation	of	non-histone	proteins.	Gene	363,	15–23.	Goldberg,	Y.P.,	McMurray,	C.T.,	Zeisler,	J.,	Almqvist,	E.,	Sillence,	D.,	Richards,	F.,	Gacy,	A.M.,	 Buchanan,	 J.,	 Telenius,	 H.,	 and	 Hayden,	 M.R.	 (1995).	 Increased	 instability	 of	intermediate	 alleles	 in	 families	 with	 sporadic	 Huntington	 disease	 compared	 to	similar	 sized	 intermediate	 alleles	 in	 the	 general	 population.	 Hum.	 Mol.	 Genet.	 4,	1911–1918.	Goll,	M.G.,	 Kirpekar,	 F.,	Maggert,	 K.A.,	 Yoder,	 J.A.,	 Hsieh,	 C.-L.,	 Zhang,	 X.,	 Golic,	 K.G.,	Jacobsen,	 S.E.,	 and	 Bestor,	 T.H.	 (2006).	 Methylation	 of	 tRNAAsp	 by	 the	 DNA	methyltransferase	homolog	Dnmt2.	Science	311,	395–398.	Gorbunova,	V.,	Seluanov,	A.,	Dion,	V.,	Sandor,	Z.,	Meservy,	J.L.,	and	Wilson,	J.H.	(2003).	Selectable	 System	 for	 Monitoring	 the	 Instability	 of	 CTG/CAG	 Triplet	 Repeats	 in	Mammalian	Cells.	Mol.	Cell.	Biol.	23,	4485–4493.	Gori,	 J.L.,	 Hsu,	 P.D.,	Maeder,	M.L.,	 Shen,	 S.,	Welstead,	 G.G.,	 and	 Bumcrot,	 D.	 (2015).	Delivery	 and	 Specificity	 of	 CRISPR/Cas9	 Genome	 Editing	 Technologies	 for	 Human	Gene	Therapy.	Human	Gene	Therapy	26,	443–451.	
	 123	
Graef,	 I.A.,	 Holsinger,	 L.J.,	 Diver,	 S.,	 Schreiber,	 S.L.,	 and	 Crabtree,	 G.R.	 (1997).	Proximity	 and	 orientation	 underlie	 signaling	 by	 the	 non-receptor	 tyrosine	 kinase	ZAP70.	EMBO	J	16,	5618–5628.	Greene,	E.,	Mahishi,	L.,	Entezam,	A.,	Kumari,	D.,	and	Usdin,	K.	(2007).	Repeat-induced	epigenetic	 changes	 in	 intron	 1	 of	 the	 frataxin	 gene	 and	 its	 consequences	 in	Friedreich	ataxia.	Nucleic	Acids	Res	35,	3383–3390.	Greer,	C.B.,	Tanaka,	Y.,	Kim,	Y.J.,	Xie,	P.,	Zhang,	M.Q.,	Park,	I.-H.,	and	Kim,	T.H.	(2015).	Histone	 Deacetylases	 Positively	 Regulate	 Transcription	 through	 the	 Elongation	Machinery.	Cell	Rep	13,	1444–1455.	Gregory,	D.J.,	Zhang,	Y.,	Kobzik,	L.,	and	Fedulov,	A.V.	(2013).	Specific	transcriptional	enhancement	of	inducible	nitric	oxide	synthase	by	targeted	promoter	demethylation.	Epigenetics	8,	1205–1212.	Grimmer,	M.R.,	 Stolzenburg,	 S.,	 Ford,	 E.,	 Lister,	 R.,	 Blancafort,	 P.,	 and	 Farnham,	 P.J.	(2014).	Analysis	of	an	artificial	zinc	finger	epigenetic	modulator:	widespread	binding	but	limited	regulation.	Nucleic	Acids	Res	42,	10856–10868.	Groner,	A.C.,	Meylan,	S.,	Ciuffi,	A.,	Zangger,	N.,	Ambrosini,	G.,	Dénervaud,	N.,	Bucher,	P.,	 and	Trono,	D.	 (2010).	KRAB–Zinc	Finger	Proteins	and	KAP1	Can	Mediate	Long-Range	 Transcriptional	 Repression	 through	 Heterochromatin	 Spreading.	 PLOS	Genetics	6,	e1000869.	Groote,	D.,	L,	M.,	Verschure,	P.J.,	and	Rots,	M.G.	(2012).	Epigenetic	Editing :	targeted	rewriting	 of	 epigenetic	 marks	 to	 modulate	 expression	 of	 selected	 target	 genes.	Nucleic	Acids	Res	40,	10596–10613.	Gruber,	 S.,	 Arumugam,	 P.,	 Katou,	 Y.,	 Kuglitsch,	 D.,	 Helmhart,	W.,	 Shirahige,	 K.,	 and	Nasmyth,	K.	(2006).	Evidence	that	Loading	of	Cohesin	Onto	Chromosomes	Involves	Opening	of	Its	SMC	Hinge.	Cell	127,	523–537.	Guilinger,	 J.P.,	 Pattanayak,	 V.,	 Reyon,	D.,	 Tsai,	 S.Q.,	 Sander,	 J.D.,	 Joung,	 J.K.,	 and	 Liu,	D.R.	 (2014).	 Broad	 specificity	 profiling	 of	 TALENs	 results	 in	 engineered	 nucleases	with	improved	DNA-cleavage	specificity.	Nature	Methods	11,	429–435.	Hanawalt,	 P.C.	 (2002).	 Subpathways	 of	 nucleotide	 excision	 repair	 and	 their	regulation.	Oncogene	21,	8949.	Harley,	H.G.,	Rundle,	S.A.,	MacMillan,	J.C.,	Myring,	J.,	Brook,	J.D.,	Crow,	S.,	Reardon,	W.,	Fenton,	 I.,	 Shaw,	 D.J.,	 and	 Harper,	 P.S.	 (1993).	 Size	 of	 the	 unstable	 CTG	 repeat	sequence	in	relation	to	phenotype	and	parental	transmission	in	myotonic	dystrophy.	Am.	J.	Hum.	Genet.	52,	1164–1174.	Hathaway,	N.A.,	Bell,	O.,	Hodges,	C.,	Miller,	E.L.,	Neel,	D.S.,	and	Crabtree,	G.R.	(2012).	Dynamics	and	Memory	of	Heterochromatin	in	Living	Cells.	Cell	149,	1447–1460.	Hellman,	A.,	 and	Chess,	 A.	 (2007).	 Gene	Body-Specific	Methylation	 on	 the	Active	X	Chromosome.	Science	315,	1141–1143.	
	 124	
Herman,	 D.,	 Jenssen,	 K.,	 Burnett,	 R.,	 Soragni,	 E.,	 Perlman,	 S.L.,	 and	 Gottesfeld,	 J.M.	(2006a).	Histone	deacetylase	inhibitors	reverse	gene	silencing	in	Friedreich’s	ataxia.	Nat.	Chem.	Biol.	2,	551–558.	Herman,	 D.,	 Jenssen,	 K.,	 Burnett,	 R.,	 Soragni,	 E.,	 Perlman,	 S.L.,	 and	 Gottesfeld,	 J.M.	(2006b).	Histone	deacetylase	inhibitors	reverse	gene	silencing	in	Friedreich’s	ataxia.	Nature	Chemical	Biology	2,	551.	Hilton,	 I.B.,	D’Ippolito,	A.M.,	Vockley,	C.M.,	Thakore,	P.I.,	Crawford,	G.E.,	Reddy,	T.E.,	and	 Gersbach,	 C.A.	 (2015).	 Epigenome	 editing	 by	 a	 CRISPR-Cas9-based	acetyltransferase	 activates	 genes	 from	 promoters	 and	 enhancers.	 Nature	Biotechnology	33,	510–517.	Ho,	S.N.,	Biggar,	S.R.,	Spencer,	D.M.,	Schreiber,	S.L.,	and	Crabtree,	G.R.	(1996).	Dimeric	ligands	 define	 a	 role	 for	 transcriptional	 activation	 domains	 in	 reinitiation.	 Nature	
382,	822–826.	Hockemeyer,	D.,	Soldner,	F.,	Beard,	C.,	Gao,	Q.,	Mitalipova,	M.,	DeKelver,	R.C.,	Katibah,	G.E.,	 Amora,	 R.,	 Boydston,	 E.A.,	 Zeitler,	 B.,	 et	 al.	 (2009).	 Efficient	 targeting	 of	expressed	 and	 silent	 genes	 in	 human	 ESCs	 and	 iPSCs	 using	 zinc-finger	 nucleases.	Nature	Biotechnology	27,	851–857.	Hockemeyer,	D.,	Wang,	H.,	Kiani,	S.,	Lai,	C.S.,	Gao,	Q.,	Cassady,	J.P.,	Cost,	G.J.,	Zhang,	L.,	Santiago,	Y.,	Miller,	J.C.,	et	al.	(2011).	Genetic	engineering	of	human	pluripotent	cells	using	TALE	nucleases.	Nature	Biotechnology	29,	731–734.	Hockly,	E.,	Richon,	V.M.,	Woodman,	B.,	Smith,	D.L.,	Zhou,	X.,	Rosa,	E.,	Sathasivam,	K.,	Ghazi-Noori,	S.,	Mahal,	A.,	Lowden,	P.A.S.,	et	al.	 (2003).	Suberoylanilide	hydroxamic	acid,	a	histone	deacetylase	inhibitor,	ameliorates	motor	deficits	in	a	mouse	model	of	Huntington’s	disease.	PNAS	100,	2041–2046.	Holkers,	 M.,	 Maggio,	 I.,	 Liu,	 J.,	 Janssen,	 J.M.,	 Miselli,	 F.,	 Mussolino,	 C.,	 Recchia,	 A.,	Cathomen,	T.,	and	Gonçalves,	M.A.F.V.	(2013).	Differential	integrity	of	TALE	nuclease	genes	 following	 adenoviral	 and	 lentiviral	 vector	 gene	 transfer	 into	 human	 cells.	Nucleic	Acids	Res	41,	e63–e63.	Holmans,	 P.A.,	 Massey,	 T.H.,	 and	 Jones,	 L.	 (2017).	 Genetic	 modifiers	 of	 Mendelian	disease:	Huntington’s	disease	and	the	trinucleotide	repeat	disorders.	Hum	Mol	Genet	
26,	R83–R90.	Holsinger,	L.J.,	 Spencer,	D.M.,	Austin,	D.J.,	 Schreiber,	 S.L.,	 and	Crabtree,	G.R.	 (1995).	Signal	transduction	in	T	lymphocytes	using	a	conditional	allele	of	Sos.	Proc	Natl	Acad	Sci	U	S	A	92,	9810–9814.	Hong,	D.-H.,	and	Li,	T.	 (2002).	Complex	Expression	Pattern	of	RPGR	Reveals	a	Role	for	 Purine-Rich	 Exonic	 Splicing	 Enhancers.	 Invest.	 Ophthalmol.	 Vis.	 Sci.	 43,	 3373–3382.	Hornstra,	 I.K.,	 Nelson,	 D.L.,	 Warren,	 S.T.,	 and	 Yang,	 T.P.	 (1993).	 High	 resolution	methylation	 analysis	 of	 the	 FMR1	 gene	 trinucleotide	 repeat	 region	 in	 fragile	 X	syndrome.	Hum.	Mol.	Genet.	2,	1659–1665.	
	 125	
Hruscha,	A.,	Krawitz,	P.,	Rechenberg,	A.,	Heinrich,	V.,	Hecht,	J.,	Haass,	C.,	and	Schmid,	B.	 (2013).	 Efficient	 CRISPR/Cas9	 genome	 editing	 with	 low	 off-target	 effects	 in	zebrafish.	Development	140,	4982–4987.	Hsu,	 P.D.,	 Scott,	 D.A.,	Weinstein,	 J.A.,	 Ran,	 F.A.,	 Konermann,	 S.,	 Agarwala,	 V.,	 Li,	 Y.,	Fine,	E.J.,	Wu,	X.,	 Shalem,	O.,	 et	 al.	 (2013).	DNA	 targeting	 specificity	of	RNA-guided	Cas9	nucleases.	Nature	Biotechnology	31,	827–832.	Huang,	Y.-H.,	Su,	J.,	Lei,	Y.,	Brunetti,	L.,	Gundry,	M.C.,	Zhang,	X.,	 Jeong,	M.,	Li,	W.,	and	Goodell,	 M.A.	 (2017).	 DNA	 epigenome	 editing	 using	 CRISPR-Cas	 SunTag-directed	DNMT3A.	Genome	Biology	18,	176.	Hubert,	 L.,	 Lin,	 Y.,	 Dion,	 V.,	 and	 Wilson,	 J.H.	 (2011).	 Xpa	 deficiency	 reduces	 CAG	trinucleotide	repeat	instability	in	neuronal	tissues	in	a	mouse	model	of	SCA1.	Hum.	Mol.	Genet.	20,	4822–4830.	Huisman,	C.,	Wijst,	M.G.	van	der,	Falahi,	F.,	Overkamp,	J.,	Karsten,	G.,	Terpstra,	M.M.,	Kok,	K.,	Zee,	A.G.	van	der,	Schuuring,	E.,	Wisman,	G.B.A.,	et	al.	(2015).	Prolonged	re-expression	 of	 the	 hypermethylated	 gene	 EPB41L3	 using	 artificial	 transcription	factors	and	epigenetic	drugs.	Epigenetics	10,	384–396.	Hurt,	 J.A.,	 Thibodeau,	 S.A.,	 Hirsh,	 A.S.,	 Pabo,	 C.O.,	 and	 Joung,	 J.K.	 (2003).	 Highly	specific	 zinc	 finger	 proteins	 obtained	 by	 directed	 domain	 shuffling	 and	 cell-based	selection.	PNAS	100,	12271–12276.	Hwang,	W.Y.,	 Fu,	 Y.,	 Reyon,	 D.,	Maeder,	M.L.,	 Tsai,	 S.Q.,	 Sander,	 J.D.,	 Peterson,	 R.T.,	Yeh,	 J.-R.J.,	 and	 Joung,	 J.K.	 (2013).	 Efficient	 genome	 editing	 in	 zebrafish	 using	 a	CRISPR-Cas	system.	Nature	Biotechnology	31,	227–229.	Ishino,	Y.,	Shinagawa,	H.,	Makino,	K.,	Amemura,	M.,	and	Nakata,	A.	(1987).	Nucleotide	sequence	of	 the	 iap	gene,	responsible	 for	alkaline	phosphatase	 isozyme	conversion	in	 Escherichia	 coli,	 and	 identification	 of	 the	 gene	 product.	 J	 Bacteriol	 169,	 5429–5433.	Jacobs,	J.Z.,	Ciccaglione,	K.M.,	Tournier,	V.,	and	Zaratiegui,	M.	(2014).	Implementation	of	the	CRISPR-Cas9	system	in	fission	yeast.	Nature	Communications	5,	5344.	Jacome,	 A.,	 and	 Fernandez-Capetillo,	 O.	 (2011).	 Lac	 operator	 repeats	 generate	 a	traceable	fragile	site	in	mammalian	cells.	EMBO	Reports	12,	1032–1038.	Jaworski,	A.,	Rosche,	W.A.,	Gellibolian,	R.,	Kang,	S.,	Shimizu,	M.,	Bowater,	R.P.,	Sinden,	R.R.,	and	Wells,	R.D.	(1995).	Mismatch	repair	in	Escherichia	coli	enhances	instability	of	(CTG)n	triplet	repeats	from	human	hereditary	diseases.	PNAS	92,	11019–11023.	Je,	 H.-S.,	 Lu,	 Y.,	 Yang,	 F.,	 Nagappan,	 G.,	 Zhou,	 J.,	 Jiang,	 Z.,	 Nakazawa,	 K.,	 and	 Lu,	 B.	(2009).	 Chemically	 Inducible	 Inactivation	 of	 Protein	 Synthesis	 in	 Genetically	Targeted	Neurons.	J	Neurosci	29,	6761–6766.	Jia,	 H.,	 Morris,	 C.D.,	 Williams,	 R.M.,	 Loring,	 J.F.,	 and	 Thomas,	 E.A.	 (2015).	 HDAC	inhibition	 imparts	beneficial	 transgenerational	effects	 in	Huntington’s	disease	mice	via	altered	DNA	and	histone	methylation.	PNAS	112,	E56–E64.	
	 126	
Jia,	H.,	Wang,	Y.,	Morris,	C.D.,	 Jacques,	V.,	Gottesfeld,	 J.M.,	Rusche,	 J.R.,	 and	Thomas,	E.A.	 (2016).	 The	 Effects	 of	 Pharmacological	 Inhibition	 of	 Histone	 Deacetylase	 3	(HDAC3)	in	Huntington’s	Disease	Mice.	PLOS	ONE	11,	e0152498.	Jinek,	M.,	Chylinski,	K.,	Fonfara,	I.,	Hauer,	M.,	Doudna,	J.A.,	and	Charpentier,	E.	(2012).	A	 Programmable	 Dual-RNA–Guided	 DNA	 Endonuclease	 in	 Adaptive	 Bacterial	Immunity.	Science	337,	816–821.	Jones,	P.A.	(1999).	The	DNA	methylation	paradox.	Trends	Genet.	15,	34–37.	Jones,	 P.A.	 (2012).	 Functions	 of	 DNA	methylation:	 islands,	 start	 sites,	 gene	 bodies	and	beyond.	Nature	Reviews	Genetics	13,	484–492.	Joung,	 J.K.,	 and	 Sander,	 J.D.	 (2013).	 TALENs:	 a	 widely	 applicable	 technology	 for	targeted	genome	editing.	Nature	Reviews	Molecular	Cell	Biology	14,	49–55.	Juillerat,	 A.,	 Dubois,	 G.,	 Valton,	 J.,	 Thomas,	 S.,	 Stella,	 S.,	 Maréchal,	 A.,	 Langevin,	 S.,	Benomari,	N.,	Bertonati,	C.,	 Silva,	G.H.,	 et	al.	 (2014).	Comprehensive	analysis	of	 the	specificity	 of	 transcription	 activator-like	 effector	 nucleases.	 Nucleic	 Acids	 Res	 42,	5390–5402.	Kang,	C.B.,	Hong,	Y.,	Dhe-Paganon,	S.,	and	Yoon,	H.S.	 (2008).	FKBP	Family	Proteins:	Immunophilins	with	Versatile	Biological	Functions.	NSG	16,	318–325.	Kao,	H.-Y.,	 Downes,	M.,	 Ordentlich,	 P.,	 and	 Evans,	 R.M.	 (2000).	 Isolation	 of	 a	 novel	histone	 deacetylase	 reveals	 that	 class	 I	 and	 class	 II	 deacetylases	 promote	 SMRT-mediated	repression.	Genes	Dev.	14,	55–66.	Katzen,	 F.	 (2007).	 Gateway(®)	 recombinational	 cloning:	 a	 biological	 operating	system.	Expert	Opin	Drug	Discov	2,	571–589.	Kennedy,	M.J.,	Hughes,	R.M.,	Peteya,	L.A.,	Schwartz,	J.W.,	Ehlers,	M.D.,	and	Tucker,	C.L.	(2010).	Rapid	blue	light	induction	of	protein	interactions	in	living	cells.	Nat	Methods	
7,	973–975.	Khare,	D.,	Ziegelin,	G.,	Lanka,	E.,	and	Heinemann,	U.	 (2004).	Sequence-specific	DNA	binding	 determined	 by	 contacts	 outside	 the	 helix-turn-helix	 motif	 of	 the	 ParB	homolog	KorB.	Nature	Structural	&	Molecular	Biology	11,	656–663.	Kick,	 L.,	 Kirchner,	 M.,	 and	 Schneider,	 S.	 (2017).	 CRISPR-Cas9:	 From	 a	 bacterial	immune	 system	 to	 genome-edited	 human	 cells	 in	 clinical	 trials.	 Bioengineered	 8,	280–286.	Kim,	G.-D.,	Ni,	J.,	Kelesoglu,	N.,	Roberts,	R.J.,	and	Pradhan,	S.	(2002).	Co-operation	and	communication	 between	 the	 human	 maintenance	 and	 de	 novo	 DNA	 (cytosine-5)	methyltransferases.	The	EMBO	Journal	21,	4183–4195.	Kim,	G.S.,	 Jung,	H.-E.,	Kim,	J.-S.,	and	Lee,	Y.C.	(2015).	Mutagenesis	Study	Reveals	the	Rim	of	Catalytic	Entry	Site	of	HDAC4	and	-5	as	 the	Major	Binding	Surface	of	SMRT	Corepressor.	PLOS	ONE	10,	e0132680.	
	 127	
Kleinstiver,	B.P.,	Prew,	M.S.,	Tsai,	S.Q.,	Topkar,	V.V.,	Nguyen,	N.T.,	Zheng,	Z.,	Gonzales,	A.P.W.,	 Li,	 Z.,	 Peterson,	 R.T.,	 Yeh,	 J.-R.J.,	 et	 al.	 (2015).	 Engineered	 CRISPR-Cas9	nucleases	with	altered	PAM	specificities.	Nature	523,	481–485.	Kleinstiver,	 B.P.,	 Pattanayak,	 V.,	 Prew,	M.S.,	 Tsai,	 S.Q.,	 Nguyen,	 N.T.,	 Zheng,	 Z.,	 and	Joung,	J.K.	(2016).	High-fidelity	CRISPR–Cas9	nucleases	with	no	detectable	genome-wide	off-target	effects.	Nature	529,	490–495.	Knight,	S.J.L.,	Flannery,	A.V.,	Hirst,	M.C.,	Campbell,	L.,	Christodoulou,	Z.,	Phelps,	S.R.,	Pointon,	 J.,	 Middleton-Price,	 H.R.,	 Barnicoat,	 A.,	 Pembrey,	 M.E.,	 et	 al.	 (1993).	Trinucleotide	repeat	amplification	and	hypermethylation	of	a	CpG	 island	 in	FRAXE	mental	retardation.	Cell	74,	127–134.	Kohler,	J.J.,	and	Bertozzi,	C.R.	(2003).	Regulating	Cell	Surface	Glycosylation	by	Small	Molecule	Control	of	Enzyme	Localization.	Chemistry	&	Biology	10,	1303–1311.	Kohwi,	 Y.,	 Wang,	 H.,	 and	 Kohwi-Shigematsu,	 T.	 (1993).	 A	 single	 trinucleotide,	5’AGC3’/5’GCT3’,	of	the	triplet-repeat	disease	genes	confers	metal	ion-induced	non-B	DNA	structure.	Nucleic	Acids	Res.	21,	5651–5655.	Koide,	 R.,	 Ikeuchi,	 T.,	 Onodera,	 O.,	 Tanaka,	 H.,	 Igarashi,	 S.,	 Endo,	 K.,	 Takahashi,	 H.,	Kondo,	R.,	Ishikawa,	A.,	Hayashi,	T.,	et	al.	(1994).	Unstable	expansion	of	CAG	repeat	in	hereditary	dentatorubral–pallidoluysian	atrophy	(DRPLA).	Nature	Genetics	6,	9.	Konermann,	S.,	Brigham,	M.D.,	Trevino,	A.E.,	Hsu,	P.D.,	Heidenreich,	M.,	Le	Cong,	Platt,	R.J.,	 Scott,	 D.A.,	 Church,	 G.M.,	 and	 Zhang,	 F.	 (2013).	 Optical	 control	 of	 mammalian	endogenous	transcription	and	epigenetic	states.	Nature	500,	472–476.	Kovtun,	 I.V.,	 Thornhill,	 A.R.,	 and	 McMurray,	 C.T.	 (2004).	 Somatic	 deletion	 events	occur	during	early	embryonic	development	and	modify	the	extent	of	CAG	expansion	in	subsequent	generations.	Hum.	Mol.	Genet.	13,	3057–3068.	Kovtun,	I.V.,	Liu,	Y.,	Bjoras,	M.,	Klungland,	A.,	Wilson,	S.H.,	and	McMurray,	C.T.	(2007).	OGG1	 initiates	age-dependent	CAG	 trinucleotide	expansion	 in	somatic	cells.	Nature	
447,	447–452.	Kumari,	 D.,	 Biacsi,	 R.E.,	 and	 Usdin,	 K.	 (2011).	 Repeat	 Expansion	 Affects	 Both	Transcription	Initiation	and	Elongation	in	Friedreich	Ataxia	Cells.	J.	Biol.	Chem.	286,	4209–4215.	Kunkel,	 T.A.,	 and	 Erie,	 D.A.	 (2005).	 Dna	 Mismatch	 Repair.	 Annual	 Review	 of	Biochemistry	74,	681–710.	Kurdistani,	 S.K.,	 Robyr,	 D.,	 Tavazoie,	 S.,	 and	 Grunstein,	 M.	 (2002).	 Genome-wide	binding	map	of	the	histone	deacetylase	Rpd3	in	yeast.	Nature	Genetics	31,	248–254.	Kwon,	 D.Y.,	 Zhao,	 Y.-T.,	 Lamonica,	 J.M.,	 and	 Zhou,	 Z.	 (2017).	 Locus-specific	 histone	deacetylation	using	a	 synthetic	CRISPR-Cas9-based	HDAC.	Nature	Communications	
8,	15315.	
	 128	
Lahm,	A.,	Paolini,	C.,	Pallaoro,	M.,	Nardi,	M.C.,	Jones,	P.,	Neddermann,	P.,	Sambucini,	S.,	Bottomley,	M.J.,	 Surdo,	 P.L.,	 Carfı,́	 A.,	 et	 al.	 (2007).	 Unraveling	 the	 hidden	 catalytic	activity	of	vertebrate	class	IIa	histone	deacetylases.	PNAS	104,	17335–17340.	Larson,	 A.G.,	 Elnatan,	D.,	 Keenen,	M.M.,	 Trnka,	M.J.,	 Johnston,	 J.B.,	 Burlingame,	 A.L.,	Agard,	D.A.,	Redding,	S.,	and	Narlikar,	G.J.	(2017).	Liquid	droplet	formation	by	HP1α	suggests	a	role	for	phase	separation	in	heterochromatin.	Nature	547,	236–240.	Laurent,	L.,	Wong,	E.,	Li,	G.,	Huynh,	T.,	Tsirigos,	A.,	Ong,	C.T.,	Low,	H.M.,	Sung,	K.W.K.,	Rigoutsos,	 I.,	 Loring,	 J.,	 et	 al.	 (2010).	 Dynamic	 changes	 in	 the	 human	 methylome	during	differentiation.	Genome	Res.	20,	320–331.	Lee,	 J.-M.,	 Ramos,	 E.M.,	 Lee,	 J.-H.,	 Gillis,	 T.,	 Mysore,	 J.S.,	 Hayden,	 M.R.,	 Warby,	 S.C.,	Morrison,	P.,	Nance,	M.,	Ross,	C.A.,	et	al.	(2012).	CAG	repeat	expansion	in	Huntington	disease	determines	age	at	onset	in	a	fully	dominant	fashion.	Neurology	78,	690–695.	Lee,	 M.G.,	 Wynder,	 C.,	 Bochar,	 D.A.,	 Hakimi,	 M.-A.,	 Cooch,	 N.,	 and	 Shiekhattar,	 R.	(2006).	 Functional	 Interplay	 between	 Histone	 Demethylase	 and	 Deacetylase	Enzymes.	Mol.	Cell.	Biol.	26,	6395–6402.	Levskaya,	A.,	Weiner,	O.D.,	Lim,	W.A.,	and	Voigt,	C.A.	(2009).	Spatiotemporal	control	of	cell	signalling	using	a	light-switchable	protein	interaction.	Nature	461,	997–1001.	Li,	 F.,	 Papworth,	 M.,	 Minczuk,	 M.,	 Rohde,	 C.,	 Zhang,	 Y.,	 Ragozin,	 S.,	 and	 Jeltsch,	 A.	(2007).	 Chimeric	DNA	methyltransferases	 target	DNA	methylation	 to	 specific	DNA	sequences	and	repress	expression	of	target	genes.	Nucleic	Acids	Res.	35,	100–112.	Li,	 Y.,	 Polak,	U.,	 Bhalla,	A.D.,	 Rozwadowska,	N.,	 Butler,	 J.S.,	 Lynch,	D.R.,	Dent,	 S.Y.R.,	and	 Napierala,	 M.	 (2015).	 Excision	 of	 Expanded	 GAA	 Repeats	 Alleviates	 the	Molecular	Phenotype	of	Friedreich’s	Ataxia.	Mol.	Ther.	23,	1055–1065.	Liang,	 F.-S.,	 Ho,	W.Q.,	 and	 Crabtree,	 G.R.	 (2011).	 Engineering	 the	 ABA	 Plant	 Stress	Pathway	for	Regulation	of	Induced	Proximity.	Sci.	Signal.	4,	rs2–rs2.	Lin,	 Y.,	 and	Wilson,	 J.H.	 (2007).	 Transcription-Induced	 CAG	 Repeat	 Contraction	 in	Human	 Cells	 Is	 Mediated	 in	 Part	 by	 Transcription-Coupled	 Nucleotide	 Excision	Repair.	Mol.	Cell.	Biol.	27,	6209–6217.	Lin,	 A.,	 Giuliano,	 C.J.,	 Sayles,	 N.M.,	 and	 Sheltzer,	 J.M.	 CRISPR/Cas9	 mutagenesis	invalidates	a	putative	cancer	dependency	targeted	in	on-going	clinical	trials.	ELife	6.	Lin,	 Y.,	 Dion,	 V.,	 and	 Wilson,	 J.H.	 (2005).	 A	 novel	 selectable	 system	 for	 detecting	expansion	of	CAG.CTG	repeats	in	mammalian	cells.	Mutat.	Res.	572,	123–131.	Lin,	Y.,	Dion,	V.,	and	Wilson,	J.H.	(2006).	Transcription	promotes	contraction	of	CAG	repeat	tracts	in	human	cells.	Nat	Struct	Mol	Biol	13,	179–180.	Lin,	 Y.,	 Dent,	 S.Y.R.,	 Wilson,	 J.H.,	 Wells,	 R.D.,	 and	 Napierala,	 M.	 (2010).	 R	 loops	stimulate	genetic	instability	of	CTG·CAG	repeats.	PNAS	107,	692–697.	
	 129	
Liu,	 G.,	 Chen,	 X.,	 Bissler,	 J.J.,	 Sinden,	 R.R.,	 and	 Leffak,	 M.	 (2010).	 Replication-dependent	 instability	 at	 (CTG)	 x	 (CAG)	 repeat	 hairpins	 in	 human	 cells.	Nat.	 Chem.	Biol.	6,	652–659.	Liu,	 K.J.,	 Arron,	 J.R.,	 Stankunas,	 K.,	 Crabtree,	 G.R.,	 and	 Longaker,	 M.T.	 (2007).	Chemical	 rescue	 of	 cleft	 palate	 and	midline	defects	 in	 conditional	GSK-3beta	mice.	Nature	446,	79–82.	Liu,	P.Q.,	Rebar,	E.J.,	Zhang,	L.,	Liu,	Q.,	Jamieson,	A.C.,	Liang,	Y.,	Qi,	H.,	Li,	P.X.,	Chen,	B.,	Mendel,	 M.C.,	 et	 al.	 (2001).	 Regulation	 of	 an	 endogenous	 locus	 using	 a	 panel	 of	designed	zinc	finger	proteins	targeted	to	accessible	chromatin	regions.	Activation	of	vascular	endothelial	growth	factor	A.	J.	Biol.	Chem.	276,	11323–11334.	Liu,	 Q.,	 Zhang,	 P.,	 Wang,	 D.,	 Gu,	 W.,	 and	 Wang,	 K.	 (2017).	 Interrogating	 the	“unsequenceable”	genomic	 trinucleotide	repeat	disorders	by	 long-read	sequencing.	Genome	Medicine	9,	65.	Liu,	X.S.,	Wu,	H.,	Ji,	X.,	Stelzer,	Y.,	Wu,	X.,	Czauderna,	S.,	Shu,	J.,	Dadon,	D.,	Young,	R.A.,	and	 Jaenisch,	 R.	 (2016).	 Editing	DNA	Methylation	 in	 the	Mammalian	 Genome.	 Cell	
167,	233-247.e17.	Liu,	X.S.,	Wu,	H.,	Krzisch,	M.,	Wu,	X.,	Graef,	J.,	Muffat,	J.,	Hnisz,	D.,	Li,	C.H.,	Yuan,	B.,	Xu,	C.,	et	al.	(2018).	Rescue	of	Fragile	X	Syndrome	Neurons	by	DNA	Methylation	Editing	of	the	FMR1	Gene.	Cell	172,	979-992.e6.	Liu,	X.S.,	Wu,	H.,	Krzisch,	M.,	Wu,	X.,	Graef,	J.,	Muffat,	J.,	Hnisz,	D.,	Li,	C.H.,	Yuan,	B.,	Xu,	C.,	et	al.	Rescue	of	Fragile	X	Syndrome	Neurons	by	DNA	Methylation	Editing	of	 the	FMR1	Gene.	Cell.	Lo,	C.-L.,	Choudhury,	S.R.,	 Irudayaraj,	 J.,	and	Zhou,	F.C.	(2017).	Epigenetic	Editing	of	
Ascl1	Gene	in	Neural	Stem	Cells	by	Optogenetics.	Scientific	Reports	7,	42047.	Long,	C.,	McAnally,	 J.R.,	Shelton,	 J.M.,	Mireault,	A.A.,	Bassel-Duby,	R.,	and	Olson,	E.N.	(2014).	 Prevention	 of	 muscular	 dystrophy	 in	 mice	 by	 CRISPR/Cas9–mediated	editing	of	germline	DNA.	Science	345,	1184–1188.	Loomis,	E.W.,	Eid,	J.S.,	Peluso,	P.,	Yin,	J.,	Hickey,	L.,	Rank,	D.,	McCalmon,	S.,	Hagerman,	R.J.,	 Tassone,	 F.,	 and	 Hagerman,	 P.J.	 (2013).	 Sequencing	 the	 unsequenceable:	Expanded	CGG-repeat	alleles	of	the	fragile	X	gene.	Genome	Res	23,	121–128.	Loomis,	 E.W.,	 Sanz,	 L.A.,	 Chédin,	 F.,	 and	 Hagerman,	 P.J.	 (2014).	 Transcription-Associated	 R-Loop	 Formation	 across	 the	 Human	 FMR1	 CGG-Repeat	 Region.	 PLOS	Genetics	10,	e1004294.	Lyko,	F.	(2018).	The	DNA	methyltransferase	family:	a	versatile	toolkit	for	epigenetic	regulation.	Nature	Reviews	Genetics	19,	81–92.	MacDonald,	M.E.,	Ambrose,	C.M.,	Duyao,	M.P.,	Myers,	R.H.,	Lin,	C.,	Srinidhi,	L.,	Barnes,	G.,	 Taylor,	 S.A.,	 James,	 M.,	 Groot,	 N.,	 et	 al.	 (1993).	 A	 novel	 gene	 containing	 a	trinucleotide	 repeat	 that	 is	 expanded	 and	 unstable	 on	 Huntington’s	 disease	chromosomes.	Cell	72,	971–983.	
	 130	
Maeder,	M.L.,	Linder,	S.J.,	Reyon,	D.,	Angstman,	J.F.,	Fu,	Y.,	Sander,	J.D.,	and	Joung,	J.K.	(2013a).	 Robust,	 synergistic	 regulation	 of	 human	 gene	 expression	 using	 TALE	activators.	Nature	Methods	10,	243–245.	Maeder,	M.L.,	Linder,	S.J.,	Cascio,	V.M.,	Fu,	Y.,	Ho,	Q.H.,	and	Joung,	J.K.	(2013b).	CRISPR	RNA–guided	activation	of	endogenous	human	genes.	Nature	Methods	10,	977.	Mali,	P.,	Yang,	L.,	Esvelt,	K.M.,	Aach,	J.,	Guell,	M.,	DiCarlo,	J.E.,	Norville,	J.E.,	and	Church,	G.M.	(2013a).	RNA-Guided	Human	Genome	Engineering	via	Cas9.	Science	339,	823–826.	Mali,	P.,	Aach,	J.,	Stranges,	P.B.,	Esvelt,	K.M.,	Moosburner,	M.,	Kosuri,	S.,	Yang,	L.,	and	Church,	G.M.	(2013b).	CAS9	transcriptional	activators	for	target	specificity	screening	and	paired	nickases	 for	cooperative	genome	engineering.	Nature	Biotechnology	31,	833.	Malvaez,	 M.,	 McQuown,	 S.C.,	 Rogge,	 G.A.,	 Astarabadi,	 M.,	 Jacques,	 V.,	 Carreiro,	 S.,	Rusche,	 J.R.,	and	Wood,	M.A.	(2013).	HDAC3-selective	inhibitor	enhances	extinction	of	cocaine-seeking	behavior	in	a	persistent	manner.	PNAS	110,	2647–2652.	Manley,	K.,	Shirley,	T.L.,	Flaherty,	L.,	and	Messer,	A.	(1999).	Msh2	deficiency	prevents	
in	vivo	somatic	instability	of	the	CAG	repeat	in	Huntington	disease	transgenic	mice.	Nature	Genetics	23,	471.	Margueron,	R.,	and	Reinberg,	D.	(2010).	Chromatin	structure	and	the	inheritance	of	epigenetic	information.	Nature	Reviews	Genetics	11,	285–296.	Mariamé,	B.,	Kappler-Gratias,	S.,	Kappler,	M.,	Balor,	S.,	Gallardo,	F.,	and	Bystricky,	K.	(2018).	 Real-time	 visualization	 and	 quantification	 of	 human	 Cytomegalovirus	replication	 in	 living	 cells	 using	 the	 ANCHOR	 DNA	 labeling	 technology.	 BioRxiv	300111.	McCampbell,	 A.,	 Taye,	 A.A.,	 Whitty,	 L.,	 Penney,	 E.,	 Steffan,	 J.S.,	 and	 Fischbeck,	 K.H.	(2001).	 Histone	 deacetylase	 inhibitors	 reduce	 polyglutamine	 toxicity.	 PNAS	 98,	15179–15184.	McFarland,	K.N.,	 Liu,	 J.,	 Landrian,	 I.,	 Godiska,	R.,	 Shanker,	 S.,	 Yu,	 F.,	 Farmerie,	W.G.,	and	Ashizawa,	T.	 (2015).	SMRT	Sequencing	of	Long	Tandem	Nucleotide	Repeats	 in	SCA10	 Reveals	 Unique	 Insight	 of	 Repeat	 Expansion	 Structure.	 PLoS	 ONE	 10,	e0135906.	McMurray,	C.T.	(2010).	Mechanisms	of	trinucleotide	repeat	instability	during	human	development.	Nat	Rev	Genet	11,	786–799.	Meckler,	 J.F.,	 Bhakta,	M.S.,	 Kim,	M.-S.,	Ovadia,	R.,	Habrian,	 C.H.,	 Zykovich,	A.,	 Yu,	A.,	Lockwood,	 S.H.,	 Morbitzer,	 R.,	 Elsäesser,	 J.,	 et	 al.	 (2013).	 Quantitative	 analysis	 of	TALE–DNA	interactions	suggests	polarity	effects.	Nucleic	Acids	Res	41,	4118–4128.	Mendenhall,	 E.M.,	 Williamson,	 K.E.,	 Reyon,	 D.,	 Zou,	 J.Y.,	 Ram,	 O.,	 Joung,	 J.K.,	 and	Bernstein,	B.E.	(2013).	Locus-specific	editing	of	histone	modifications	at	endogenous	enhancers.	Nature	Biotechnology	31,	1133–1136.	
	 131	
Merienne,	 N.,	 Vachey,	 G.,	 de	 Longprez,	 L.,	 Meunier,	 C.,	 Zimmer,	 V.,	 Perriard,	 G.,	Canales,	 M.,	 Mathias,	 A.,	 Herrgott,	 L.,	 Beltraminelli,	 T.,	 et	 al.	 (2017).	 The	 Self-Inactivating	KamiCas9	System	for	the	Editing	of	CNS	Disease	Genes.	Cell	Reports	20,	2980–2991.	Miller,	J.,	McLachlan,	A.D.,	and	Klug,	A.	(1985).	Repetitive	zinc-binding	domains	in	the	protein	transcription	factor	IIIA	from	Xenopus	oocytes.	EMBO	J.	4,	1609–1614.	Mirkin,	S.M.	(2007).	Expandable	DNA	repeats	and	human	disease.	Nature	447,	932–940.	Mittelman,	D.,	Moye,	C.,	Morton,	 J.,	 Sykoudis,	K.,	 Lin,	Y.,	 Carroll,	D.,	 and	Wilson,	 J.H.	(2009).	Zinc-finger	directed	double-strand	breaks	within	CAG	repeat	tracts	promote	repeat	instability	in	human	cells.	Proc.	Natl.	Acad.	Sci.	U.S.A.	106,	9607–9612.	Mojica,	F.J.M.,	Díez-Villaseñor,	C.,	García-Martínez,	J.,	and	Almendros,	C.	(2009).	Short	motif	 sequences	 determine	 the	 targets	 of	 the	 prokaryotic	 CRISPR	 defence	 system.	Microbiology	155,	733–740.	Monckton,	D.G.,	Wong,	L.J.,	Ashizawa,	T.,	and	Caskey,	C.T.	(1995).	Somatic	mosaicism,	germline	 expansions,	 germline	 reversions	 and	 intergenerational	 reductions	 in	myotonic	dystrophy	males:	small	pool	PCR	analyses.	Hum.	Mol.	Genet.	4,	1–8.	Moore,	 M.,	 Klug,	 A.,	 and	 Choo,	 Y.	 (2001).	 Improved	 DNA	 binding	 specificity	 from	polyzinc	 finger	 peptides	 by	 using	 strings	 of	 two-finger	 units.	 Proc.	 Natl.	 Acad.	 Sci.	U.S.A.	98,	1437–1441.	Mootz,	H.D.,	and	Muir,	T.W.	(2002).	Protein	Splicing	Triggered	by	a	Small	Molecule.	J.	Am.	Chem.	Soc.	124,	9044–9045.	Morita,	S.,	Noguchi,	H.,	Horii,	T.,	Nakabayashi,	K.,	Kimura,	M.,	Okamura,	K.,	Sakai,	A.,	Nakashima,	H.,	Hata,	K.,	Nakashima,	K.,	et	al.	(2016).	Targeted	DNA	demethylation	in	
vivo	 using	 dCas9–peptide	 repeat	 and	 scFv–TET1	 catalytic	 domain	 fusions.	 Nature	Biotechnology	34,	1060–1065.	Nadel,	 Y.,	Weisman-Shomer,	 P.,	 and	 Fry,	M.	 (1995).	 The	 fragile	 X	 syndrome	 single	strand	 d(CGG)n	 nucleotide	 repeats	 readily	 fold	 back	 to	 form	unimolecular	 hairpin	structures.	J.	Biol.	Chem.	270,	28970–28977.	Nageshwaran,	 S.,	 and	 Festenstein,	 R.	 (2015).	 Epigenetics	 and	 Triplet-Repeat	Neurological	Diseases.	Front.	Neurol.	262.	Nanda,	 J.S.,	 Kumar,	 R.,	 and	Raghava,	 G.P.S.	 (2016).	 dbEM:	A	 database	 of	 epigenetic	modifiers	curated	from	cancerous	and	normal	genomes.	Scientific	Reports	6,	19340.	Niu,	 J.,	Zhang,	B.,	and	Chen,	H.	(2014).	Applications	of	TALENs	and	CRISPR/Cas9	in	Human	Cells	and	Their	Potentials	for	Gene	Therapy.	Mol	Biotechnol	56,	681–688.	Nunna,	S.,	Reinhardt,	R.,	Ragozin,	S.,	and	Jeltsch,	A.	(2014).	Targeted	Methylation	of	the	Epithelial	Cell	Adhesion	Molecule	(EpCAM)	Promoter	to	Silence	Its	Expression	in	Ovarian	Cancer	Cells.	PLOS	ONE	9,	e87703.	
	 132	
Oberlé,	I.,	Rousseau,	F.,	Heitz,	D.,	Kretz,	C.,	Devys,	D.,	Hanauer,	A.,	Boué,	J.,	Bertheas,	M.F.,	 and	 Mandel,	 J.L.	 (1991).	 Instability	 of	 a	 550-base	 pair	 DNA	 segment	 and	abnormal	methylation	in	fragile	X	syndrome.	Science	252,	1097–1102.	Orr,	H.T.,	and	Zoghbi,	H.Y.	(2007).	Trinucleotide	Repeat	Disorders.	Annual	Review	of	Neuroscience	30,	575–621.	Orr,	H.T.,	Chung,	M.,	Banfi,	S.,	Jr,	T.J.K.,	Servadio,	A.,	Beaudet,	A.L.,	McCall,	A.E.,	Duvick,	L.A.,	Ranum,	L.P.W.,	and	Zoghbi,	H.Y.	(1993).	Expansion	of	an	unstable	trinucleotide	CAG	repeat	in	spinocerebellar	ataxia	type	1.	Nature	Genetics	4,	221.	Otten,	A.D.,	and	Tapscott,	S.J.	(1995).	Triplet	repeat	expansion	in	myotonic	dystrophy	alters	the	adjacent	chromatin	structure.	PNAS	92,	5465–5469.	Ouellet,	D.L.,	Cherif,	K.,	Rousseau,	 J.,	and	Tremblay,	 J.P.	 (2017).	Deletion	of	 the	GAA	repeats	 from	 the	 human	 frataxin	 gene	 using	 the	 CRISPR-Cas9	 system	 in	 YG8R-derived	cells	and	mouse	models	of	Friedreich	ataxia.	Gene	Therapy	24,	265–274.	Park,	C.-Y.,	Halevy,	T.,	Lee,	D.R.,	Sung,	J.J.,	Lee,	J.S.,	Yanuka,	O.,	Benvenisty,	N.,	and	Kim,	D.-W.	 (2015).	 Reversion	 of	 FMR1	Methylation	 and	 Silencing	 by	 Editing	 the	Triplet	Repeats	in	Fragile	X	iPSC-Derived	Neurons.	Cell	Reports	13,	234–241.	Pavletich,	N.P.,	and	Pabo,	C.O.	(1991).	Zinc	finger-DNA	recognition:	crystal	structure	of	a	Zif268-DNA	complex	at	2.1	A.	Science	252,	809–817.	Pearson,	C.E.,	Sinden,	R.R.,	Wang,	Y.-H.,	and	Griffith,	J.D.	(1998).	Structural	analysis	of	slipped-strand	DNA	 (S-DNA)	 formed	 in	 (CTG)n·(CAG)n	 repeats	 from	 the	myotonic	dystrophy	locus.	Nucl.	Acids	Res.	26,	816–823.	Pearson,	 C.E.,	 Tam,	 M.,	 Wang,	 Y.-H.,	 Montgomery,	 S.E.,	 Dar,	 A.C.,	 Cleary,	 J.D.,	 and	Nichol,	 K.	 (2002).	 Slipped-strand	 DNAs	 formed	 by	 long	 (CAG)*(CTG)	 repeats:	slipped-out	repeats	and	slip-out	junctions.	Nucleic	Acids	Res.	30,	4534–4547.	Perez-Pinera,	 P.,	 Ousterout,	 D.G.,	 Brunger,	 J.M.,	 Farin,	 A.M.,	 Glass,	 K.A.,	 Guilak,	 F.,	Crawford,	G.E.,	Hartemink,	A.J.,	and	Gersbach,	C.A.	 (2013a).	Synergistic	and	tunable	human	 gene	 activation	 by	 combinations	 of	 synthetic	 transcription	 factors.	 Nature	Methods	10,	239–242.	Perez-Pinera,	 P.,	 Kocak,	 D.D.,	 Vockley,	 C.M.,	 Adler,	 A.F.,	 Kabadi,	 A.M.,	 Polstein,	 L.R.,	Thakore,	 P.I.,	 Glass,	 K.A.,	 Ousterout,	 D.G.,	 Leong,	 K.W.,	 et	 al.	 (2013b).	 RNA-guided	gene	 activation	 by	 CRISPR-Cas9–based	 transcription	 factors.	 Nature	 Methods	 10,	973.	Pinto,	 B.S.,	 Saxena,	 T.,	 Oliveira,	 R.,	 Méndez-Gómez,	 H.R.,	 Cleary,	 J.D.,	 Denes,	 L.T.,	McConnell,	 O.,	 Arboleda,	 J.,	 Xia,	 G.,	 Swanson,	 M.S.,	 et	 al.	 (2017).	 Impeding	Transcription	 of	 Expanded	 Microsatellite	 Repeats	 by	 Deactivated	 Cas9.	 Molecular	Cell	68,	479-490.e5.	Pinto,	 R.M.,	 Dragileva,	 E.,	 Kirby,	 A.,	 Lloret,	 A.,	 Lopez,	 E.,	 Claire,	 J.S.,	 Panigrahi,	 G.B.,	Hou,	C.,	Holloway,	K.,	Gillis,	T.,	et	al.	(2013).	Mismatch	Repair	Genes	Mlh1	and	Mlh3	
	 133	
Modify	CAG	 Instability	 in	Huntington’s	Disease	Mice:	Genome-Wide	 and	Candidate	Approaches.	PLOS	Genet	9,	e1003930.	Polstein,	L.R.,	Perez-Pinera,	P.,	Kocak,	D.D.,	Vockley,	C.M.,	Bledsoe,	P.,	Song,	L.,	Safi,	A.,	Crawford,	 G.E.,	 Reddy,	 T.E.,	 and	 Gersbach,	 C.A.	 (2015).	 Genome-wide	 specificity	 of	DNA	 binding,	 gene	 regulation,	 and	 chromatin	 remodeling	 by	 TALE-	 and	CRISPR/Cas9-based	transcriptional	activators.	Genome	Res.	25,	1158–1169.	Portela,	 A.,	 and	 Esteller,	 M.	 (2010).	 Epigenetic	 modifications	 and	 human	 disease.	Nature	Biotechnology	28,	1057–1068.	Punga,	 T.,	 and	 Bühler,	 M.	 (2010).	 Long	 intronic	 GAA	 repeats	 causing	 Friedreich	ataxia	impede	transcription	elongation.	EMBO	Mol	Med	2,	120–129.	Qasim,	W.,	Amrolia,	P.J.,	Samarasinghe,	S.,	Ghorashian,	S.,	Zhan,	H.,	Stafford,	S.,	Butler,	K.,	Ahsan,	G.,	Gilmour,	K.,	Adams,	S.,	et	al.	(2015).	First	Clinical	Application	of	Talen	Engineered	Universal	CAR19	T	Cells	in	B-ALL.	Blood	126,	2046–2046.	Qi,	L.S.,	Larson,	M.H.,	Gilbert,	L.A.,	Doudna,	 J.A.,	Weissman,	 J.S.,	Arkin,	A.P.,	and	Lim,	W.A.	(2013).	Repurposing	CRISPR	as	an	RNA-Guided	Platform	for	Sequence-Specific	Control	of	Gene	Expression.	Cell	152,	1173–1183.	Rafalska-Metcalf,	 I.U.,	 and	 Janicki,	 S.M.	 (2007).	 Show	 and	 tell:	 visualizing	 gene	expression	in	living	cells.	J	Cell	Sci	120,	2301–2307.	Rando,	 O.J.,	 and	 Chang,	 H.Y.	 (2009).	 Genome-Wide	 Views	 of	 Chromatin	 Structure.	Annual	Review	of	Biochemistry	78,	245–271.	Reddy,	 K.,	 Tam,	 M.,	 Bowater,	 R.P.,	 Barber,	 M.,	 Tomlinson,	 M.,	 Nichol	 Edamura,	 K.,	Wang,	 Y.-H.,	 and	 Pearson,	 C.E.	 (2011).	 Determinants	 of	 R-loop	 formation	 at	convergent	bidirectionally	 transcribed	 trinucleotide	 repeats.	Nucleic	Acids	Res.	39,	1749–1762.	Reddy,	K.,	Schmidt,	M.H.M.,	Geist,	J.M.,	Thakkar,	N.P.,	Panigrahi,	G.B.,	Wang,	Y.-H.,	and	Pearson,	 C.E.	 (2014).	 Processing	 of	 double-R-loops	 in	 (CAG)·(CTG)	 and	 C9orf72	(GGGGCC)·(GGCCCC)	repeats	causes	instability.	Nucleic	Acids	Res.	42,	10473–10487.	Reyon,	 D.,	 Tsai,	 S.Q.,	 Khayter,	 C.,	 Foden,	 J.A.,	 Sander,	 J.D.,	 and	 Joung,	 J.K.	 (2012).	FLASH	 assembly	 of	 TALENs	 for	 high-throughput	 genome	 editing.	 Nature	Biotechnology	30,	460–465.	Rinaldi,	 F.C.,	 Doyle,	 L.A.,	 Stoddard,	 B.L.,	 and	 Bogdanove,	 A.J.	 (2017).	 The	 effect	 of	increasing	numbers	of	repeats	on	TAL	effector	DNA	binding	specificity.	Nucleic	Acids	Res	45,	6960–6970.	Robert,	 M.-F.,	 Morin,	 S.,	 Beaulieu,	 N.,	 Gauthier,	 F.,	 Chute,	 I.C.,	 Barsalou,	 A.,	 and	MacLeod,	A.R.	(2003).	DNMT1	is	required	to	maintain	CpG	methylation	and	aberrant	gene	silencing	in	human	cancer	cells.	Nature	Genetics	33,	61–65.	Robertson,	 K.D.	 (2005).	 DNA	 methylation	 and	 human	 disease.	 Nature	 Reviews	Genetics	6,	597.	
	 134	
Robertson,	 K.D.,	 and	 Wolffe,	 A.P.	 (2000).	 DNA	 methylation	 in	 health	 and	 disease.	Nature	Reviews	Genetics	1,	11.	Rogers,	J.M.,	Barrera,	L.A.,	Reyon,	D.,	Sander,	J.D.,	Kellis,	M.,	Joung,	J.K.,	and	Bulyk,	M.L.	(2015).	Context	influences	on	TALE–DNA	binding	revealed	by	quantitative	profiling.	Nature	Communications	6,	7440.	Ross,	 C.A.,	 and	 Tabrizi,	 S.J.	 (2011).	 Huntington’s	 disease:	 from	 molecular	pathogenesis	to	clinical	treatment.	The	Lancet	Neurology	10,	83–98.	Saad,	H.,	Gallardo,	F.,	Dalvai,	M.,	Tanguy-le-Gac,	N.,	Lane,	D.,	and	Bystricky,	K.	(2014).	DNA	 dynamics	 during	 early	 double-strand	 break	 processing	 revealed	 by	 non-intrusive	imaging	of	living	cells.	PLoS	Genet.	10,	e1004187.	Santillan,	 B.A.,	 Moye,	 C.,	 Mittelman,	 D.,	 and	 Wilson,	 J.H.	 (2014).	 GFP-based	fluorescence	assay	 for	CAG	repeat	 instability	 in	 cultured	human	cells.	PLoS	ONE	9,	e113952.	Saveliev,	 A.,	 Everett,	 C.,	 Sharpe,	 T.,	 Webster,	 Z.,	 and	 Festenstein,	 R.	 (2003).	 DNA	triplet	 repeats	 mediate	 heterochromatin-protein-1-sensitive	 variegated	 gene	silencing.	Nature	422,	909–913.	Schmidt,	M.H.M.,	and	Pearson,	C.E.	(2016).	Disease-associated	repeat	instability	and	mismatch	repair.	DNA	Repair	38,	117–126.	Schweitzer,	 J.K.,	 and	 Livingston,	 D.M.	 (1997).	 Destabilization	 of	 CAG	 Trinucleotide	Repeat	Tracts	by	Mismatch	Repair	Mutations	in	Yeast.	Hum.	Mol.	Genet.	6,	349–355.	Segal,	D.J.,	Dreier,	B.,	Beerli,	R.R.,	 and	Barbas,	C.F.	 (1999).	Toward	controlling	gene	expression	at	will:	 Selection	and	design	of	 zinc	 finger	domains	 recognizing	each	of	the	5′-GNN-3′	DNA	target	sequences.	PNAS	96,	2758–2763.	Shah,	 S.A.,	 Erdmann,	 S.,	 Mojica,	 F.J.M.,	 and	 Garrett,	 R.A.	 (2013).	 Protospacer	recognition	motifs.	RNA	Biology	10,	891–899.	Shahbazian,	 M.D.,	 and	 Grunstein,	 M.	 (2007).	 Functions	 of	 Site-Specific	 Histone	Acetylation	and	Deacetylation.	Annual	Review	of	Biochemistry	76,	75–100.	Shi,	Y.,	Lan,	F.,	Matson,	C.,	Mulligan,	P.,	Whetstine,	J.R.,	Cole,	P.A.,	Casero,	R.A.,	and	Shi,	Y.	(2004).	Histone	Demethylation	Mediated	by	the	Nuclear	Amine	Oxidase	Homolog	LSD1.	Cell	119,	941–953.	Shukla,	 S.,	 Kavak,	 E.,	 Gregory,	 M.,	 Imashimizu,	 M.,	 Shutinoski,	 B.,	 Kashlev,	 M.,	Oberdoerffer,	 P.,	 Sandberg,	 R.,	 and	 Oberdoerffer,	 S.	 (2011).	 CTCF-promoted	 RNA	polymerase	II	pausing	links	DNA	methylation	to	splicing.	Nature	479,	74–79.	Slaymaker,	 I.M.,	 Gao,	 L.,	 Zetsche,	 B.,	 Scott,	 D.A.,	 Yan,	 W.X.,	 and	 Zhang,	 F.	 (2016).	Rationally	engineered	Cas9	nucleases	with	improved	specificity.	Science	351,	84–88.	
	 135	
Snowden,	 A.W.,	 Gregory,	 P.D.,	 Case,	 C.C.,	 and	 Pabo,	 C.O.	 (2002).	 Gene-Specific	Targeting	of	H3K9	Methylation	Is	Sufficient	for	Initiating	Repression	In	Vivo.	Current	Biology	12,	2159–2166.	Soragni,	E.,	 and	Gottesfeld,	 J.M.	 (2016).	Translating	HDAC	 inhibitors	 in	Friedreich’s	ataxia.	Expert	Opinion	on	Orphan	Drugs	4,	961–970.	Soragni,	E.,	Miao,	W.,	 Iudicello,	M.,	 Jacoby,	D.,	De	Mercanti,	S.,	Clerico,	M.,	Longo,	F.,	Piga,	 A.,	 Ku,	 S.,	 Campau,	 E.,	 et	 al.	 (2014).	 Epigenetic	 therapy	 for	 Friedreich	 ataxia.	Ann.	Neurol.	76,	489–508.	Spange,	 S.,	 Wagner,	 T.,	 Heinzel,	 T.,	 and	 Krämer,	 O.H.	 (2009).	 Acetylation	 of	 non-histone	 proteins	modulates	 cellular	 signalling	 at	multiple	 levels.	 The	 International	Journal	of	Biochemistry	&	Cell	Biology	41,	185–198.	Spencer,	D.M.,	Wandless,	T.J.,	 Schreiber,	 S.L.,	 and	Crabtree,	G.R.	 (1993).	 Controlling	signal	transduction	with	synthetic	ligands.	Science	262,	1019–1024.	Stankunas,	K.,	Bayle,	J.H.,	Gestwicki,	J.E.,	Lin,	Y.-M.,	Wandless,	T.J.,	and	Crabtree,	G.R.	(2003).	 Conditional	 protein	 alleles	 using	 knockin	 mice	 and	 a	 chemical	 inducer	 of	dimerization.	Mol.	Cell	12,	1615–1624.	Stanton,	B.Z.,	Chory,	E.J.,	and	Crabtree,	G.R.	(2018).	Chemically	induced	proximity	in	biology	and	medicine.	Science	359,	eaao5902.	Steffan,	J.S.,	Bodai,	L.,	Pallos,	J.,	Poelman,	M.,	McCampbell,	A.,	Apostol,	B.L.,	Kazantsev,	A.,	Schmidt,	E.,	Zhu,	Y.-Z.,	Greenwald,	M.,	et	al.	(2001).	Histone	deacetylase	inhibitors	arrest	polyglutamine-dependent	neurodegeneration	in	Drosophila.	Nature	413,	739.	Steinbach,	P.,	Gläser,	D.,	Vogel,	W.,	Wolf,	M.,	 and	Schwemmle,	S.	 (1998).	The	DMPK	gene	of	severely	affected	myotonic	dystrophy	patients	is	hypermethylated	proximal	to	the	largely	expanded	CTG	repeat.	Am	J	Hum	Genet	62,	278–285.	Stine,	O.C.,	Pleasant,	N.,	Franz,	M.L.,	Abbott,	M.H.,	Folstein,	S.E.,	and	Ross,	C.A.	(1993).	Correlation	 between	 the	 onset	 age	 of	 Huntington’s	 disease	 and	 length	 of	 the	trinucleotide	repeat	in	IT-15.	Hum	Mol	Genet	2,	1547–1549.	Stöger,	R.,	Kajimura,	T.M.,	Brown,	W.T.,	and	Laird,	C.D.	(1997).	Epigenetic	Variation	Illustrated	by	DNA	Methylation	Patterns	of	the	Fragile-X	Gene	FMR1.	Hum	Mol	Genet	
6,	1791–1801.	Stolzenburg,	S.,	Rots,	M.G.,	Beltran,	A.S.,	Rivenbark,	A.G.,	Yuan,	X.,	Qian,	H.,	Strahl,	B.D.,	and	 Blancafort,	 P.	 (2012).	 Targeted	 silencing	 of	 the	 oncogenic	 transcription	 factor	SOX2	in	breast	cancer.	Nucleic	Acids	Res	40,	6725–6740.	Strom,	A.R.,	 Emelyanov,	A.V.,	Mir,	M.,	 Fyodorov,	D.V.,	 Darzacq,	 X.,	 and	Karpen,	 G.H.	(2017).	 Phase	 separation	 drives	 heterochromatin	 domain	 formation.	 Nature	 547,	241–245.	
	 136	
Suelves,	 N.,	 Kirkham-McCarthy,	 L.,	 Lahue,	 R.S.,	 and	 Ginés,	 S.	 (2017).	 A	 selective	inhibitor	of	histone	deacetylase	3	prevents	cognitive	deficits	and	suppresses	striatal	CAG	repeat	expansions	in	Huntington’s	disease	mice.	Scientific	Reports	7,	6082.	Sutcliffe,	 J.S.,	Nelson,	D.L.,	 Zhang,	F.,	 Pieretti,	M.,	Caskey,	C.T.,	 Saxe,	D.,	 and	Warren,	S.T.	(1992).	DNA	methylation	represses	FMR-1	transcription	in	fragile	X	syndrome.	Hum.	Mol.	Genet.	1,	397–400.	Tacke,	 R.,	 and	Manley,	 J.L.	 (1999).	 Determinants	 of	 SR	 protein	 specificity.	 Current	Opinion	in	Cell	Biology	11,	358–362.	Tanenbaum,	 M.E.,	 Gilbert,	 L.A.,	 Qi,	 L.S.,	 Weissman,	 J.S.,	 and	 Vale,	 R.D.	 (2014).	 A	Protein-Tagging	 System	 for	 Signal	 Amplification	 in	 Gene	 Expression	 and	Fluorescence	Imaging.	Cell	159,	635–646.	Tomé,	S.,	Holt,	I.,	Edelmann,	W.,	Morris,	G.E.,	Munnich,	A.,	Pearson,	C.E.,	and	Gourdon,	G.	 (2009).	 MSH2	 ATPase	 Domain	 Mutation	 Affects	 CTG•CAG	 Repeat	 Instability	 in	Transgenic	Mice.	PLOS	Genetics	5,	e1000482.	Tomé,	S.,	Manley,	K.,	Simard,	J.P.,	Clark,	G.W.,	Slean,	M.M.,	Swami,	M.,	Shelbourne,	P.F.,	Tillier,	 E.R.M.,	Monckton,	 D.G.,	Messer,	 A.,	 et	 al.	 (2013).	MSH3	 polymorphisms	 and	protein	levels	affect	CAG	repeat	instability	in	Huntington’s	disease	mice.	PLoS	Genet.	
9,	e1003280.	Tsai,	Y.-C.,	Greenberg,	D.,	Powell,	J.,	Hoijer,	I.,	Ameur,	A.,	Strahl,	M.,	Ellis,	E.,	Jonasson,	I.,	 Pinto,	 R.M.,	Wheeler,	 V.,	 et	 al.	 (2017).	 Amplification-free,	 CRISPR-Cas9	 Targeted	Enrichment	and	SMRT	Sequencing	of	Repeat-Expansion	Disease	Causative	Genomic	Regions.	BioRxiv	203919.	Usdin,	 K.,	 and	Woodford,	 K.J.	 (1995).	 CGG	 repeats	 associated	with	 DNA	 instability	and	chromosome	fragility	form	structures	that	block	DNA	synthesis	in	vitro.	Nucleic	Acids	Res.	23,	4202–4209.	Usdin,	 K.,	 House,	 N.C.M.,	 and	 Freudenreich,	 C.H.	 (2015).	 Repeat	 instability	 during	DNA	 repair:	 Insights	 from	 model	 systems.	 Critical	 Reviews	 in	 Biochemistry	 and	Molecular	Biology	50,	142–167.	Valton,	 J.,	Dupuy,	A.,	Daboussi,	F.,	Thomas,	S.,	Maréchal,	A.,	Macmaster,	R.,	Melliand,	K.,	 Juillerat,	 A.,	 and	Duchateau,	 P.	 (2012).	 Overcoming	 Transcription	Activator-like	Effector	 (TALE)	 DNA	 Binding	 Domain	 Sensitivity	 to	 Cytosine	 Methylation.	 J.	 Biol.	Chem.	287,	38427–38432.	Venkatesh,	S.,	and	Workman,	J.L.	(2015).	Histone	exchange,	chromatin	structure	and	the	regulation	of	transcription.	Nature	Reviews	Molecular	Cell	Biology	16,	178–189.	Verkerk,	A.J.M.H.,	Pieretti,	M.,	Sutcliffe,	 J.S.,	Fu,	Y.-H.,	Kuhl,	D.P.A.,	Pizzuti,	A.,	Reiner,	O.,	Richards,	S.,	Victoria,	M.F.,	Zhang,	F.,	et	al.	(1991).	Identification	of	a	gene	(FMR-1)	containing	 a	 CGG	 repeat	 coincident	 with	 a	 breakpoint	 cluster	 region	 exhibiting	length	variation	in	fragile	X	syndrome.	Cell	65,	905–914.	
	 137	
Verschure,	 P.J.,	 van	 der	 Kraan,	 I.,	 de	 Leeuw,	 W.,	 van	 der	 Vlag,	 J.,	 Carpenter,	 A.E.,	Belmont,	 A.S.,	 and	 van	 Driel,	 R.	 (2005).	 In	 vivo	 HP1	 targeting	 causes	 large-scale	chromatin	condensation	and	enhanced	histone	lysine	methylation.	Mol.	Cell.	Biol.	25,	4552–4564.	Vojta,	A.,	Dobrinić,	P.,	Tadić,	V.,	Bočkor,	L.,	Korać,	P.,	Julg,	B.,	Klasić,	M.,	and	Zoldoš,	V.	(2016).	Repurposing	the	CRISPR-Cas9	system	for	targeted	DNA	methylation.	Nucleic	Acids	Res	44,	5615–5628.	Wang,	A.,	Kurdistani,	 S.K.,	 and	Grunstein,	M.	 (2002).	Requirement	 of	Hos2	Histone	Deacetylase	for	Gene	Activity	in	Yeast.	Science	298,	1412–1414.	Wang,	 L.,	 Lin,	 J.,	 Zhang,	 T.,	 Xu,	 K.,	 Ren,	 C.,	 and	 Zhang,	 Z.	 (2013).	 Simultaneous	screening	 and	 validation	 of	 effective	 zinc	 finger	 nucleases	 in	 yeast.	 PLoS	 ONE	 8,	e64687.	Wang,	 Z.,	 Zang,	 C.,	 Cui,	 K.,	 Schones,	 D.E.,	 Barski,	 A.,	 Peng,	W.,	 and	 Zhao,	 K.	 (2009).	Genome-wide	mapping	of	HATs	and	HDACs	reveals	distinct	 functions	 in	active	and	inactive	genes.	Cell	138,	1019–1031.	Warby,	S.C.,	Montpetit,	A.,	Hayden,	A.R.,	Carroll,	J.B.,	Butland,	S.L.,	Visscher,	H.,	Collins,	J.A.,	 Semaka,	 A.,	 Hudson,	 T.J.,	 and	 Hayden,	 M.R.	 (2009).	 CAG	 Expansion	 in	 the	Huntington	Disease	Gene	Is	Associated	with	a	Specific	and	Targetable	Predisposing	Haplogroup.	Am	J	Hum	Genet	84,	351–366.	Waryah,	C.B.,	Moses,	C.,	Arooj,	M.,	and	Blancafort,	P.	(2018).	Zinc	Fingers,	TALEs,	and	CRISPR	Systems:	A	Comparison	of	Tools	 for	Epigenome	Editing.	Methods	Mol.	Biol.	
1767,	19–63.	Xu,	G.L.,	and	Bestor,	T.H.	(1997).	Cytosine	methylation	targetted	to	pre-determined	sequences.	Nat.	Genet.	17,	376–378.	Xu,	X.,	Tao,	Y.,	Gao,	X.,	Zhang,	L.,	Li,	X.,	Zou,	W.,	Ruan,	K.,	Wang,	F.,	Xu,	G.,	and	Hu,	R.	(2016).	A	CRISPR-based	approach	for	targeted	DNA	demethylation.	Cell	Discovery	2,	16009.	Yandim,	C.,	Natisvili,	T.,	and	Festenstein,	R.	(2013).	Gene	regulation	and	epigenetics	in	Friedreich’s	ataxia.	J.	Neurochem.	126	Suppl	1,	21–42.	Yang,	S.,	Chang,	R.,	Yang,	H.,	Zhao,	T.,	Hong,	Y.,	Kong,	H.E.,	Sun,	X.,	Qin,	Z.,	Jin,	P.,	Li,	S.,	et	al.	CRISPR/Cas9-mediated	gene	editing	ameliorates	neurotoxicity	in	mouse	model	of	Huntington’s	disease.	J	Clin	Invest	127,	2719–2724.	Yang,	X.,	Han,	H.,	De	Carvalho,	D.D.,	Lay,	F.D.,	 Jones,	P.A.,	and	Liang,	G.	(2014).	Gene	body	methylation	 can	 alter	 gene	 expression	 and	 is	 a	 therapeutic	 target	 in	 cancer.	Cancer	Cell	26,	577–590.	Yazawa,	 M.,	 Sadaghiani,	 A.M.,	 Hsueh,	 B.,	 and	 Dolmetsch,	 R.E.	 (2009).	 Induction	 of	protein-protein	 interactions	 in	 live	cells	using	 light.	Nature	Biotechnology	27,	941–945.	
	 138	
Yeakley,	J.M.,	Morfin,	J.P.,	Rosenfeld,	M.G.,	and	Fu,	X.D.	(1996).	A	complex	of	nuclear	proteins	mediates	 SR	protein	binding	 to	 a	purine-rich	 splicing	 enhancer.	 PNAS	93,	7582–7587.	You,	S.-H.,	Lim,	H.-W.,	Sun,	Z.,	Broache,	M.,	Won,	K.-J.,	and	Lazar,	M.A.	(2013).	Nuclear	receptor	co-repressors	are	required	for	the	histone-deacetylase	activity	of	HDAC3	in	
vivo.	Nature	Structural	&	Molecular	Biology	20,	182–187.	Zetsche,	 B.,	 Volz,	 S.E.,	 and	 Zhang,	 F.	 (2015).	 A	 split-Cas9	 architecture	 for	 inducible	genome	editing	and	transcription	modulation.	Nat.	Biotechnol.	33,	139–142.	Zhang,	F.,	Cong,	L.,	Lodato,	S.,	Kosuri,	S.,	Church,	G.M.,	and	Arlotta,	P.	(2011).	Efficient	construction	 of	 sequence-specific	 TAL	 effectors	 for	 modulating	 mammalian	transcription.	Nature	Biotechnology	29,	149–153.	Zhang,	 F.,	 Bodycombe,	 N.E.,	 Haskell,	 K.M.,	 Sun,	 Y.L.,	Wang,	 E.T.,	Morris,	 C.A.,	 Jones,	L.H.,	Wood,	L.D.,	and	Pletcher,	M.T.	(2017).	A	flow	cytometry-based	screen	identifies	MBNL1	modulators	that	rescue	splicing	defects	 in	myotonic	dystrophy	type	I.	Hum	Mol	Genet	26,	3056–3068.	Zhang,	L.,	Spratt,	S.K.,	Liu,	Q.,	Johnstone,	B.,	Qi,	H.,	Raschke,	E.E.,	Jamieson,	A.C.,	Rebar,	E.J.,	 Wolffe,	 A.P.,	 and	 Case,	 C.C.	 (2000).	 Synthetic	 zinc	 finger	 transcription	 factor	action	at	an	endogenous	chromosomal	site.	Activation	of	the	human	erythropoietin	gene.	J.	Biol.	Chem.	275,	33850–33860.	Zhao,	X.-N.,	and	Usdin,	K.	 (2015).	The	Repeat	Expansion	Diseases:	The	dark	side	of	DNA	repair.	DNA	Repair	32,	96–105.	Zharkov,	D.O.	(2008).	Base	excision	DNA	repair.	Cell.	Mol.	Life	Sci.	65,	1544–1565.	Zhou,	X.,	Naik,	S.,	Dakhova,	O.,	Dotti,	G.,	Heslop,	H.E.,	and	Brenner,	M.K.	(2016).	Serial	Activation	 of	 the	 Inducible	 Caspase	 9	 Safety	 Switch	 After	 Human	 Stem	 Cell	Transplantation.	Mol	Ther	24,	823–831.	
	
	 	
	 139	
Appendix	A:	Articles	
	
	 140	
Uncovering	the	Interplay	Between	Epigenome	Editing	Efficiency	and	Sequence	Context	Using	a	Novel	Inducible	Targeting	System		 Bin	Yang1,	Alicia	Borgeaud1,2,	Lorène	Aeschbach1,	and	Vincent	Dion1*				1:	University	of	Lausanne,	Faculty	of	Biology	and	Medicine,	Center	for	Integrative	Genomics,	Bâtiment	Génopode,	1015-Lausanne,	Switzerland.	2:	current	address:	MRC	Laboratory	of	Molecular	Biology,	Francis	Crick	Avenue,	Cambridge	Biomedical	Campus,	Cambridge	CB2	0QH,	UK	*:	Corresponding	author:	Vincent.dion@unil.ch		Keywords:	Epigenome	editing,	synthetic	biology,	chromatin,	gene	expression,	histone	deacetylases,	expanded	CAG/CTG	repeats.		 	
	 141	
Abstract	Epigenome	 editing	 is	 an	 attractive	 way	 to	 manipulate	 gene	 expression.	 However,	editing	efficiencies	depend	on	the	DNA	sequence	context	 in	a	manner	that	remains	poorly	understood.	Here	we	developed	a	novel	system	in	which	any	protein	can	be	recruited	at	will	to	a	GFP	reporter.	We	named	it	ParB/ANCHOR-mediated	Inducible	Targeting	(PInT).	Using	PInT,	we	tested	how	CAG/CTG	repeat	size	affects	the	ability	of	 histone	 deacetylases	 to	 modulate	 gene	 expression.	 We	 found	 that	 repeat	expansion	reduces	the	effectiveness	of	silencing	brought	about	by	HDAC5	targeting.	This	repeat-length	specificity	was	abolished	when	we	inhibited	HDAC3	activity.	Our	data	guide	the	use	of	these	histone	deacetylases	in	manipulating	chromatin.	PInT	can	be	adapted	to	study	the	effect	of	virtually	any	sequence	on	epigenome	editing.		Key	points:	
- PInT:	a	novel	assay	to	test	the	effect	of	DNA	sequence	on	epigenome	editing.	
- HDAC5-mediated	silencing	is	more	efficient	at	short	compared	to	expanded	CAG/CTG	repeats.	
- HDAC3	activity	is	responsible	for	the	allele-size	effect	of	HDAC5-mediated	gene	silencing.		 	
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Introduction:	
Chromatin	structure	impinges	on	every	DNA-based	transaction,	from	replication	and	DNA	repair	to	transcription.	Thus,	it	is	not	surprising	that	epigenome	editing	is	being	harnessed	both	to	understand	basic	molecular	mechanisms	and	to	treat	disease	(1).	Epigenome	editing	is	now	most	commonly	carried	out	via	the	use	of	the	domain	of	a	chromatin	modifier,	 or	EpiEffector,	 fused	 to	 a	 catalytically	dead	Cas9	 (dCas9).	The	fusion	protein	is	targeted	to	a	locus	of	choice	by	way	of	a	customizable	single	guide	RNA	 (sgRNA)	 (2-10).	 Examples	 of	 dCas9-mediated	 epigenome	 editing	 include	altering	chromatin	states	by	either	targeting	Krüppel-associated	box	(KRAB)	(6)	or	the	 histone	 acetyltransferase	 domain	 of	 p300	 (2),	 thereby	 reducing	 or	 promoting	enhancer	 function,	 respectively.	 Moreover,	 epigenome	 editing	 using	 Cas9-based	approaches	have	been	used	to	modify	disease	phenotypes	in	cells	and	in	vivo	(11,12).	
It	 is	 currently	 not	 possible	 to	 predict	 whether	 targeting	 a	 specific	 locus	 with	 a	particular	 dCas9-EpiEffector	 fusion	 will	 result	 in	 efficient	 chromatin	 modification	and	alteration	of	 gene	 expression.	 Several	 reasons	have	been	proposed	 to	 account	for	this,	ranging	from	the	sequence	of	the	sgRNA	and	the	distance	of	its	target	from	the	 transcriptional	 start	 site	 (3-5),	 the	 chromatin	 structure	 already	 present	 at	 the	target	 locus	 (13-18)(BioRxiv:	 https://doi.org/10.1101/228601)	 ,	 and/or	 the	 exact	EpiEffector	 used	 (2,4,10,16,18).	 Indeed,	 the	 same	 EpiEffector	 targeted	 at	 different	loci	 can	 have	 very	 different	 effects	 (10,16),	 highlighting	 that	 DNA	 context	 affects	EpiEffectors	in	ways	that	are	not	understood.		
Some	 DNA	 sequences	 can	 have	 profound	 effects	 on	 nucleosome	 positioning	 and	chromatin	 structure	 (19).	 A	 prime	 example	 of	 this	 is	 the	 expansion	 of	 CAG/CTG	repeats,	which	causes	14	different	neurological	and	neuromuscular	diseases	(20,21).	In	healthy	individuals,	these	sequences	have	less	than	35	repeats	at	any	one	disease	locus.	 However,	 they	 can	 expand	 and	 reach	 up	 to	 thousands	 of	 triplets.	 Once	expanded,	CAG/CTG	repeats	lead	to	changes	in	gene	expression	in	their	vicinity	and	to	a	heterochromatic-like	state	(22-25).	How	these	repetitive	sequences	might	affect	epigenome	editing	is	unknown.			
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Here,	 we	 developed	 a	 method	 to	 understand	 how	 DNA	 sequence	 context	 can	influence	 epigenome	 editing	 efficiency.	 We	 named	 the	 system	 ParB/ANCHOR-mediated	 induced	 targeting	 (PInT).	 With	 PInT,	 any	 protein	 of	 interest	 can	 be	targeted	near	a	sequence	of	choice.	ParB,	a	bacterial	protein,	forms	oligomers	once	it	nucleates	at	its	non-repetitive	binding	site,	INT	(26).	Fusing	a	protein	of	interest	to	ParB	leads	to	the	recruitment	of	many	of	the	desired	molecules	to	the	INT	locus.	The	targeting	 is	 inducible	 as	 we	 coupled	 ParB/ANCHOR	 to	 a	 chemically	 induced	proximity	(CIP)	system	derived	from	plants	(27).	The	target	sequence	is	embedded	in	a	GFP	mini	gene	(28)	such	that	the	effect	of	targeting	on	gene	expression	is	easily	monitored.	 Using	 PInT,	we	 uncovered	 an	 unexpected	 effect	 of	 expanded	 CAG/CTG	repeats	 on	 the	 effectiveness	 of	 histone	 deacetylase	 5	 (HDAC5)	 to	 modulate	 gene	expression	and	found	that	this	was	due	to	the	catalytic	activity	of	HDAC3.		
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Materials	and	Methods:	
Cell	culture	conditions	and	cell	line	construction	
The	majority	of	 the	cell	 lines	used,	 including	all	 the	parental	 lines,	were	genotyped	by	
Microsynth,	 AG	 (Switzerland)	 and	 found	 to	 be	 HEK293.2sus.	 They	 were	 free	 of	
mycoplasma	 as	 assayed	 by	 the	Mycoplasma	 check	 service	 of	 GATC	 Biotech.	 The	 cells	
were	maintained	 in	DMEM	containing	10%	FBS,	penicillin,	and	streptomycin,	as	well	as	
the	appropriate	selection	markers	at	the	following	concentrations:	15	µg	ml-1	blasticidin,	
1µg	 ml-1	 puromycin,	 150µg	 ml-1	 hygromycin,	 400	 µg	 ml-1	 G418,	 and/or	 400	 µg	 ml-1	
zeocin.	The	incubators	were	set	at	37	°C	with	5%	CO2.	Whereas	FBS	was	used	to	maintain	
the	cells,	dialyzed	calf	serum	was	used	at	the	same	concentration	for	all	the	experiments	
presented	here.	The	ABA	concentration	used	was	500	µM,	unless	otherwise	 indicated.	
Doxycycline	(dox)	was	used	at	a	concentration	of	2	µg	ml-1	in	all	experiments.	
A	schematic	of	cell	line	construction	and	pedigree	is	found	in	Figure	S1,	and	the	lines	are	
listed	 in	Table	S1.	This	 table	 includes	 the	plasmids	made	 for	cell	 line	construction.	The	
plasmids	used	for	transient	transfections	are	found	in	Table	S2.	For	each	cell	line,	single	
clones	were	 picked	 and	 tested	 for	 expression	 of	 ParB-ABI	 and	 PYL-fusions	 by	western	
blotting	 using	 the	 protocol	 described	 before	 (29).	 Briefly,	 whole	 cell	 extracts	 were	
obtained,	and	 their	protein	content	was	quantified	using	 the	Pierce	BCA	Protein	Assay	
Kit	 (ThermoScientific).	 Proteins	 were	 then	 run	 onto	 Tris-glycine	 10%	 SDS	 PAGE	 gels	
before	being	transferred	onto	nitrocellulose	membrane	(Axonlab).	The	membranes	were	
blocked	 using	 the	 Blocking	 Buffer	 for	 Fluorescent	 Western	 Blotting	 (Rockland),	 and	
primary	antibodies	were	added	overnight.	Membranes	were	 then	washed	 followed	by	
the	addition	of	 the	secondary	antibody	 (diluted	1	 to	2000).	The	 fluorescent	 signal	was	
detected	 using	 an	 Odyssey	 Imaging	 System	 (Li-CoR).	 All	 antibodies	 used	 are	 found	 in	
Table	 S3.	 To	 assess	 repeat	 sizes,	 we	 amplified	 the	 repeat	 tracts	 using	 oVIN-0459	 and	
oVIN-0460	with	 the	UNG	 and	 dUTP-containing	 PCR	 as	 described(30)	 and	 then	 Sanger-
sequenced	by	Microsynth	AG	(Switzerland).	The	sequences	of	all	the	primers	used	in	this	
study	are	found	in	Table	S4.	
The	 ParB-INT	 sequence	 system	 used	 here	 is	 the	 c2	 version	 described	 previously	 (26),	
except	 that	 the	 ParB	 protein	was	 codon-optimized	 for	 expression	 in	 human	 cells.	 It	 is	
also	called	ANCHOR1	and	 is	distributed	by	NeoVirTech.	 ParB-ABI	 (pBY-008),	PYL	 (pAB-
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NEO-PYL),	 PYL-HDAC5	 (pAB(EXPR-PYL-HDAC5-NEO))	 and	 PYL-HDAC3	 (pAB(EXPR-PYL-
HDAC3-NEO))	 constructs	were	 randomly	 inserted	and	 single	 clones	were	 then	 isolated	
(Table	 S1).	 GFP-reporter	 cassettes	 were	 inserted	 using	 Flp-mediated	 recombination	
according	 to	 the	 manufacturer’s	 instruction	 (Thermo	 Scientific).	 Single	 colonies	 were	
picked	and	screened	for	zeocin	sensitivity	to	ensure	that	the	insertion	site	was	correct.	
Targeting	assays	
For	 targeting	 assays	 involving	 transient	 transfections,	 cells	 were	 plated	 onto	 poly-D-
lysine-coated	12-well	plates	at	a	density	of	6x105	cells	per	well	and	transfected	using	1	
µg	 of	 DNA	 per	 well	 and	 Lipofectamine	 2000	 or	 Lipofectamine	 3000	 (Thermofisher	
Scientific).	6	hours	after	transfection,	the	medium	was	replaced	with	one	containing	dox	
and	ABA	 or	DMSO.	 48h	 after	 the	 transfection,	 the	 cells	were	 split,	 and	 fresh	medium	
with	dox	and	ABA	or	DMSO	was	replenished.	On	the	fifth	day,	samples	were	detached	
from	the	plate	with	PBS	+	1	mM	EDTA	for	flow	cytometry	analysis.		
In	the	case	of	the	stable	cell	lines,	cells	were	seeded	at	a	density	of	4x105		per	well	in	12-
well	 plates.	 The	media	 included	dox	 and	ABA	or	DMSO.	 The	medium	was	 changed	48	
hours	 later	and	 left	 to	grow	for	another	48	hours.	The	cells	were	 then	resuspended	 in	
500µl	PBS	+	1	mM	EDTA	for	flow	cytometry	analysis.		
Flow	cytometry	and	analysis	
We	used	an	Accuri	C6	flow	cytometer	from	BD	and	measured	the	fluorescence	in	at	least	
12	500	 cells	 for	each	 treatment.	 The	 raw	data	was	exported	as	 FCS	 files	 and	analyzed	
using	FlowJo	version	10.0.8r1.		
Chromatin	immunoprecipitation	
For	 chromatin	 immunoprecipitation,	 the	 cells	 were	 treated	 as	 for	 the	 targeting	
experiments	 except	 that	 we	 used	 10	 cm	 dishes	 and	 4x106	 cells.	 After	 96	 hours	 of	
incubation,	paraformaldehyde	was	added	to	the	medium	to	a	final	concentration	of	1%	
and	 the	 cells	were	 incubated	 for	 10	minutes	 at	 room	 temperature.	 The	 samples	were	
then	quenched	with	0.125	M	PBS-glycine	for	5	minutes	at	room	temperature.	Samples	
were	then	centrifuged,	the	supernatant	was	discarded,	and	the	cell	pellets	were	washed	
with	 ice-cold	 PBS	 twice.	 The	 samples	were	 split	 into	 107	 cell	 aliquots	 and	 either	 used	
immediately	or	stored	-75	°C	for	later	use.	Sonication	was	done	using	a	Bioruptor	for	25	
to	 30	min.	 DNA	 shearing	was	 visualized	 by	 agarose	 gel	 electrophoresis	 after	 crosslink	
reversal	and	RNase	treatment.	20%	of	sonicated	supernatant	was	used	per	IP,	with	3	μg	
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anti-FLAG	 (M2,	 Sigma),	 anti-PAN	 acetylated	 H3	 (Merck),	 or	 anti-IgG	 (3E8,	 Santa	 Cruz	
Biotechnology)	on	Protein	G	Sepharose	4	Fast	Flow	beads	(GE	healthcare).	The	samples	
were	 incubated	 at	 4°C	 overnight	 and	 then	 washed	 with	 progressively	 more	 stringent	
conditions.	After	the	IP,	the	samples	were	de-crosslinked	and	purified	using	a	QIAquick	
PCR	purification	kit	(Qiagen)	and	analyzed	using	a	qPCR.	
Quantitative	PCR	
Quantitative	 PCR	was	 performed	with	 the	 FastStart	Universal	 SYBR	Green	Master	Mix	
(Roche)	using	a	7900HT	Fast	Real-Time	PCR	System	in	a	384-Well	Block	Module	(Applied	
Biosystems™).	 Primers	 used	 to	 detect	 enrichment	 at	 the	 INT	 sequence	 and	 at	ACTA1	
gene	are	 listed	 in	 Table	 S4.	Ct	 values	were	analyzed	using	 the	 SDS	 Software	 v2.4.	 The	
percentage	of	input	reported	was	obtained	by	dividing	the	amount	of	precipitated	DNA	
for	the	locus	of	interest	by	the	amount	in	the	input	samples	multiplied	by	100%.		
Statistics	
We	 determined	 statistical	 significance	 in	 the	 targeting	 experiments	 using	 a	 two-tailed	
paired	Student’s	t-test	because	the	samples	treated	with	DMSO	and	ABA	were	from	the	
same	original	population	and	treated	side-by-side.	For	 the	ChIP	samples,	 the	 test	used	
was	 a	 two-tailed	 Student’s	 t-test.	 All	 the	 statistical	 analyses	were	done	using	R	 studio	
version	3.4.0.	We	concluded	that	there	was	a	significant	difference	when	P	<	0.05.			
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Results:	
ParB/ANCHOR-mediated	induced	targeting	(PInT)	
We	designed	PInT	(Fig.	1)	 to	be	modular	and	highly	controllable.	 It	contains	a	GFP	mini	gene	that	harbours	two	GFP	exons	flanking	the	intron	of	the	mouse	Pem1	gene	(28,29).	 A	 doxycycline-inducible	 TetOn	 promoter	 drives	 the	 expression	 of	 the	reporter.	This	 cassette	 is	 always	 inserted	at	 the	 same	genomic	 location	as	a	 single	copy	integrant	in	T-Rex	Flp-In	HEK293	cells.	Inside	the	intron,	we	inserted	a	1029	bp	non-repetitive	 sequence,	 INT,	 that	 contains	 four	 binding	 sites	 for	 dimers	 of	 the	
Burkholderia	cenocepacia	ParB	protein.	Once	bound	 to	 INT,	ParB	oligomerizes	 in	a	sequence-independent	 manner,	 recruiting	 up	 to	 200	 ParB	 molecules	 (31).	 This	ParB/ANCHOR	 system	was	 first	 used	 in	 live	 yeast	 cells	 to	 visualize	 double-strand	break	 repair	 (26).	 More	 recently,	 it	 has	 been	 used	 to	 monitor	 the	 mobility	 of	 a	genomic	locus	upon	activation	of	transcription	(32)	and	to	visualize	viral	replication	(33)	in	live	mammalian	cells.	We	made	the	system	inducible	by	fusing	ParB	to	a	plant	protein	 called	 ABSCISIC	 ACID	 INSENSITIVE	 (ABI),	 which	 dimerizes	 with	PYRABACTIN	RESISTANCE1-LIKE	(PYL)	upon	addition	of	abscisic	acid	(ABA)	to	the	culture	medium	(27).	ABA	is	a	plant	hormone	that	is	not	toxic	to	human	cells,	making	this	 CIP	 system	 especially	convenient.	 Within	 319bp	 of	 the	INT	 sequence,	 there	 is	 a	 cloning	site	that	can	be	used	to	insert	any	DNA	 motif.	 Thus,	 fusing	 any	protein	of	interest	to	PYL	allows	for	full	temporal	control	over	the	recruitment	of	a	protein	of	interest	near	a	DNA	sequence	of	choice.	
Fig.	1:	Schematic	of	PInT.	The	GFP	reporter	is	driven	by	an	inducible	Tet-On	promoter.	
It	contains	an	intron	harbouring	an	INT	sequence,	which	mediates	the	recruitment	and	
oligomerization	of	ParB.	We	fused	ParB	to	ABI,	a	plant	protein	that	binds	PYL	only	in	
the	presence	of	abscisic	acid	 (ABA).	Fusing	PYL	 to	any	protein	of	 interest	 leads	 to	 its	
inducible	 recruitment	 319bp	 away	 from	 a	 cloning	 site	 that	 can	 be	 used	 to	 insert	 a	
sequence	 of	 choice.	 The	 PYL	 construct	 contains	 a	 3xFLAG	 tag	whereas	 the	 ParB-ABI	
fusion	includes	3xHA.	They	both	contain	SV40	nuclear	localization	signals.	
	It	was	important	to	determine	whether	the	components	of	PInT	affect	the	expression	of	 the	 GFP	 reporter.	 We	 first	 tested	 whether	 ABA	 changed	 GFP	 expression	 in	
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GFP(CAG)0	cells	(28).	These	cells	carry	the	GFP	mini	gene	without	the	INT	sequence	or	any	additional	sequences	in	the	intron	(see	Table	S1	and	Fig.	S1	for	details	on	cell	line	construction).	We	found	that	treatment	with	up	to	at	least	500	µM	of	ABA,	which	induces	 the	dimerization	between	PYL	and	ABI,	did	not	affect	GFP	expression	(Fig.	S2AB).	We	also	transiently	transfected	GFP(CAG)0	cells	with	plasmids	expressing	the	ParB-ABI	fusion.	This	had	no	detectable	effect	on	the	behaviour	of	the	reporter	(Fig.	S2C).	We	next	inserted	the	INT	sequence	inside	the	Pem1	intron	and	integrated	this	construct	 using	 site-directed	 recombination,	 generating	 GFP-INT	 cells.	 These	 cells	contain	INT	but	no	additional	sequence	within	the	intron.	They	do	not	express	ParB-ABI.	We	 found	 that	 the	 insertion	of	 the	 INT	sequence	had	 little,	 if	 any,	discernable	effect	 on	 the	 GFP	 expression	 (Fig.	 S2D).	 We	 conclude	 that	 by	 themselves,	 the	individual	components	of	PInT	do	not	significantly	interfere	with	GFP	expression.		
We	 then	 stably	 integrated	 both	 the	 GFP-INT	 reporter	 and	 the	 ParB-ABI	 fusion	 to	generate	 GFP-INT-B	 cells.	We	 found	 a	 decrease	 in	 GFP	 expression	 that	 correlated	with	high	 levels	 of	ParB-ABI	 (Fig.	 S2EFG),	 suggesting	 that	 the	binding	of	ParB-ABI	has	 a	 predictable	 effect	 on	 the	 GFP	 reporter.	 To	 avoid	 any	 complication,	 we	integrated	 ParB-ABI	 early	 in	 the	 construction	 pipeline	 such	 that	 all	 the	 cell	 lines	presented	here	contain	the	same	amount	of	ParB-ABI	(Fig.	S1).	
Next,	 we	 determined	 the	 efficiency	 of	 targeting	 PYL	 to	 the	 INT	 sequence	 and	 the	consequences	on	GFP	expression.	We	used	nB-Y	 cells,	which	 contain	 the	GFP	mini	gene	 with	 the	 INT	 sequence,	 stably	 express	 both	 ParB-ABI	 (B)	 and	 PYL	 (Y),	 and	contain	 n	 CAG	 repeats,	 in	 this	 case	 either	 16,	which	 is	 in	 the	 normal	 range,	 or	 an	expanded	 repeat	 of	 91	 triplets	 (Fig.	 2A,	 Fig.	 S3A).	 We	 found,	 using	 chromatin	immunoprecipitation	 followed	 by	 qPCR	 (ChIP-qPCR),	 that	 only	 0.1%	 of	 the	 input	DNA	could	be	precipitated	when	we	treated	the	cells	with	the	vehicle,	DMSO,	alone.	By	contrast,	the	addition	of	ABA	to	the	cell	media	increased	the	association	of	PYL	to	the	 INT	 locus	 significantly,	 reaching	 1.9	 and	 2.5%	 of	 the	 input	 chromatin	 pulled	down	in	16B-Y	or	91B-Y	cells,	respectively	(Fig.	2B).	These	results	demonstrate	the	inducible	nature	of	the	system	and	show	that	the	presence	of	the	expansion	does	not	interfere	with	 the	 targeting	 efficiency.	 Importantly,	 PYL	 targeting	had	no	 effect	 on	GFP	 expression	 as	 measured	 by	 flow	 cytometry	 (Fig.	 2C).	We	 conclude	 that	 PInT	
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works	as	an	inducible	targeting	system	and	that	PYL	targeting	is	efficient	and	does	not	further	affect	gene	expression.	
Fig.	2:	Inducible	targeting	of	PYL	
at	the	GFP	reporter.	A)	Schematic	
representation	 of	 16B-Y	 (left)	 and	
91B-Y	 (right)	 cell	 lines.	 B)	 ChIP-
qPCR	 using	 antibodies	 against	
FLAG	to	pull	down	PYL	at	INT	and	
ACTA1	 in	 16B-Y	 cells	 (left,	 N=4)	
and	 91B-Y	 cells	 (right,	 N=4).	 The	
error	 bars	 represent	 the	 standard	
error.	 C)	 Representative	 flow	
cytometry	 profiles	 as	 well	 as	
quantification	 of	 the	 GFP	
expression	in	16B-Y	(left,	N=6)	and	
91B-Y	 (right,	N=6)	cells.	The	error	
bars	 are	 the	 standard	 deviation	
around	the	mean.		
HDAC5	 silencing	 depends	 on	
CAG/CTG	repeat	size	
We	next	sought	to	test	whether	we	could	manipulate	GFP	expression	using	HDAC5.	This	class	IIa	deacetylase	impacts	gene	silencing	and	heterochromatin	maintenance	(34,35)	as	well	 as	 cell	proliferation	 (35,36).	The	PYL-HDAC5	 fusion	was	 functional	since	 GFP-INT	 cells	 transiently	 expressing	 this	 fusion	 had	 slightly	 lower	 GFP	expression	 than	 those	 expressing	 PYL	 alone	 (Fig.	 S4A).	We	 created	 isogenic	 nB-Y-HDAC5	cells	that	express	stably	a	PYL-HDAC5	fusion	and	have	16	or	59	CAG	repeats	within	the	GFP	reporter	(Fig.	3A).	We	found	that	adding	ABA	to	these	cells	led	to	an	increase	in	pull-down	efficiency	of	PYL-HDAC5	at	the	INT	locus	from	0.06%	to	2.2%	in	16B-Y-HDAC5	cells	and	 from	0.1%	to	3%	of	 input	 in	 the	presence	of	59	repeats	(Fig.	3B).	This	was	accompanied	by	a	significant	2-fold	decrease	in	GFP	expression	in	59B-Y-HDAC5	cells,	whereas	the	decrease	was	of	3	folds	in	16B-Y-HDAC5	cells	(Fig.	3C,	P=0.001	and	P=	0.0015	using	a	paired	Student’s	t-test	comparing	conditions	with	ABA	to	those	with	DMSO	only	in	16B-Y-HDAC5	and	59B-Y-HDAC5	cells,	respectively).	Remarkably,	the	decrease	in	expression	was	significantly	lower	in	the	context	of	an	expanded	repeat	(Fig.	3C,	P=0.0001	comparing	the	decrease	in	expression	upon	ABA	addition	 between	 the	 16B-Y-HDAC5	 and	 59B-Y-HDAC5	 using	 a	 Student’s	 t-test).	
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Targeting	efficiency	of	PYL-HDAC5	does	not	account	 for	 the	repeat	size-dependent	effect	since	 it	was	slightly	higher	 in	59B-Y-HDAC5	than	 in	16B-Y-HDAC5	cells	 (Fig.	3B).	 To	 determine	 whether	 the	 effect	 is	 due	 to	 targeting	 at	 the	 INT	 locus,	 we	transiently	expressed	PYL-HDAC5	 in	GFP(CAG)0B	cells,	which	have	no	 INT	 in	 their	GFP	 reporter	 but	 express	 ParB-ABI.	 Adding	 ABA	 to	 these	 cells	 did	 not	 affect	 GFP	expression	(Fig.	S4BC),	suggesting	that	the	presence	of	the	INT	sequence	is	essential.	Moreover,	PYL-HDAC5	targeting	reduced	the	levels	of	acetylated	histone	H3	(acH3)	(P=0.0001	 and	 P=0.024	comparing	 DMSO	 treated	 and	ABA-treated	 16B-Y-HDAC5	 and	59B-Y-HDAC5,	 respectively,	 using	a	Student’s	t-test),	as	measured	by	ChIP-qPCR.	 The	 decrease	 in	 acH3	upon	 targeting	 was	 greater	 in	16B-Y-HDAC5	 than	 in	 16B-Y	 cells	(P=0.006	using	a	Student’s	t-test),	consistent	 with	 a	 role	 for	 HDAC5	in	 silencing	 gene	 expression.	Interestingly,	 the	 acH3	 levels	 at	the	 INT	 sequence	 were	 similar	between	 16B-Y	 and	 91B-Y	 and	between	 16B-Y-HDAC5	 and	 59B-Y-HDAC5	 (Fig.	 3DE,	 P=0.95,	 and	P=0.25,	 respectively	 using	 a	Student’s	 t-test),	 suggesting	 that	the	 acH3	 levels	 are	 unaffected	 by	the	 expansion.	 We	 conclude	 that	PYL-HDAC5	 targeting	 silences	better	 the	 lines	 with	 the	 shorter	repeats.		
Fig.	 3:	 PYL-HDAC5	 targeting	
induces	 silencing	 in	 a	 repeat-length	 dependent	 manner.	 A)	 Schematic	
representation	 of	 16B-Y-HDAC5	 (left)	 and	 59B-Y-HDAC5	 (right)	 cells.	 B)	 ChIP-qPCR	
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using	antibodies	against	FLAG	to	pull	down	PYL-HDAC5	at	 INT	and	ACTA1	 in	16B-Y-
HDAC5	cells	(left,	N=4)	and	59B-Y-HDAC5	cells	(right,	N=4).	The	error	bars	represent	
the	standard	error.	C)	Quantification	of	GFP	expression	upon	 incubation	with	ABA	or	
DMSO	in	16B-Y-HDAC5	(left,	N=6)	and	59B-Y-HDAC5	(right,	N=6)	cells.	The	error	bars	
show	 the	 standard	 deviation	 around	 the	 mean.	 D)	 ChIP-qPCR	 data	 using	 a	 pan-
acetylated	H3	antibody	to	pull	down	the	INT	and	ACTA1	loci	in	16B-Y-HDAC5	(left,	N=4)	
and	59B-Y-HDAC5	 (right,	N=4)	 cells.	The	 error	bars	 represent	 the	 standard	error.	E)	
ChIP-qPCR	data	using	a	pan-acetylated	H3	antibody	to	pull	down	the	INT	and	ACTA1	
loci	 in	 16B-Y	 (left,	 N=4)	 and	 91B-Y	 (right,	 N=4)	 cells.	 The	 error	 bars	 represent	 the	
standard	error.	
The	N-terminal	domain	of	HDAC5	mediates	silencing	
Class	 I	 HDACs	 derive	 their	 catalytic	 activity	 in	 vitro	 from	 a	 conserved	 tyrosine	residue	that	helps	coordinate	a	zinc	ion	essential	for	catalysis	(37).	By	contrast,	class	IIa	enzymes,	 like	HDAC5,	have	a	histidine	 instead	of	 tyrosine	at	 the	analogous	site,	which	considerably	lowers	HDAC	activity	(37).	In	fact,	the	H1006Y	mutant	had	more	than	30-fold	increase	in	its	HDAC	activity	compared	to	the	wild	type	enzyme	(37).	To	determine	whether	 the	catalytic	activity	of	HDAC5	potentiates	 the	decrease	 in	GFP	expression	 upon	 targeting,	 we	 compared	 the	 silencing	 activity	 of	 wild-type	 PYL-HDAC5,	 the	 H1006A	 loss-of-function	 mutant,	 and	 the	 H1006Y	 gain-of-function	mutant	 by	 transient	 transfection	 in	 40B	 cells,	which	 contain	 the	GFP-INT	 reporter	with	 40	 CAGs	 and	 express	 ParB-ABI	 (Fig.	 4A).	 The	 effect	 on	 silencing	 seen	 upon	targeting	of	the	wild-type	PYL-HDAC5	fusion	was	lower	when	delivered	by	transient	transfection	compared	to	the	stable	cell	lines.	Nevertheless,	under	these	conditions,	targeting	 PYL-HDAC5-H1006A	 or	 PYL-HDAC5-H1006Y	 could	 both	 silence	 the	transgene	compared	to	targeting	PYL	alone	(Fig	4B;	P=	0.01	and	0.0008,	respectively,	using	 a	 Student’s	 t-test),	 suggesting	 that	 tampering	 with	 the	 catalytic	 activity	 of	HDAC5	 does	 not	 influence	 silencing	 of	 our	 GFP	 reporter.	Moreover,	 targeting	 PYL	fused	to	the	catalytic	domain	of	HDAC5	did	not	shift	GFP	expression	(Fig.	4B).	Indeed,	we	 find	 that	 the	 silencing	 activity	 was	contained	within	 the	N-terminal	 part	 of	HDAC5,	 which	 characterizes	 class	 IIa	enzymes.	Further	truncations	(Fig.	4AB)	are	consistent	with	a	model	by	which	the	coiled-coil	 domain	 of	 HDAC5,	 which	 is	responsible	 for	 homo	 and	
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heterodimerization	of	class	IIa	enzymes	in	vitro	(38),	contains	the	silencing	activity.		
Fig.	4:	The	silencing	activity	of	HDAC5	is	contained	in	its	N-terminal	domain.	A)	
Mutants	 and	 truncations	 of	 HDAC5	 fused	 to	 PYL.	 The	 coiled-coil	 (CC)	 domain	 is	
indicated	 in	purple,	 the	deacetylase	domain	 (HDAC)	 in	orange.	B)	Ratio	of	 the	mean	
GFP	 intensities	 in	 40B	 cells	 between	 ABA	 and	 DMSO	 only	 treatment	 of	 40B	 cells	
transiently	transfected	with	plasmids	containing	the	constructs	shown	in	A.	Construct	1:	
N=7,	 P=0.0002	 versus	 PYL;	 construct	 2:	 N=7,	 P=0.01	 versus	 PYL;	 construct	 3:	 N=7,	
P=0.0008	versus	PYL;	construct	4:	N=7,	P=0.88	versus	PYL;	construct	5:	N=7,	P=0.0012	
versus	PYL;	construct	6:	N=3,	P=0.0003	versus	PYL.	In	all	cases,	we	used	a	Student's	t-
test	to	calculate	the	P-values.	The	error	bars	show	the	standard	deviation	around	the	
mean.	*:	P≤0.01	compared	to	PYL	targeting.	
PYL-HDAC3	targeting	enhances	GFP	expression	independently	of	its	catalytic	activity	
HDAC5	 is	 thought	 to	 mediate	 histone	 deacetylation	 by	 recruiting	 other	 HDACs,	including	HDAC3	(39).	Therefore,	we	hypothesized	that	PYL-HDAC3	targeting	should	have	 the	 same	 effect	 on	 GFP	 expression	 as	 PYL-HDAC5	 targeting.	 To	 address	 this	directly,	 we	made	 a	 PYL-HDAC3	 fusion	 and	 overexpressed	 it	 in	 40B	 cells	without	targeting	 (Fig.	 S4D).	We	 found	 that	 there	was	a	 slight	decrease	 in	GFP	expression,	suggesting	that	the	construct	could	silence	gene	expression.	Next,	we	generated	nB-Y-HDAC3	cells	and	compared	GFP	intensities	with	and	without	ABA.	Contrary	to	our	initial	 hypothesis,	 we	 found	 that	 targeting	 PYL-HDAC3	 in	 both	 16B-Y-HDAC3	 and	89B-Y-HDAC3	 increased	 GFP	 expression	 by	 1.5	 fold	 (Fig.	 S5AB,	 P=0.0004	 and	P=0.001	using	paired	Student’s	t-tests	comparing	ABA	and	DMSO	treatments	in	16B-Y-HDAC3	and	89B-Y-HDAC3,	respectively).	The	effect	appeared	direct	since	adding	ABA	 to	 GFP(CAG)0B	 cells	 transiently	 expressing	 PYL-HDAC3	 did	 not	 affect	 GFP	expression	 (Fig.	 S4E).	 The	 increase	 in	 GFP	 expression	 in	 nB-Y-HDAC3	 cells	 was	accompanied	 by	 an	 efficient	 targeting	 of	 the	 PYL-HDAC3	 fusion	 (Fig.	 S5C)	 and	 an	increase	 in	 acH3	 levels	 (Fig.	 S5D).	 However,	 treatment	 with	 the	 HDAC3-specific	small	molecule	inhibitor	RGFP966	(40)	did	not	affect	the	increase	in	GFP	expression	in	 neither	 16B-Y-HDAC3	 nor	 89B-Y-HDAC3	 cells	 (Fig.	 S5E).	 We	 conclude	 that	targeting	PYL-HDAC3	increases	GFP	expression	 independently	of	 its	HDAC	activity,	consistent	 with	 the	 observation	 that	 HDAC3	 has	 an	 essential	 role	 during	development	that	does	not	involve	its	HDAC	activity	(41).		
HDAC3	 activity	 is	 required	 for	 the	 repeat	 size-specificity	 upon	 HDAC5-mediated	
silencing	
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Although	 HDAC3	 targeting	 did	 not	 have	 the	 expected	 effect	 on	 GFP	 expression,	evidence	shows	that	its	catalytic	activity	is	implicated	in	HDAC5-mediated	silencing	(39).	To	determine	the	potential	catalytic	role	of	HDAC3	in	this	context,	we	targeted	PYL	(Fig.	5A)	or	PYL-HDAC5	(Fig.	5B)	to	our	GFP	reporter	in	nB-Y	and	nB-Y-HDAC5	cells	while	 cultivating	 the	 cells	 in	 the	presence	of	RGFP966.	We	 find	 that	although	this	treatment	had	no	effect	on	PYL	targeting	(Fig.	5A),	it	abolished	the	allele-length	specificity	 of	 PYL-HDAC5	 targeting,	 leading	 to	 a	 silencing	 efficiency	 of	 2.4	 and	 2.5	folds	 for	 16B-Y-HDAC5	 and	 59B-Y-HDAC5,	 respectively	 (Fig.	 5B,	 P=	 0.77	 using	 a	Student’s	t-test).	This	is	in	contrast	to	the	RGFP966-free	conditions	where	targeting	PYL-HDAC5	 silenced	 better	 the	 normal-sized	 allele	 (Fig.	 3).	 These	 results	 suggest	that	HDAC3	mediates	the	CAG	repeat	size-dependency	upon	PYL-HDAC5	targeting.		
Fig.	5:	HDAC3	activity	is	required	
for	 the	 allele-specificity	 upon	
HDAC5-mediated	 silencing.	 A)	
Quantification	of	GFP	intensity	upon	
targeting	 in	 the	 presence	 of	
RGFP966	 or	 the	 vehicle,	 DMSO,	 in	
16B-Y	(N=6)	and	91B-Y	cells	(N=6).	
Note	 that	 the	 data	 for	 the	 DMSO-
treated	cells	is	the	same	as	in	Fig.	2C.	
The	addition	of	DMSO	did	not	affect	GFP	expression,	and	we	therefore	pooled	the	data.	
B)	Quantification	of	GFP	 intensity	upon	 targeting	 in	 the	presence	of	RGFP966	or	 the	
vehicle,	 DMSO,	 in	 16B-Y-HDAC5	 (N=6)	 and	 59B-Y-HDAC5	 cells	 (N=6).	 Note	 that	 the	
data	for	the	DMSO-treated	cells	is	the	same	as	in	Fig.	3C.	The	addition	of	DMSO	did	not	
affect	 GFP	 expression,	 and	 we	 therefore	 pooled	 the	 data.	 The	 error	 bars	 show	 the	
standard	deviation	around	the	mean.		 	
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Discussion:	
We	 presented	 here	 a	 novel	 assay	 to	 investigate	 the	 effect	 of	 a	 DNA	 sequence	 of	interest	on	the	efficiency	of	a	chosen	EpiEffector	 in	altering	gene	expression.	As	an	example	of	how	the	DNA	context	may	affect	the	activity	of	an	EpiEffector,	we	showed	that	 expanded	 CAG/CTG	 repeats	 decrease	 the	 silencing	 efficiency	 of	 HDAC5.	Moreover,	 we	 determined	 that	 this	 allele-length	 specificity	 depends	 on	 HDAC3	activity,	highlighting	the	potential	of	PInT	in	uncovering	unique	mechanistic	insights.	These	 data	 provide	 evidence	 that	 local	 DNA	 sequence	 context	 is	 an	 important	determinant	 of	 epigenome	 editing,	 independently	 of	 the	 efficiency	 or	 mode	 of	targeting.		
PInT	 could	 be	 used	 for	 many	 different	 applications.	 First,	 the	 intron	 can	 host	sequences	 beyond	 CAG/CTG	 repeats.	 Indeed,	 the	 GFP	 mini	 gene	 we	 used	 here,	without	the	targeting	components,	was	recently	used	to	monitor	the	effect	of	a	RNA	polymerase	III	gene	on		RNA	polymerase	II-mediated	transcription	(42).	Second,	it	is	often	 difficult	 to	 differentiate	 between	 a	 chromatin	 modifier	 changing	 gene	expression	 because	 of	 a	 local	 effect	 on	 chromatin	 structure	 or	 indirectly	 through	changes	 in	 the	 transcriptome.	 PInT	 allows	 making	 that	 distinction	 thanks	 to	 its	inducible	 nature.	 Indeed,	 we	 found	 that	 overexpressing	 PYL-HDAC5	 had	 a	 small	effect	on	gene	expression	at	the	GFP	reporter	and	that	targeting	it	further	decreased	expression.	 We	 could	 conclude	 that	 PYL-HDAC5	 can	 act	 locally	 to	 silence	 the	transgene.	 This	 is	 useful	 in	 dissecting	 the	 mechanisms	 of	 action	 of	 EpiEffectors.	Third,	 we	 demonstrated,	 using	 mutants	 and	 truncations	 of	 HDAC5,	 that	 we	 can	quickly	 screen	 for	 protein	 domains	 and	 mutants	 that	 are	 most	 effective	 in	modulating	 gene	 expression.	 Thus,	 PInT	 could	 be	 used	 to	 design	 peptides	 with	sufficient	 activity	 to	 be	 useful	 in	 downstream	 epigenomic	 editing	 applications,	 for	example	when	 using	 dCas9	 fusions	 in	 vivo.	 A	 current	 limitation	 of	 the	 S.	pyogenes	Cas9	 for	 in	 vivo	 applications	 is	 its	 large	 size,	 which	 is	 at	 the	 limit	 of	what	 adeno-associated	viral	vectors	can	accommodate	(43).	Even	with	the	smaller	orthologues,	fitting	a	dCas9	 fusion	 inside	a	gene	delivery	vector	 is	a	challenge.	Therefore,	being	able	 to	 trim	 an	 EpiEffector	 down	 to	 a	 small	 domain	 may	 help	 optimizing	downstream	applications	and	translation.		
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The	 observation	 that	HDAC5	 targeting	 has	 a	 differential	 effect	 on	 gene	 expression	depending	 on	 the	 size	 of	 the	 repeat	 tract	 is	 surprising.	 Our	 data	 suggest	 that	 the	deacetylase	 activity	 of	 HDAC3	 is	 required	 for	 this	 effect.	 Importantly,	 we	 cannot	currently	rule	out	that	RGFP966	may	inhibit	other	HDACs	that	would	be	responsible	for	this	effect.	Nevertheless,	 this	small	molecule	 is	highly	selective	for	HDAC3	(40),	making	 this	 HDAC	 the	 most	 likely	 candidate	 for	 driving	 allele-specific	 silencing.	HDAC3	 could	 be	 setting	 up	 an	 asymmetry	 between	 the	 two	 size	 alleles	 in	 several	ways.	For	 instance,	 it	could	deacetylate	histones	(those	residues	not	recognized	by	the	pan-acetylated	histone	H3	antibody	that	we	used)	or	non-histone	proteins	in	the	vicinity	 of	 the	 expanded	 CAG/CTG	 repeat	 prior	 to	HDAC5	 targeting.	More	work	 is	required	to	understand	further	the	mechanism	of	the	repeat	length-specific	silencing.	
Several	studies	have	suggested	that	 the	ectopic	 insertion	of	an	expanded	CAG/CTG	repeat	 in	 mice	 could	 induce	 changes	 in	 chromatin	 structure	 in	 the	 abutting	sequences.	An	early	example	was	the	random	insertion	of	arrays	of	transgenes,	each	carrying	192	CAGs	(44),	which	led	to	the	silencing	of	the	transgenes	independently	of	 the	 site	 of	 genomic	 integration.	 In	 addition,	 inserting	 a	 40	 kb	 human	 genomic	region	 containing	 the	DMPK	 gene	 along	with	 an	 expansion	 of	 600	 CTGs	 (45),	 or	 a	13.5Kb	region	containing	the	human	SCA7	gene	with	92	CAGS	(46)	all	led	to	changes	in	chromatin	marks	near	the	expansion.	 It	has	been	unclear,	however,	whether	the	presence	of	endogenous	sequence	elements,	like	CpG	islands	(47)	and	CTCF	binding	sites	 (25,48),	 is	necessary	 for	 this	effect.	Our	data	 show	 that	91	CAGs,	without	 the	flanking	sequences	normally	present	at	the	DMPK	gene	from	whence	this	repeat	was	cloned	(49),	does	not	 lead	to	significant	changes	 in	 the	 levels	of	acetylated	histone	H3	 in	 its	 vicinity.	 These	 data	 suggest	 that	 the	 flanking	 sequence	 elements	 play	important	 roles	 in	 the	 induction	 and/or	 maintenance	 of	 heterochromatic	 marks	surrounding	expanded	CAG/CTG	repeats.	
Recently,	 a	 number	 of	 studies	 have	 proposed	 that	 silencing	 the	 expanded	 repeat	allele	 without	 affecting	 the	 expression	 of	 the	 normally	 sized	 allele	 may	 lead	 to	 a	novel	therapeutic	approach	for	expanded	CAG/CTG	repeats	(50-52).	However,	only	one	factor,	which	is	essential	for	mouse	development	(52),	has	been	identified	so	far.	We	speculate	that	PInT	may	be	adapted	to	screen	for	allele	length-specific	silencers,	
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which	could	help	uncover	novel	therapeutic	options	for	expanded	CAG/CTG	repeat	disorders.	
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Appendix	B:	R	script	
	
Install	the	necessary	R	package		install.packages("ggplot2")	install.packages("limma")	install.packages("tidyr")	install.packages("dplyr")	install.packages("Hmisc")	require(ggplot2)	require(tidyr)	require(dplyr)	require(limma)	require(Hmisc)	
	
Flow	cytometry	histogram	#	load	data	library(readxl)	HEKBYH516	<-	read_excel("~/Desktop/Capri/FC/FC	example/HEKBYH516.xlsx")	View(HEKBYH516)		#	reorganize	dataset		b	<-	gather(HEKBYH516,													"Sample",													"Value",													control,	sample)	print(b)		#try	to	plot	with	default	setting	c	<-	ggplot(data=b,													aes(x=log10(Value),																																		colour=Sample													))	+			geom_density()		#	plot	the	graph	with	desired	parameters	d	<-	c	+			scale_color_manual(values=c("control"="black",	"sample"="darkorchid3"),																						labels=c("DMSO",	"ABA"))+			##remove	margin	between	0	and	data			scale_y_continuous(expand	=	c(0,0),																						breaks	=	seq(0,	2.5,	0.5),																						limits=c(0,	2.5))+			scale_x_continuous(expand	=	c(0,0),																						breaks	=	seq(0,	10,	2),																						limits=c(0,	10))+			xlab("GFP	intensity")+			ylab("Density")+	
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			theme(panel.grid.major	=	element_blank(),									panel.background	=	element_blank(),									axis.line.y		=	element_line(colour	=	"black"),									axis.line.x		=	element_line(colour	=	"black")												)	print(d)		
Flow	cytometry	data	analysis	in	same	cell	line	#	Load	data	HEBYH5161	<-	read_excel("~/Desktop/Capri/HDAC5	FC/H516/HEKBYH5161.xlsx")		#	h516	Sample	vs	control	#	h516	<-	gather(HEBYH5161,															"Sample",															"Value",															control1,control2,control3,control4,sample1,sample2,sample3,sample4)	#	Raw	data	calculation	sampleh516m<-c(mean(h516$Value[h516$Sample=="sample1"],na.rm	=	T),	mean(h516$Value[h516$Sample=="sample2"],na.rm	=	T),															mean(h516$Value[h516$Sample=="sample3"],na.rm	=	T),mean(h516$Value[h516$Sample=="sample4"],na.rm	=	T))		controlh516m<-c(mean(h516$Value[h516$Sample=="control1"],na.rm	=	T),	mean(h516$Value[h516$Sample=="control2"],na.rm	=	T),																mean(h516$Value[h516$Sample=="control3"],na.rm	=	T),	mean(h516$Value[h516$Sample=="control4"],na.rm	=	T))		#calculate	p	value	h516ttest	<-	t.test(sampleh516m,controlh516m,	paired=	TRUE)	h516pval	<-	formatC(h516ttest$p.value,	format	=	"e",	digits	=	1)		#	ggPlot	#	prepare	dataframe	h516data	<-	data.frame(mfi=c(sampleh516m/1e6,	controlh516m/1e6),																							sampleid=rep(c("ABA",	"DMSO"),	c(length(sampleh516m),	length(controlh516logm))))	print(h516data)		#reorder	the	group	order	on	the	boxplot	h516data$sampleid	<-	factor(h516data$sampleid,																														levels	=	c("DMSO","ABA"),	ordered	=	TRUE)		#	Plot	ggplot(data=h516data,	aes(x=sampleid,	y=mfi)	)	+				
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#	add	points			geom_jitter(data=h516data,	size=1,	color="black",width	=	0.1			)	+					#	Changing	axis	ticks,	y	axis	name	with	numbers	on	y	axis			scale_y_continuous(name	=	"	",																						breaks	=	seq(0,	4,	1),																						limits=c(0,	4))+				#	add	mean	(if	you	like	it	dashed,	add	'linetype	=	"dashed"'	within	brackets)			stat_summary(fun.y	=	mean,	geom	=	"errorbar",	aes(ymax	=	..y..,	ymin	=	..y..),	width	=	0.2,	color="black")	+				#	add	error	bars	corresponding	to	mean+/-sd			stat_summary(fun.data=mean_sdl,	fun.args	=	list(mult=1),	geom="errorbar",	width=0.1,	color="black")	+				#	Add	x	axis	label			xlab("")	+						#	Add	title			ggtitle("	")	+				#	Choose	font	size			theme(axis.title.y	=	element_text(size=20),									plot.title	=	element_text(size=20,	hjust	=	0.5),									text	=	element_text(size=20))	+				#	Diplay	only	x	and	y	axes	without	any	backgroud			theme(axis.line	=	element_line(colour	=	"black"),									panel.grid.major	=	element_blank(),									panel.grid.minor	=	element_blank(),									panel.border	=	element_blank(),									panel.background	=	element_blank())		
	
Flow	cytometry	data	analysis	between	different	repeat	length	lines	library(readxl)		#	Load	data	HEBYH5161	<-	read_excel("~/Desktop/Capri/HDAC5	FC/H516/HEKBYH5161.xlsx")	HEKBYH559	<-	read_excel("~/Desktop/Capri/HDAC5	FC/H559/HEKBYH559.xlsx")		#	h516	Sample	vs	control	#	h516	<-	gather(HEBYH5161,																"Sample",																"Value",																control1,control2,control3,control4,sample1,sample2,sample3,sample4)	#	Raw	data	calculation	#	
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sampleh516m<-c(mean(h516$Value[h516$Sample=="sample1"],na.rm	=	T),	mean(h516$Value[h516$Sample=="sample2"],na.rm	=	T),																mean(h516$Value[h516$Sample=="sample3"],na.rm	=	T),mean(h516$Value[h516$Sample=="sample4"],na.rm	=	T))	controlh516m<-c(mean(h516$Value[h516$Sample=="control1"],na.rm	=	T),	mean(h516$Value[h516$Sample=="control2"],na.rm	=	T),																	mean(h516$Value[h516$Sample=="control3"],na.rm	=	T),	mean(h516$Value[h516$Sample=="control4"],na.rm	=	T))		#calculate	ratio	between	aba/dmso	#	h516ratio<-	data.frame(sampleh516m/controlh516m,fix.empty.names	=	FALSE)		#	h559	Sample	vs	control	#	h559	<-	gather(HEKBYH559,																"Sample",																"Value",																control1,control2,control3,control4,sample1,sample2,sample3,sample4)	#	Raw	data	calculation	#	sampleh559m<-c(mean(h559$Value[h559$Sample=="sample1"],na.rm	=	T),	mean(h559$Value[h559$Sample=="sample2"],na.rm	=	T),																mean(h559$Value[h559$Sample=="sample3"],na.rm	=	T),mean(h559$Value[h559$Sample=="sample4"],na.rm	=	T))		controlh559m<-c(mean(h559$Value[h559$Sample=="control1"],na.rm	=	T),	mean(h559$Value[h559$Sample=="control2"],na.rm	=	T),																	mean(h559$Value[h559$Sample=="control3"],na.rm	=	T),	mean(h559$Value[h559$Sample=="control4"],na.rm	=	T))		#calculate	ratio	between	aba/dmso	#	h559ratio<-	data.frame(sampleh559m/controlh559m,	fix.empty.names	=	FALSE)		#	ggPlot	#	#	prepare	dataframe	#	h516ratio$cells	<-	rep("H5CAG16",	4)	h559ratio$cells	<-	rep("H5CAG59",	4)	colnames(h516ratio)	<-	c("ratio",	"cells")	colnames(h559ratio)	<-	c("ratio",	"cells")	ratios	<-	rbind(h516ratio,	h559ratio)	#calculate	p	value	#	h5ttest	<-	t.test(h516ratio$ratio,h559ratio$ratio,	paired=	TRUE)	h5pval	<-	formatC(h5ttest$p.value,	format	=	"e",	digits	=	1)		#draw	plot#	ggplot(data=ratios,	aes(x=cells,	y=ratio)	)	+			#	add	points	#			geom_jitter(data=ratios,	size=1,	color="black",	width	=	0.1			)	+				#	Changing	axis	ticks,	y	axis	name	with	numbers	on	y	axis	#	
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		scale_y_continuous(name	=	“	“,																						breaks	=	seq(0,	0.6,	0.2),																						limits=c(0,	0.6))+				#	add	mean	(if	you	like	it	dashed,	add	‘linetype	=	“dashed”’	within	brackets)	#			stat_summary(fun.y	=	mean,	geom	=	"errorbar",	aes(ymax	=	..y..,	ymin	=	..y..),	width	=	0.2,	color="black")	+				#	add	error	bars	corresponding	to	mean+/-sd	#			stat_summary(fun.data=mean_sdl,	fun.args	=	list(mult=1),	geom="errorbar",	width=0.1,	color="black")	+				#	Add	x	axis	label	#			xlab("")	+						#	Add	title			ggtitle("	")	+				#	Choose	font	size			theme(axis.title.y	=	element_text(size=20),									plot.title	=	element_text(size=20,	hjust	=	0.5),									text	=	element_text(size=20))	+				#	Diplay	only	x	and	y	axes	without	any	backgroud			theme(axis.line	=	element_line(colour	=	"black"),									panel.grid.major	=	element_blank(),									panel.grid.minor	=	element_blank(),									panel.border	=	element_blank(),									panel.background	=	element_blank())		
Flow	cytometry	data	analysis	for	HDAC5	truncations		#	Load	data	aliciapyl	<-	read_excel("~/Desktop/PhDthesis/Figure	III./Alicia	truncation/FC/aliciapyl.xlsx")	aliciahdac5	<-	read_excel("~/Desktop/PhDthesis/Figure	III./Alicia	truncation/FC/aliciahdac5.xlsx")	aliciaNT	<-	read_excel("~/Desktop/PhDthesis/Figure	III./Alicia	truncation/FC/aliciaNT.xlsx")	aliciaCC	<-	read_excel("~/Desktop/PhDthesis/Figure	III./Alicia	truncation/FC/aliciaCC.xlsx")	aliciaCD	<-	read_excel("~/Desktop/PhDthesis/Figure	III./Alicia	truncation/FC/aliciaCD.xlsx")		#	PYL	Sample	vs	control	#	citb40pyl	<-	gather(aliciapyl,																					"Sample",																					"Value",								control1,control2,control3,control4,sample1,sample2,sample3,sample4)	
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#	Raw	data	calculation	samplecitb40pylm<-c(mean(citb40pyl$Value[citb40pyl$Sample=="sample1"],na.rm	=	T),	mean(citb40pyl$Value[citb40pyl$Sample=="sample2"],na.rm	=	T),																					mean(citb40pyl$Value[citb40pyl$Sample=="sample3"],na.rm	=	T),mean(citb40pyl$Value[citb40pyl$Sample=="sample4"],na.rm	=	T))		controlcitb40pylm<-c(mean(citb40pyl$Value[citb40pyl$Sample=="control1"],na.rm	=	T),	mean(citb40pyl$Value[citb40pyl$Sample=="control2"],na.rm	=	T),																						mean(citb40pyl$Value[citb40pyl$Sample=="control3"],na.rm	=	T),	mean(citb40pyl$Value[citb40pyl$Sample=="control4"],na.rm	=	T))		#calculate	p	value	citb40pylttest	<-	t.test(samplecitb40pylm,controlcitb40pylm,	paired=	TRUE)	citb40pylpval	<-	formatC(citb40pylttest$p.value,	format	=	"e",	digits	=	1)		#calculate	ratio	between	aba/dmso	citb40pylratio<-	data.frame(samplecitb40pylm/controlcitb40pylm,fix.empty.names	=	FALSE)		#	wildtype	HDAC5	Sample	vs	control	#	citb40hdac5	<-	gather(aliciahdac5,																							"Sample",																							"Value",	control1,control2,control3,control4,sample1,sample2,sample3,sample4)	#	Raw	data	calculation	samplecitb40hdac5m<-c(mean(citb40hdac5$Value[citb40hdac5$Sample=="sample1"],na.rm	=	T),	mean(citb40hdac5$Value[citb40hdac5$Sample=="sample2"],na.rm	=	T),																							mean(citb40hdac5$Value[citb40hdac5$Sample=="sample3"],na.rm	=	T),mean(citb40hdac5$Value[citb40hdac5$Sample=="sample4"],na.rm	=	T))		controlcitb40hdac5m<-c(mean(citb40hdac5$Value[citb40hdac5$Sample=="control1"],na.rm	=	T),	mean(citb40hdac5$Value[citb40hdac5$Sample=="control2"],na.rm	=	T),																								mean(citb40hdac5$Value[citb40hdac5$Sample=="control3"],na.rm	=	T),	mean(citb40hdac5$Value[citb40hdac5$Sample=="control4"],na.rm	=	T))	#calculate	p	value	citb40hdac5ttest	<-	t.test(samplecitb40hdac5m,controlcitb40hdac5m,	paired=	TRUE)	citb40hdac5pval	<-	formatC(citb40hdac5ttest$p.value,	format	=	"e",	digits	=	1)		#calculate	ratio	between	aba/dmso	citb40hdac5ratio<-	data.frame(samplecitb40hdac5m/controlcitb40hdac5m,fix.empty.names	=	FALSE)		#	N	terminal	Sample	vs	control	#	citb40nt	<-	gather(aliciaNT,																				"Sample",																				"Value",	
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control1,control2,control3,control4,sample1,sample2,sample3,sample4)		#	Raw	data	calculation	samplecitb40ntm<-c(mean(citb40nt$Value[citb40nt$Sample=="sample1"],na.rm	=	T),	mean(citb40nt$Value[citb40nt$Sample=="sample2"],na.rm	=	T),																				mean(citb40nt$Value[citb40nt$Sample=="sample3"],na.rm	=	T),mean(citb40nt$Value[citb40nt$Sample=="sample4"],na.rm	=	T))		controlcitb40ntm<-c(mean(citb40nt$Value[citb40nt$Sample=="control1"],na.rm	=	T),	mean(citb40nt$Value[citb40nt$Sample=="control2"],na.rm	=	T),																					mean(citb40nt$Value[citb40nt$Sample=="control3"],na.rm	=	T),	mean(citb40nt$Value[citb40nt$Sample=="control4"],na.rm	=	T))		#calculate	p	value	citb40ntttest	<-	t.test(samplecitb40ntm,controlcitb40ntm,	paired=	TRUE)	citb40ntpval	<-	formatC(citb40ntttest$p.value,	format	=	"e",	digits	=	1)		#calculate	ratio	between	aba/dmso	citb40ntratio<-	data.frame(samplecitb40ntm/controlcitb40ntm,fix.empty.names	=	FALSE)		#	Coiled-coil	HDAC5	Sample	vs	control	#	citb40cc	<-	gather(aliciaCC,																				"Sample",																				"Value",																				control1,control2,control3,sample1,sample2,sample3)		#	Raw	data	calculation	samplecitb40ccm<-c(mean(citb40cc$Value[citb40cc$Sample=="sample1"],na.rm	=	T),	mean(citb40cc$Value[citb40cc$Sample=="sample2"],na.rm	=	T),																				mean(citb40cc$Value[citb40cc$Sample=="sample3"],na.rm	=	T))		controlcitb40ccm<-c(mean(citb40cc$Value[citb40cc$Sample=="control1"],na.rm	=	T),	mean(citb40cc$Value[citb40cc$Sample=="control2"],na.rm	=	T),																					mean(citb40cc$Value[citb40cc$Sample=="control3"],na.rm	=	T))		#calculate	p	value	citb40ccttest	<-	t.test(samplecitb40ccm,controlcitb40ccm,	paired=	TRUE)	citb40ccpval	<-	formatC(citb40ccttest$p.value,	format	=	"e",	digits	=	1)		#calculate	ratio	between	aba/dmso	citb40ccratio<-	data.frame(samplecitb40ccm/controlcitb40ccm,fix.empty.names	=	FALSE)		#	catalytic	domain	Sample	vs	control	#	citb40cd	<-	gather(aliciaCD,																				"Sample",																				"Value",					control1,control2,control3,control4,sample1,sample2,sample3,sample4)	
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	#	Raw	data	calculation	samplecitb40cdm<-c(mean(citb40cd$Value[citb40cd$Sample=="sample1"],na.rm	=	T),	mean(citb40cd$Value[citb40cd$Sample=="sample2"],na.rm	=	T),																				mean(citb40cd$Value[citb40cd$Sample=="sample3"],na.rm	=	T),mean(citb40cd$Value[citb40cd$Sample=="sample4"],na.rm	=	T))		controlcitb40cdm<-c(mean(citb40cd$Value[citb40cd$Sample=="control1"],na.rm	=	T),	mean(citb40cd$Value[citb40cd$Sample=="control2"],na.rm	=	T),																					mean(citb40cd$Value[citb40cd$Sample=="control3"],na.rm	=	T),	mean(citb40cd$Value[citb40cd$Sample=="control4"],na.rm	=	T))		#calculate	p	value	citb40cdttest	<-	t.test(samplecitb40cdm,controlcitb40cdm,	paired=	TRUE)	citb40cdpval	<-	formatC(citb40cdttest$p.value,	format	=	"e",	digits	=	1)		#calculate	ratio	between	aba/dmso	citb40cdratio<-	data.frame(samplecitb40cdm/controlcitb40cdm,fix.empty.names	=	FALSE)		#	prepare	dataframe	citb40pylratio$cells	<-	rep("PYL",	4)	colnames(citb40pylratio)	<-	c("ratio",	"cells")		citb40hdac5ratio$cells	<-	rep("HDAC5",	4)	colnames(citb40hdac5ratio)	<-	c("ratio",	"cells")		citb40ntratio$cells	<-	rep("N	terminal",	4)	colnames(citb40ntratio)	<-	c("ratio",	"cells")		citb40ccratio$cells	<-	rep("Coiled-Coil",	3)	colnames(citb40ccratio)	<-	c("ratio",	"cells")		citb40cdratio$cells	<-	rep("catalytic	domain",	4)	colnames(citb40cdratio)	<-	c("ratio",	"cells")		ratioABall	<-	rbind(citb40pylratio,citb40hdac5ratio,																				citb40ntratio,citb40ccratio,	citb40cdratio)		#	P	value	calculation	between	POI	verses	PYL	HDAC5ttest	<-	t.test(citb40pylratio$ratio,citb40hdac5ratio$ratio,	paired=	TRUE)	HDAC5pval	<-	formatC(HDAC5ttest$p.value,	format	=	"e",	digits	=	1)		NTttest	<-	t.test(citb40pylratio$ratio,citb40ntratio$ratio,	paired=	TRUE)	NTpval	<-	formatC(NTttest$p.value,	format	=	"e",	digits	=	1)		CCttest	<-	t.test(citb40pylratio$ratio,citb40ccratio$ratio,	paired=	F)	CCpval	<-	formatC(CCttest$p.value,	format	=	"e",	digits	=	1)		
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CDttest	<-	t.test(citb40pylratio$ratio,citb40cdratio$ratio,	paired=	TRUE)	CDpval	<-	formatC(CDttest$p.value,	format	=	"e",	digits	=	1)		#try	to	order	data	manually	ratioABall_table	<-	table(ratioABall$cells)	ratioABall_levels	<-	names(ratioABall_table)[order(ratioABall_table)]		#set	the	presentation	order	ratioABall$cell2	<-	factor(ratioABall$cells,	levels	=	c("PYL","HDAC5","N	terminal","Coiled-Coil",																																																					"catalytic	domain"))		#prepare	to	set	color	for	each	sample	ratioABall$cell2	<-	as.factor(ratioABall$cell2)	colorprotein	=	c("dodgerblue2","darkorchid3","darkorchid3","darkorchid3","darkorchid3")		#draw	an	overall	ggplot	ggplot(data=ratioABall,	aes(x=cell2,	y=ratio)	)	+				#	add	points			geom_jitter(data=ratioABall,	size=1,	aes(color=	cell2),															width	=	0.1			)	+					#set	different	color	for	different	POI			scale_color_manual(values	=	colorprotein)+				#	Changing	axis	ticks,	y	axis	name	with	numbers	on	y	axis			scale_y_continuous(name	=	"	",																						breaks	=	seq(0,	1.6,	0.5),																						limits=c(0,	1.6))+				#	add	mean	(if	you	like	it	dashed,	add	'linetype	=	"dashed"'	within	brackets)			stat_summary(fun.y	=	mean,	geom	=	"errorbar",	aes(ymax	=	..y..,	ymin	=	..y..),	width	=	0.4,	color="black")	+				#	add	error	bars	corresponding	to	mean+/-sd			stat_summary(fun.data=mean_sdl,	fun.args	=	list(mult=1),	geom="errorbar",	width=0.2,	color="black")	+				#	Add	x	axis	label			xlab("")	+						#	Add	title			ggtitle("	")	+				#	Choose	font	size	
	 169	
		theme(axis.title.y	=	element_text(size=12),									plot.title	=	element_text(size=20,	hjust	=	0.5),									text	=	element_text(size=12))	+				#	Diplay	only	x	and	y	axes	without	any	backgroud			theme(axis.line	=	element_line(colour	=	"black"),									panel.grid.major	=	element_blank(),									panel.grid.minor	=	element_blank(),									panel.border	=	element_blank(),									panel.background	=	element_blank(),									axis.text.x	=	element_text(angle	=	90),									legend.position='none')		
ChIP	barplot	#	load	data	library(readxl)	chiph516	<-	read_excel("~/Desktop/Capri/H516	ChIP/HEKBYH5CAG161CHIP.xlsx")	View(chiph516)		#start	plot	the	data	par(mar	=	c(5,	6,	4,	5)	+	0.1)	chiph516mean<-	barplot(chiph516$mean,																				space	=c(0,0,0.2,0,1,0,0.2,0),																			col=c("black",	"grey"),																				ylim=c(0,3),																				border	=	"black",																			ylab="%	of	input",																			legend.text	=	TRUE,																			yaxt="n",	ann=FALSE	)	segments(chiph516mean,	chiph516$mean-chiph516$sderror,											chiph516mean,	chiph516$mean+chiph516$sderror)	arrows(chiph516mean,	chiph516$mean-chiph516$sderror,									chiph516mean,	chiph516$mean+chiph516$sderror,	lwd	=	0.5,	angle	=	90,								code	=	3,	length	=	0.05)	axis(2,	at=0:3,	labels=c(0:3))		
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Appendix	C:	ChIP	Protocal	
	
ChIP	INT:			
ChIP	material:	Trypsin	cells	and	resuspend	cells	in	10ml	DMEM	media	in	15ml	tubes.		Take	20µl	cells	in	the	mean	time	for	cell	counting.		
Fix	Add	formaldehyde	(find	in	common	chemical	room,	drawer	under	the	hood)	to	a	final	concentration	of	1%	(for	37%	stock,	add	270µl	per	10ml	media),	RT	10min	on	shaker	or	wheel.	Time	here	is	essential	for	achieving	a	perfect	sonication	pattern.	Add	Glycine	to	a	final	concentration	of	0.125M	(for	2M	stock,	add	757µl	per	10ml)	to	stop	the	crosslink,	RT	5min	on	wheel.		1000rpm	5min,	discard	supernatant	to	special	liquid	trash	under	the	hood.	Add	ice	cold	PBS	to	achieve	10	million	cells	per	ml,	then	separate	cells	to	1.5ml	Eppendorf	tubes.	Wash	with	ice	cold	PBS	twice,	3min	1000rpm	at	4	degree.	Freeze	the	pellet.			
Lysis	(NO	Chromatin	extraction”)	
• Resuspend	cell	pellet	in	LB3	buffer	(Complete	EDTA-free):	1	ml/10	million	cells	in	the	red	cap	15ml	TPX	tubes	(normal	15ml	TPP	tube	need	much	longer	time	to	sonicate)	
• Keep	on	ice		
Sonication	
	
Change	the	ddH2O	water	in	Biorupter	everytime	before	using	it	
• Biorupter	sonication		
• Sonication	conditions:	normally	15min	High	(CITB	cells),	25min	High	(CITBY40	and	CITBY40H5	cells)		
• Spin	15	min.	@	full	speed	4°C	
• Collect	each	SN	and	(Keep	20	µl	to	check	sonication	pattern,	keep	20	µl	as	qPCR	input,	keep	15	µl	for	protein	analysis)	
• store	all	the	samples	except	sonication	tubes	@	-80°C		
Check	sonication	Add	80	µl	of	crosslink	reverse	buffer	to	20	µl	samples.		Put	all	the	sample	tubes	in	the	grey	metal	container	next	to	the	water	bath.		Incubate	at	least	6H	@	65°C		Purify	the	samples	with	Qiagen	QIAquick	PCR	Purification	Kit,	elute	into	20	µl	and	load	on	a	1%	gel	and	run	for	1h	in	80V.	
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	Optimal	sonication	pattern	will	be	a	fat	DNA	band	around	300	bp	to	500	bp.	
	
Extract	Dilution	+	Pre-clearing		
	Dilute	cell	extracts	1:5	with	IP	dilution	buffer	per	sample																																																			200	µl	extract	(2	million	cells)	+	800	µl	IP	dilution	buffer				
Block	beads	Well	resuspend	beads	and	take	the	needed	amount	out	into	1.5ml	Eppendorf.	Centrifuge	800	rpm	2min	4	°C	to	remove	the	storage	liquid	(20%	ethanol)	and	wash	2	times	with	PBS	and	once	with	IP	dilution	buffer	After	final	wash,	add	final	concentration	of	1mg/ml	BSA	and	0.3mg/ml	salmon	sperm	DNA	(pre-denatured	95°C	5min	and	put	on	ice	immediately)	in	IP	dilution	buffer,	4	degree	on	wheel	for	1h	
	
Preclearing	+	IP	
• Preclear	each	extract	for	30	min	to	1	h	@	4°C	on	wheel	(20	µl	protein	G	beads	(blocked,	50%	slurry	in	IP	dilution	buffer)	for	1ml	diluted	sample	
• Spin	2	min	@	800	rpm,	collect	SN	(1ml)	
• For	each	IP:		
o 1ml	for	each	(2	million	cells)	for	IP			
	
• Add	following	beads	and	antibodies:		 HA-	IP	Ab9110	αbody	Abcam	1μg/μl	 3	µl			G	beads	Sepharose	4	Fast	Flow	 50	µl		 FLAG-	IP	Flag	M2	1μg/μl	 3	µl			G	beads	Sepharose	4	Fast	Flow	 50	µl		G	Beads	volumes:	slurry	50	%	in	IP	buffer,	(blocked:	BSA	1	mg/ml,	0.3mg/ml	salmon	sperm	DNA)	
• Incubate	overnight	on	wheel	@	4°C	
	
Washes	
• Spin	IPs	for	2	min.	@	800	rpm	@	4°C	
• Remove	SN	(keep	if	needed	in	WB)	and	wash	as	following	(every	wash	for	5	min.	
on	the	wheel,	4°C)	
• Wash	with	following	buffers	once:	wash	buffer	1,	wash	buffer	2	and	wash	buffer	3	
• Finally	wash	all	samples	twice	in	wash	buffer	4	
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• At	the	end	of	the	last	wash,	keep	¼	of	sample	(250	µl)	for	protein	analysis,	spin	as	above	and	resuspend	into	2×	SDS	sample	buffer	(20	µl),	use	¾	of	sample	(750	µl)	for	DNA	analysis	as	usual.		
Crosslink	reversal	
• (Thaw	input	DNA	and	sonication	check	samples)	
• Treat	with	Crosslink	reversal	buffer	(final	volume:	100	µl,	beads	do	not	count	as	volume:	
o Beads	(IPs):	100	µl	
o Input:	80	µl	
o Sonication:	80	µl	
• Incubate	overnight	(or	at	least	6	h)	@	65°C	
	
DNA	extraction	
• Take	samples	from	65°C	and	put	them	on	ice,	proceed	with	DNA	extraction	
• Qiagen	purification	kit:	
o Add	5	×	volume	(500	µl)	binding	buffer	PB	
o Mix	and	transfer	in	a	Qiagen	column	and	onto	a	vacuum	manifold	(or	spin,	30-60	sec,	≥10’000	g)	
o Wash	with	750	µl	wash	buffer	PE	(spin,	30-60	sec,	≥10’000	g)	
o Spin	1	min	full	speed	to	remove	EtOH	
o In	clean	Eppendorf	tubes	elute	DNA	with	20	µl	dH2O	for	sonication	pattern	check	and	50	µl	dH2O	for	qPCR	
o Spin	1	min	full	speed		
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Buffer	
	
LB3	(Julien	Marquis,	NIHS)	
- 10	mM	Tris-HCl	pH	8.0	
- 200	mM	NaCl	
- 1	mM	EDTA	
- 0.5	mM	EGTA	
- 0.1%	Na-Deoxycholate	(NaDOC)	
- 0.25%	Sodium	lauroyl	sarcosinate	(NLS)-Sigma	61743-25G	
- Protease	Inhibitor		For	50	ml:	
- 0.5	ml																1	M	Tris-HCl	(pH	8.0)	
- 2	ml																			5	M	NaCl	
- 0.1	ml																0.5	M	EDTA	(pH	8.0)	
- 50	µl																		0.5	M	EGTA	(pH	8.0)	
- 0.5	ml																10%	Na-Deoxycholate	
- 2.5	ml																5%	NLS	
- 1	x	Complete	protease	inhibitor						Add	fresh	
- dH2O	add	to	50	ml	(44.4	ml)	
	
IP	dilution	buffer	For	40	ml:	-	1.25%	Triton-X	 5	ml	(10%)	-	1	mM	EDTA	pH	8.0	 80	µl	(0.5M	stock)	-	0.5	mM	EGTA	pH	8.0	 40	µl	(0.5M	stock)	-	16.25	mM	Tris-HCl	pH	8.0	 650	µl	(1M	stock)	-	137.5	mM	NaCl	 1.1	ml	(5M	stock)	-	dH2O	 32.73	ml	1	x	Complete	protease	inhibitor	Add	fresh	 		
Wash	1	For	100	ml:	-0.1%	SDS																																																																																													1ml	(10%	stock)	-1%	Trition																																																																																										1ml		-20mM	Tris-HCl	pH	8.0																																																																				2ml	(1M	stock)	-2mM	EDTA	pH	8.0																																																																												400µl	(0.5M	stock)	-300	mM	NaCl																																																																																						6ml	(5M	stock)	Filter		
Wash	2	For	100	ml:	-0.1%	SDS																																																																																													1ml	(10%	stock)	-1%	Trition																																																																																										1ml	-20mM	Tris-HCl	pH	8.0																																																																				2ml	(1M	stock)	-2mM	EDTA	pH	8.0																																																																												400µl	(0.5M	stock)	-500	mM	NaCl																																																																																						10ml	(5M	stock)	Filter	
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Wash	3	For	100	ml:	-1%	NP-40																																																																																													1ml	-1%	Na-deoxycholate																																																																									10ml	(10%	stock)	-10mM	Tris-HCl	pH	8.0																																																																					1ml	(1M	stock)	-1mM	EDTA	pH	8.0																																																																													200µl	(0.5M	stock)	-250mM	LiCl																																																																																									26ml	(4.8M	stock)	Filter		
Wash	4	For	100	ml:	-10mM	Tris-HCl	pH	8.0																																																																					1ml	(1M	stock)	-1mM	EDTA	pH	8.0																																																																													200µl	(0.5M	stock)	Filter	
	
Crosslink	Reversal	Buffer	For	500ml:	-1%	SDS																																																																																																	50ml	(10%	stock)	-0.1M	NaHCO3																																																																																					50ml	(1M	stock)	-0.5mM	EDTA	pH	8.0																																																																									0.5ml	(0.5M	stock)	-20mM	Tris-HCl	pH	8.0																																																																					10ml	(1M	stock)	-RNase:	final	concentration	100μg/ml																																									Add	fresh	
	
	
	
